NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01793909,Type 2 Diabetes and Exercise Function in Single Leg Exercises,https://clinicaltrials.gov/study/NCT01793909,,COMPLETED,"This study plans to learn more about the effects of type 2 diabetes (T2DM) on exercise blood flow and muscle oxygen uptake. This study will evaluate \& compare exercise function during single leg plantar flexion exercise in a total of 45 subjects from the Denver area (15 lean controls, 15 people with T2DM, and 15 overweight control subjects).

Differences between the exercise responses in people with T2DM and healthy people will help further identify the disease process of T2DM and direct future research of treatments and interventions.",YES,Type 2 Diabetes,OTHER: Single Leg Exercise Training,"Change in Muscle Oxygen Saturation, The investigators evaluated the dynamics of muscle deoxygenation (O2 extraction) using near infrared spectroscopy (NIRS) during single leg plantar flexion exercise to identify the predominant mechanisms of oxygen delivery versus oxygen utilization abnormalities in the muscle of T2DM during the transition from rest to exercise. These measurements were gathered continuously for 2-5 minutes of multiple exercise bouts within two visits, one prior to the exercise intervention period and one post exercise intervention., 4.5 hrs each, pre- and post- Exercise Intervention",,,"University of Colorado, Denver",,ALL,"ADULT, OLDER_ADULT",NA,55,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,06-0062|1564|1UL1TR001082,2012-06,2018-05-31,2018-05-31,2013-02-18,2019-02-21,2023-07-12,"University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado, 80045, United States","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/09/NCT01793909/Prot_SAP_000.pdf"
NCT03980808,American Sign Language-Accessible Diabetes Education,https://clinicaltrials.gov/study/NCT03980808,ASL-ADE,COMPLETED,ASL-ADE will evaluate the efficacy of an ASL-interpreted diabetes educational intervention to the end of improving the health literacy of the target population and addressing their disparate health outcomes.,YES,Diabetes|Deafness,BEHAVIORAL: American Sign Language-Accessible Diabetes Education|BEHAVIORAL: Control Intervention,"Diabetes Health Literacy Score, Data were collected using a study-specific, knowledge-based Diabetes Health Literacy measure which included 15 forced-choice, closed-ended questions to allow for a total score ranging from 0 to 15, with higher scores reflecting better diabetes health literacy. Analysis of change of knowledge compared differences between the intervention arm and the control arm as measured by the changes to the composite scores of the knowledge-based test. One factor Analysis of Variance (ANOVA) was used to calculate the differences with an a priori alpha level of 0.05., The outcome measure results reflect a comparison of the pre and posttest immediate scores.|Frequency of Engagement in Diabetes-Related Health Behaviors, Data were collected using a study-specific questionnaire titled Your Health Behaviors that measure the frequency of diabetes-related health behaviors for a total score ranging from 7 to 35. Each of the diabetes behaviors (physical activity, work physical activity, cigarettes, smoking cessation, alcohol consumption, vegetable consumption, fruit consumption, grain consumption, junk food consumption, fast food consumption) had multiple choice answers that were scaled from 1 - n, with n being the number of options. The least healthy choice was assigned ""1"", the most healthy choice was assigned ""n"". Analysis of change in behavior compared differences between the intervention arm and the control arm as measured by the changes in the composite scores of the behavioral intervention. One factor Analysis of Variance (ANOVA) was used to compare the differences with an a priori level of 0.05., The outcome measure results for the Your Health Behaviors measure are a comparison between the pretest and the 30-day follow-up.",,,Georgia Institute of Technology,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),ALL,"ADULT, OLDER_ADULT",NA,41,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,H19229|5P30DK111024-04,2020-10-29,2021-01-26,2021-01-26,2019-06-10,2021-12-20,2023-07-10,"Center for Advanced Communications Policy, Atlanta, Georgia, 30332, United States|Deaf Link, Inc., San Antonio, Texas, 78232, United States","Study Protocol, https://storage.googleapis.com/ctgov2-large-docs/08/NCT03980808/Prot_001.pdf|Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/08/NCT03980808/SAP_002.pdf|Informed Consent Form, https://storage.googleapis.com/ctgov2-large-docs/08/NCT03980808/ICF_003.pdf"
NCT03689608,Daily vs Intermittent Restriction of Energy: Controlled Trial to Reduce Diabetes Risk (DIRECT),https://clinicaltrials.gov/study/NCT03689608,,COMPLETED,"In this randomized controlled trial, the investigators will compare the long term effectiveness of intermittent fasting (IF) versus an energy matched moderate calorie restriction (CR) over 18 months, and relative to a non-active intervention standard control (SC) in individuals who are at increased risk of developing type 2 diabetes. All participants will be required to attend the blood tests following a 12-hour overnight fast for the ""A"" visit at Month 0, 2, 6 (active) and 18 (follow up).

Fast424hGlucose: A subset of 100 participants enrolled in either IF or CR group in the parent study will be fitted with a continuous glucose monitor (CGM) to measure 24-hour glycaemic profile at month 0 and month 6.

Fast4Switch: Additional bloods will be collected after a ""B"" visit at month 6 to compare the fed to fasted switch. The B samples will be collected after a 12-hour overnight fast (CR, SC) or 20-hour fast (IF) to assess the metabolic switch to fasting in metabolites and hormones.

Fast4Stress: Additional subcutaneous adipose tissue, urine and saliva samples will be collected in \~32 men in IF and CR groups at month 0 and 6 at A and B visits to examine changes in stress response and resistance markers.

Experience2Fast: In-depth, semi-structured interviews will be carried out at month-8 follow-up visit in a subset of completers from IF or CR groups to explore the experience of intervention diets and understand contributing factors towards change and maintenance of dietary behaviours.

Fast4Flux: Additional blood samples will be collected in \~100 individuals in SC, IF and CR groups at month 0, month 2 and month 6 at A visit to measure autophagic flux in peripheral blood mononuclear cells following treatment of whole blood.",NO,Individuals at Risk of Developing Diabetes,OTHER: Intermittent Fasting (IF)|OTHER: Daily Restriction (DR)|OTHER: standard care (SC),"Postprandial glucose AUC, Change in postprandial glucose AUC, 6 months","HbA1c, Change in HbA1c, 2 months, 6 months, 18 months|Postprandial glucose, Change in postprandial glucose, 18 months|Body weight, Change in body weight in kilograms, 2 months, 6 months, 18 months|Body composition, Change in body fat mass (kg) and fat free mass (kg), 6 months, 18 months|Waist and hip circumference, Change in waist and hip circumference, 2 months, 6 months, 18 months|Blood lipids, Changes in blood lipid profile (total cholesterol, HDL-, LDL-cholesterol and triglycerides), 2 months, 6 months, 18 months|Dietary intake, Change in food intake measured by self-reported food diaries, 2 months, 6 months, 18 months|Blood pressure, Change in systolic blood pressure and diastolic blood pressure (mmHg), 2 months, 6 months, 18 months|Changes in physical Activity assessed by accelerometer, Change in average step counts measured with waist-worn actigraphy monitors, 2 months, 6 months, 18 months|Fasting glucose, Change in fasting glucose, 2 months, 6 months, 18 months|Fasting insulin, Change in fasting insulin, 2 months, 6 months, 18 months|Fasting non-esterified fatty acids (NEFA), Change in fasting NEFA levels, 2 months, 6 months, 18 months|Fasting triglyceride, Change in fasting triglyceride levels, 2 months, 6 months, 18 months|Postprandial insulin, Change in postprandial insulin, 6 months, 18 months|Postprandial non-esterified fatty acids (NEFA), Change in postprandial NEFA levels, 6 months, 18 months|Postprandial triglyceride, Change in postprandial triglyceride levels, 6 months, 18 months","Change in perceived hunger and fullness assessed by visual analogue scales (VAS), Change in subjective hunger and fullness ratings measured by 0-100 mm VAS scales, 6 months, 18 months|Change in perceived sleep quality, Change in perceived sleep quality assessed by Pittsburgh Sleep Quality Index (PSQI), with a range from 0-21 scores, higher score reflect poorer sleep quality, 2 months, 6 months, 18 months|Change in perceived eating behaviour, Change in perceived eating behaviour assessed by Three Factor Eating Questionnaire (TFEQ), which consists of 51 items to assess dietary restraint (21 items), disinhibition (16 items) and hunger (14 items), higher scores reflect higher levels on each subscale, 2 months, 6 months, 18 months|Change in perceived quality of life, Change in perceived quality of life assessed by 36-item Short Form (SF-36) health survey, with a range from 0-100 scores, higher scores reflect better quality of life, 2 months, 6 months, 18 months|Change in perceived well-being, Change in perceived well-being assessed by Personal Well-being Index, with a range from 0-10 scores, higher scores reflect greater satisfication, 2 months, 6 months, 18 months|Change in food addition score, Change in self-reported food addiction assessed by Yale Food Addiction Score (YFAS), with a range from 0-7 scores, higher scores reflect greater food addiction symptoms, 6 months, 18 months|Change in psychological distress, Change in self-reported psychological distress assessed by Kessler Psychological Distress Scale (K10) , with a range from 10-50 scores, higher scores reflect higher psychological distress, 6 months, 18 months|Change in self-reported depression, anxiety and stress level, Change in self-reported depression, anxiety and stress level assessed by Depression, Anxiety and Stress Scale (DASS), with a range from 0-42 scores on each subscale, higher scores reflect higher levels on each subscale, 2 months, 6 months, 18 months|Change in self-reported mood, Change in self-reported mood assessed by Positive and Negative Affect Schedule (PANAS), with a range from 0-100 scores, higher scores reflect more positive mood and negative mood., 2 months, 6 months, 18 months|Change in glucagon-like peptide 1 (GLP-1), Change in glucagon-like peptide 1 (GLP-1), 6 months|Change in peptide YY, Change in peptide YY, 6 months|Change in ghrelin, Change in ghrelin, 6 months|Change in gastric inhibitory polypeptide (GIP), Change in gastric inhibitory polypeptide (GIP), 6 months|Change in estradiol, Change in estradiol, 6 months|Change in testosterone, Change in testosterone, 6 months|Change in glucose (DIRECT- Fast4Switch), Change in glucose levels, 6 months|Change in non-esterified fatty acids (DIRECT- Fast4Switch), Change in non-esterified fatty acids levels (NEFA), 6 months|Change in insulin (DIRECT- Fast4Switch), Change in insulin levels, 6 months|Change in triglycerides (DIRECT- Fast4Switch), Change in triglycerides levels, 6 months|24 hours glycaemia (DIRECT-Fast424hGlucose), Changes in 24 hours glycaemia assessed by continuous glucose monitor, 6 months|Salivary cortisol (DIRECT-Fast4Stress), Change in salivary cortisol, 6 months|Gene expression (DIRECT- Fast4Stress), Change in gene expression, 6 months|Change in urinary adrenaline (DIRECT- Fast4Stress), Change in urinary adrenaline, 6 months|Change in urinary noradrenaline (DIRECT- Fast4Stress), Change in urinary noradrenaline, 6 months|Qualitative analysis (DIRECT-Experience2Fast), Patterns of participant's behaviour, characteristics and motivation that assist in or hinder from weight loss achievement by semi-structured interviews, 8 months|Change in autophagic flux (DIRECT-Fast4flux), Change in autophagic machinery protein LC3B-II in peripheral blood mononuclear cells following treatment of whole blood., 2 months, 6 months",University of Adelaide,,ALL,"ADULT, OLDER_ADULT",NA,209,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,R20180319,2018-09-26,2020-11-30,2021-11-30,2018-09-28,,2022-01-11,"University of Adelaide, Adelaide, South Australia, Australia","Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/08/NCT03689608/SAP_000.pdf"
NCT02747108,ForgIng New Paths to Prevent DIabeTes (FINDIT),https://clinicaltrials.gov/study/NCT02747108,FINDIT,COMPLETED,"This study will evaluate the effects of screening for type 2 diabetes mellitus (T2DM) and brief counseling about screening test results on weight and key health behaviors among Veterans with risk factors for T2DM. Study participants will be randomly assigned to one of two study groups: (1) Blood Test Group or (2) Brochure Group. Participants in the Blood Test Group will complete a blood test called hemoglobin A1c (HbA1c) which measures average blood sugar levels. Participants will receive brief counseling about the results from their primary care provider or someone authorized to speak on their behalf. Participants randomly selected for the Brochure Group will review a handout from the VA National Center for Health Promotion and Disease Prevention (NCP) on recommended screening tests and immunizations. All participants will be asked to complete a survey prior to study group assignment, immediately after a Primary Care appointment, 3 months after enrollment, and 12 months after enrollment.",YES,Prediabetes,BEHAVIORAL: Blood Test Group Intervention|BEHAVIORAL: Brochure Group Intervention,"Weight Change From Baseline to 12 Months, The primary outcome will be weight change 12 months after an HbA1c test and brief counseling or review of health promotion literature., 12 months","Change in Use of Medication for T2DM Prevention, The investigators will use medical record data and survey data to evaluate changes in use of medication for T2DM prevention after an HbA1c test and brief counseling or review of health promotion literature., 3 and 12 months|Changes in Participation in a Weight Management Program, The investigators will use survey data to evaluate changes in participation in a weight management program after an HbA1c test and brief counseling or review of health promotion literature., 3 months and 12 months|Changes in Perception for Risk for T2DM, The investigators will use survey data to evaluate changes in perception of risk for T2DM after an HbA1c test and brief counseling or review of health promotion literature. The Adriaanse T2DM Risk Perception Scale, which was included in the survey, measured self-assessed risk perception from 0 denoting no choice of developing T2DM to 100 denoting absolute confidence in developing T2DM., Baseline, 2 weeks, 3 months, and 12 months|Changes in Knowledge of Strategies to Prevent T2DM, The investigators will use survey data to evaluate changes in knowledge of strategies to prevent T2DM after an HbA1c test and brief counseling or review of health promotion literature. Respondents were given 3 open-ended questions to report things they could do to prevent T2DM. Each respective response to the 3 questions were coded and scored according to whether they indicated engagement in the following activities: weight loss, physical activity, use of metformin, or enrollment into a diabetes prevention program. Each question denoted with a positive response were coded with 1 whereas those that did not were coded as a 0. The three questions were summed into a final score ranging from 0 (no report of engagement in the aforementioned healthy activities) with the worst outcome to 3 (a report of 3 of the 4 aforementioned healthy activities) with the best outcome., 2 weeks, 3 months, and 12 months|Changes in Motivation to Prevent T2DM, The investigators will use survey data to evaluate changes in motivation to prevent T2DM after an HbA1c test and brief counseling or review of health promotion literature. The Treatment Self-Regulation Questionnaire (TSRQ) was included in the survey and respondents were asked about their level of motivation from 1 (Not at all motivated) to 10 (Highly motivated)., Baseline, 2 weeks, 3 months, and 12 months|Changes in Self-efficacy to Engage in Behaviors to Prevent T2DM, The investigators will use survey data to evaluate changes in self-efficacy to engage in behaviors to prevent T2DM after an HbA1c test and brief counseling or review of health promotion literature. The Perceived Competence Scale was used to measure respondent self-efficacy from 1 (lowest) to 7 (highest)., Baseline, 3 months and 12 months|Change in Physical Activity, The investigators will use survey data to evaluate changes in physical activity after an HbA1c test and brief counseling or review of health promotion literature. The International Physical Activity Questionnaire - Short Form (IPAQ-SF) was used to measure physical activity change. Respondents were asked to report how many hours and minutes within the past week they completed of vigorous physical activity, moderate physical activity, and brisk walking. The total sum of minutes for these three questions were subsequently coded into a yes/no binary variable for whether respondents met a recommended 150 minutes of overall physical activity within 7 days of being assessed. The values provided reflect a proportion of respondents that met or exceeded the 150 minute threshold of overall physical activity based on the newly generated variable that combined total minutes of vigorous physical activity, moderate physical activity, and brisk walking., Baseline, 3 months and 12 months|Change in Mental Health, The investigators will use survey data to evaluate changes in SF-12 mental health scores after an HbA1c test and brief counseling or review of health promotion literature. The SF-12 provides a calculation of (1) a physical score (PCS-12) generated from a subset of questions focused on physical health and (2) a mental health score (MCS-12) generated from a subset of questions focused on mental health. The data provided represent the mean score of the PCS-12 and MCS-12. Scores range from 0 to 100, where a zero score indicates the lowest level of physical/mental health measured by the scales and 100 indicates the highest level of physical/mental health., Baseline, 2 weeks, 3 months, and 12 months",,VA Office of Research and Development,VA Ann Arbor Healthcare System,ALL,"ADULT, OLDER_ADULT",NA,315,FED,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: PREVENTION,CDX 15-001|CDA 13-267,2015-12-02,2018-12-01,2020-03-30,2016-04-21,2020-04-06,2023-07-25,"VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, 48105-2303, United States","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/08/NCT02747108/Prot_SAP_000.pdf"
NCT04009239,Time Restricted Feeding and Metabolic Rhythms,https://clinicaltrials.gov/study/NCT04009239,Rhythm,COMPLETED,"Current guidelines for the prevention and treatment of obesity focus on caloric restriction diets and increasing physical activity, but long-term compliance to these strategies is poor. The timing of meal intake relative to the light-dark and sleep-wake cycle is rarely considered in metabolic health; and modifying meal timing is likely easier to implement in daily life than reducing caloric intake and/or increasing physical activity. This project will test whether restricting the timing of energy intake to a short-defined period during wakefulness can be used to improve fuel utilization patterns and enhance circadian rhythms in metabolic tissues to optimize health.",NO,Obesity|Diabetes,BEHAVIORAL: Time Restricted Feeding,"Total fat oxidation in response to eTRF, Total fat oxidation will measured by whole room calorimetry. Early Time Restricted Feeding (eTRF) may occur at Week 1 or Week 5 depending on randomization., Week 1 or Week 5|Total fat oxidation in response to mTRF, Total fat oxidation will measured by whole room calorimetry. Mid-day Time Restricted Feeding (mTRF) may occur at Week 1 or Week 5 depending on randomization., Week 1 or Week 5|Insulin sensitivity in response to eTRF, Insulin sensitivity measured by three identical mixed meal tolerance tests administered across the day. Early Time Restricted Feeding (eTRF) may occur at Week 1 or Week 5 depending on randomization., Week 1 or Week 5|Insulin sensitivity in response to mTRF, Insulin sensitivity measured by three identical mixed meal tolerance tests administered across the day. Mid-day Time Restricted Feeding (mTRF) may occur at Week 1 or Week 5 depending on randomization., Week 1 or Week 5|Glucose control in response to eTRF, Glucose control will be measured by a continuous glucose monitor. Mid-day Time Restricted Feeding (mTRF) may occur at Week 1 or Week 5 depending on randomization., Week 1 or Week 5|Glucose control in response to mTRF, Glucose control will be measured by a continuous glucose monitor. Early Time Restricted Feeding (eTRF) may occur at Week 1 or Week 5 depending on randomization., Week 1 or Week 5","Difference in dietary fat oxidation between experimental conditions, Dietary fat oxidation will be measured using a stable isotope tracer, Week 1 and Week 5|Difference in 24h energy expenditure between experimental conditions, 24h energy expenditure will be measured using whole room calorimetry, Week 1 and Week 5|Difference in sleep between experimental conditions, Sleep will be measured by polysomnography, Week 1 and Week 5|Difference in the melatonin rhythm between experimental conditions, The melatonin profile will be measured in plasma during constant routine protocol, Week 1 and Week 5|Difference in plasma metabolite rhythms between experimental conditions, Plasma metabolite rhythms will be measured using a constant routine protocol, Week 1 and Week 5|Difference in plasma hormone rhythms between experimental conditions, Plasma hormone rhythms will be measured using a constant routine protocol, Week 1 and Week 5|Difference in plasma gene expression rhythms between experimental conditions, Plasma gene expression rhythms will be measured using a constant routine protocol, Week 1 and Week 5|Difference in energy expenditure rhythms between experimental conditions, Energy expenditure rhythms will be measured by indirect calorimetry during a constant routine protocol, Week 1 and Week 5|Difference in substrate oxidation rhythms between experimental conditions, Substrate oxidation rhythms will be measured by indirect calorimetry during a constant routine protocol, Week 1 and Week 5",,"University of Colorado, Denver",National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),ALL,ADULT,NA,12,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE,16-2754|K01DK113063,2019-01-15,2022-04-08,2022-04-08,2019-07-05,,2022-07-14,"University of Colorado Anschutz Medical Campus, Aurora, Colorado, 80045, United States","Informed Consent Form, https://storage.googleapis.com/ctgov2-large-docs/39/NCT04009239/ICF_000.pdf"
NCT01977417,Inflammation Inhibition in Prediabetic Humans,https://clinicaltrials.gov/study/NCT01977417,INCITE,TERMINATED,"Prediabetes, characterized by elevated fasting blood sugar or exaggerated blood sugar response to sugar ingestion, effects over 79 million adult Americans and is a precursor to the development of Type 2 diabetes. Importantly, approximately 42% of Iowans (950,000) have diabetes and 32% (670,000) have prediabetes with the majority of those with prediabetes going undiagnosed. Adults with prediabetes demonstrate early signs of cardiovascular and nervous system abnormalities and are at high risk for developing overt diabetes unless aggressive lifestyle (weight loss, exercise) or pharmacological interventions are employed. Interestingly, data in recent years has linked obesity and diabetes to chronic inflammation of the blood vessels and brain areas that regulate blood pressure. Therefore, the current study will test whether a commonly used aspirin-like anti-inflammatory drug called salsalate, will improve blood vessel health and nervous system dysfunction in adults with prediabetes. Eligible subjects will have measurements of blood pressure, blood vessel function in the arms and eyes, assessments of nerve activity, and blood samples taken before and after 4 weeks of ingesting an FDA approved aspirin-like drug called salsalate. The study is important because it will identify a potentially new pharmacological strategy to treat vascular and nervous system abnormalities in overweight and obese adults with early stage type 2 diabetes using an inexpensive, generically available drug with an excellent safety record that has been used for decades to treat chronic inflammatory conditions such as rheumatoid arthritis. If proven effective, this will provide preliminary support for the concept of targeting inflammation as a new clinical approach to treating early diabetes related complications. Furthermore, the current pilot study will provide support for developing a larger clinical trial using salsalate that could potentially then be extended to patients with type 2 diabetes and cardiovascular disease, as well as lead to the development of new anti-inflammatory agents with greater specificity for selective inflammatory pathways.",YES,Prediabetes|Obese,DRUG: Salsalate|DRUG: Placebo,"Aim 1: Vascular Endothelial Function in Obese Prediabetic Adults Before and After 1 Month of Salsalate or Placebo., Brachial artery flow-mediated dilation, Change from baseline at 4 weeks",,,Gary L. Pierce,,ALL,"ADULT, OLDER_ADULT",PHASE2,21,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",201209707,2012-11,2021-04,2021-04,2013-11-06,2023-07-06,2023-09-11,"University of Iowa, Iowa City, Iowa, 52240, United States","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/17/NCT01977417/Prot_SAP_000.pdf"
NCT02566317,Stand & Move at Work,https://clinicaltrials.gov/study/NCT02566317,,COMPLETED,A trial testing the efficacy of sit-stand workstations on decreasing sitting time and increasing light-intensity physical activity in samples of office worksites.,YES,Obesity|Hypertension|Diabetes,DEVICE: Sit-Stand workstation|BEHAVIORAL: Move,"Mean Change in Light-intensity Physical Activity at Work From Baseline to 12 Months, Measured via 7d of activPAL accelerometry (value at 12 months minus value at baseline), 1 year|Mean Change in Sitting Time at Work From Baseline to 12 Months, Measured via 7d of activPAL accelerometry (value at 12 months minus value at baseline), 1 year","Clustered Metabolic Risk Score From Baseline to 12 Months, Clustered metabolic risk score (fasting glucose, insulin, triglycerides, HDL-cholesterol, blood pressure); value at 12 months minus value at baseline; higher scores indicate better outcome. The Z-score for each component (fasting glucose, insulin, triglycerides, HDL-cholesterol, blood pressure) based on the baseline mean and standard deviation of the entire group was computed and summed for each participant (HDL z-score was subtracted rather than added). The sum of these z-scores represents the metabolic risk score., 1 year","Sleep Substudy, 24h wrist accelerometry in individuals with minor-moderate sleep complaints, 1 year|Ambulatory Blood Pressure, Dynamic changes in ambulatory blood pressure in prehypertensives, 3 months|Ecological Momentary Assessment of Mood, Periodic monitoring of mood, energy, fatigue in smartphone users, 1 year|Dynamic Glucose Control, Continuous glucose monitoring in prediabetics, 3 months",Arizona State University,University of Minnesota,ALL,"ADULT, OLDER_ADULT",NA,630,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,R01CA198971,2016-01-15,2017-12-15,2018-12-15,2015-10-02,2019-07-15,2019-10-11,"Arizona State University, Tempe, Arizona, 85281, United States|University of Minnesota, Minneapolis, Minnesota, 55455, United States","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/17/NCT02566317/Prot_SAP_000.pdf"
NCT02928952,Mindful Stress Reduction in Diabetes Self-management Education for Veterans,https://clinicaltrials.gov/study/NCT02928952,Mind-STRIDE,COMPLETED,The purpose of this study is to see if adding Mindfulness training to diabetes education reduces feelings of stress and makes it easier to adhere to healthy behaviors that improve diabetes outcomes (such as hemoglobin A1c).,YES,Diabetes Mellitus,BEHAVIORAL: Mind-STRIDE,"Problem Areas in Diabetes Scale (PAID) -(Measures Diabetes Distress), A 20-item psychometrically validated self-report questionnaire on a 5 point Likert scale (0= not problem; 4= a serious problem). The scores are summed and multiplied by 1.25. Minimum value = 0; Maximum value = 100. Higher scores denote higher levels of diabetes related distress. The cutoff for significant distress is 33; a score of 40 is consistent with diabetes burn-out., baseline, 12 weeks and 24 weeks","Diabetes Self-efficacy Scale (DSES), An 8-item psychometrically validated self-report questionnaire on a 10- point Likert Scale (1= Not confident at all; 10 = Totally confident). This scale measures diabetes self efficacy, a critical pathway to improved self-management that refers to an individual's confidence in their ability to perform key diabetes self-management behaviors. Scores are derived as the mean of the 8 questions. Minimum score =1; Maximum Score = 10. Higher scores denote higher diabetes self-efficacy., baseline, 12 weeks and 24 weeks|Hemoglobin A1c (A1C), A blood test that measures the percentage of glycated hemoglobin in red blood cells as a means of estimating the average blood sugar concentrations for the preceding two to three months. Lower percentage denote better blood glucose levels and may range from 4.5% in persons without diabetes t0 \>15% in persons with poorly managed hyperglycemia. . An A1C \<7% has been associated with prevention of diabetes complications. A1C\>9% denotes chronic,severe blood glucose elevation. All tests were performed at VAPHS according to National Glyco-hemoglobin Standardization Program-approved methods., baseline, 12 weeks and 24 weeks|Mindfulness Attention and Awareness Scale (MAAS), A 15-item psychometrically validated questionnaire on a 6-point Likert scale (1=Almost Always and 6= Never) The scale is scored by computing the mean of the 15 items. (Minimum score = 1; maximum score = 6). Higher scores reflect higher levels of dispositional (trait) mindfulness. Average score in the general US population is 4.22. Mindfulness is a mental state achieved by focusing one's awareness on the present moment, while calmly acknowledging and accepting one's feelings, thoughts, and bodily sensations., baseline, 12 weeks and 24 weeks|Body Weight, Weight in pounds, baseline, 12 weeks and 24 weeks|Blood Pressure, Change in mean arterial blood pressure, calculated as blood pressure + 2 (diastolic blood pressure) divided by 3., baseline, 12 weeks and 24 weeks|Patient Health Questionnaire (PHQ8), The Patient Health Questionnaire (PHQ-8) is a standardized, validated scale that assesses 8 key symptoms of depression experienced over the prior two weeks on a 4-point Likert scale (0=not at all; 3= nearly every day). It is the same as the PHQ-9, without the question regarding suicidal ideation. Score is the sum of the 8 items (Minimum value =0; Maximum= 24). A score of 10 or greater is considered major depression, 20 or more is severe major depression., baseline, 12 weeks and 24 weeks|PTSD Checklist- Civilian Version (PCL-C), The Abbreviated PCL-C is a validated 6-item civilian version of the PTSD check- list designed for use in general medical settings to assess symptoms of PTSD using a 5-point Likert scale. Scores reflect how much the participant has been bothered by specific PTSD symptoms during the past month. (0= ""not at all; 4= ""extremely"") .Scores are summed. (Minimum value =0; maximum values = 24). Scores \>14 are suggestive of PTSD, with higher scores reflecting greater PTSD symptoms., baseline, 12 weeks and 24 weeks|Summary of Diabetes Self-Care Activities (SDSCA), General Diet, A 2-item subscale of the psychometrically validated SDSCA that measures the frequency of general dietary behaviors each day over the past 7-days and number of days per week over the past month (0= no days; 7 = 7 days). Scores = mean number of days per week ( Minimum score =0; maximum score = 7) . Higher scores denote healthier dietary behaviors., baseline, 12 weeks and 24 weeks|Summary of Diabetes Self-Care Activities (SDSCA), Specific Diet, A 2-item subscale of the psychometrically validated SDSCA that measures the frequency of eating fruits and vegetables and high fat foods each day over the past 7-days. Minimum maximum values = (0= no days; 7 = 7 days). 1 item is scored as mean number of days (Minimum score =0; maximum score = 7), while the 2nd item is summed and reversed (0= 7days; 7= 0 days). The scores for the two items are summed for the subscale score (Minimum score=0; maximum score =7) Higher scores denote healthier dietary behaviors.

Each subscale of the SDSCA is scored separately, without a calculated composite score., baseline, 12 weeks and 24 weeks|Summary of Diabetes Self-Care Activities (SDSCA) Space Carbohydrates, One item from the SDSCA that assesses the number of days over the past 7-days in which the participant spaced carbohydrates evenly throughout the day. Minimum score 0; maximum score 7. Higher scores denote healthier dietary behaviors., baseline, 12 weeks and 24 weeks|Summary of Diabetes Self-Care Activities (SDSCA)- Exercise, A 2-item subscale of the SDSCA that measures the number of days over the past 7-days on which the participant engaged in physical activity . Score = mean score of days over the past 7 days (Min.=1; Max.=7). Higher scores denote healthier exercise behaviors.

Each SDSCA subscale scored separately., baseline, 12 weeks, 24 weeks|Summary of Diabetes Self-Care Activities (SDSCA)- - Footcare, A 2-item subscale of the SDSCA that measures the number of days the participant 1) inspected their feet and 2) inspected the inside of their shoes over the past 7-days. Score = mean number of days (Min=0; max=7). Higher scores denote healthier footcare behaviors., baseline, 12 weeks, 24 weeks|Summary of Diabetes Self-Care Activities (SDSCA)- Blood Glucose Testing, A 2-item subscale of the SDSCA that measures 1) the number of days on which the participant tested their blood glucose over the past 7 days and 2) the number of days on which they tested their blood glucose according to the number of times recommended by their health care provider over the past 7-days. Scores= mean number of days per week. Minimum score is 0 Maximum score is 7.Higher scores denote healthier self-monitoring behaviors.

Each SDSCA subscale scored separately, baseline, 12 weeks, 24 weeks|Summary of Diabetes Self-Care Activities (SDSCA)- - Smoking, A 2-item subscale of the SDSCA that measures 1) whether the participant smoked even a puff of a cigarette in the past 7 days (0=no; 1= yes) and 2) if so, the number of cigarettes smoked on an average day. The scores are summed. Minimum score =0, maximum score = \>40. Lower scores denote healthier smoking behaviors., baseline,12 weeks, 24 weeks|Summary of Diabetes Self-Care Activities (SDSCA)- - Medication Adherence, A 2-item subscale of the SDCSA that measures the frequency of 1) taking prescribed insulin and 2)prescribed number of diabetes pills each day over the past 7-days. Scores from the 2 items are summed. Minimum score =0; maximum score = 7). Higher scores denote greater adherence to diabetes medications. Participants entered N/A if they were not prescribed insulin or diabetes pills.

Each subscale of the SDSCA is scored independently with no calculated composite score., baseline, 12 weeks, 24 weeks","Change in 6-item PROMIS Short Form v1.0 Pain Interference 6 b, A psychometrically validated 7-item instrument on a 5 point Likert scale (1= ""not at all""- 5 and ""very much"") determining the degree to which pain has interfered with aspects of daily living during the past 7 days. It is a general and not disease-specific measure of pain. Scores are summed (Min. value = 6; Max value =35). Total raw scores are then converted into a T-score for each participant. The T-scores rescales the raw score into a standardized score with a mean of 50 and a standard deviation of 10. A score of 50 is the average for the United States general population with a standard deviation of 10., baseline, 12 weeks and 24 weeks|Insomnia Severity Index (ISI), Seven psychometrically tested items on a 4 point Likert scale that measure difficulty falling asleep and staying asleep (0= none; 4=very severe) and satisfaction with current sleep patterns (0=very satisfied; 4=very dissatisfied), Noticeable impairment of quality of life (0= not noticeable; 4= very much noticeable), Worry/distress re: sleep (0=not at all worried; 4=very much worried); Interference of sleep problem to daily functioning (0=not interfering; 4= very much interfering). Scores are summed. Minimum score = 0; maximum score = 20). Higher scores denote greater insomnia severity. Scores over 14 denote insomnia; Scores 8 to 14 denote subthreshold insomnia., baseline, 12 weeks and 24 weeks",VA Office of Research and Development,,ALL,"ADULT, OLDER_ADULT",NA,132,FED,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,NRI 15-150,2016-11-01,2020-04-09,2020-04-09,2016-10-10,2021-03-10,2021-05-28,"VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA, Pittsburgh, Pennsylvania, 15240, United States","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/52/NCT02928952/Prot_SAP_000.pdf"
NCT01884545,Genetic Risk and Health Coaching for Type 2 Diabetes and Coronary Heart Disease,https://clinicaltrials.gov/study/NCT01884545,,COMPLETED,"The purpose of this study is to examine whether the use of genetic test information and/or health coaching in patient risk counseling for heart disease and diabetes affect health behaviors and health outcomes in active-duty Air Force (ADAF), beneficiaries or dependents and Air Force retiree patients.

Total of 400 subjects will be enrolled. They will be randomly(like flipping a coin)assigned to 4 groups: 1)Standard risk assessment (SRA)only; 2)SRA plus genetic risk information (SRA+G); 3)SRA plus health coaching (SRA+HC); or 4)SRA, genetic risk information, and health coaching (SRA+G+HC). Subjects randomized to the two genetic arms will have blood collected for testing of investigational coronary heart disease (CHD) and type 2 diabetes (T2D) risk markers. Participants in the two groups that include health coaching will be assigned to a trained certified health coach for a period of 6 months. The duration of the study is 12 months with 3 in person visits (baseline, 6 months and 12 months) and completion of surveys at 6 weeks and 3 month time points.",YES,"Coronary Heart Disease, Susceptibility to, 5|Prediabetic State",BEHAVIORAL: Health coaching|GENETIC: Genetic risk counseling|BEHAVIORAL: Standard risk assessment,"Dietary Intake as Measured by Percent Energy From Fat, Dietary intake as measured by percent energy from fat, adjusted for baseline, 12 months|Dietary Intake as Measured by Daily Grams of Fiber, Dietary intake as measured by daily grams of fiber, adjusted for baseline, 12 months|Physical Activity, as Measured by the Stanford Brief Activity Survey (SBAS), The Stanford Brief Activity Survey is a 2-item survey that assesses two categories of physical activity - work and leisure. There are five options for degree of activity to choose from in each of the two areas of activity. Activity categories (inactive, light-intensity activity, moderate-intensity activity, hard-intensity activity, and very hard-intensity) are represented in a table of different patterns. Degree of work activity is represented on the vertical axis and degree of leisure activity is represented on the horizontal axis. The overall activity level category is determined by where the two responses intersect., 12 months|Smoking Status, 12 months|Medication Adherence as Measured by Morisky Adherence Survey MMAS8, Scores of the MMAS-8 range from 0 to 8. A score below 6 indicates low adherence, a score between 6 \< 8 medium adherence and a score of 8 high adherence., 12 months|Weight, Weight in kg, 12 months|Waist Circumference, Waist circumference in cm, 12 months|Systolic Blood Pressure, Systolic blood pressure in mmHg, 12 months|Diastolic Blood Pressure, Diastolic blood pressure in mmHg, 12 months|High-density Lipoprotein (HDL), High-density lipoprotein (HDL) in mg/dL, 12 months|Low-density Lipoprotein (LDL), Low-density lipoprotein (LDL) in mg/dL, 12 months|Triglycerides, Triglycerides in mg/dL, 12 months","Fasting Blood Glucose, Adjusted for baseline, 12 months|Body Mass Index (BMI), 12 months|Total Cholesterol, Adjusted for baseline, 12 months|AF Composite Fitness Scores, Last annual fitness exam result, collected as pass or fail, 12 months|Framingham Risk Score (FRS), 12 months|Diabetes Risk Score, 12 months|Perceived Risk for Coronary Heart Disease (CHD), Investigator developed questions assessing level of personal perceived risk, fear, anger, worry regarding CHD risk. The consequences subscale ranges from 6-30. Higher scores on the consequences represent strongly held beliefs about negative consequences of the illness. The personal control subscale ranges from 6-30 and the treatment control subscale ranges from 2-10. Higher scores on the personal control and treatment control represent positive beliefs about the controllability of the illness. The emotional representations scores range from 6-30. Higher score indicates higher levels of worry or anxiety about risk of illness., 6 months|Perceived Risk for Type 2 Diabetes (T2D), Investigator developed questions assessing level of personal perceived risk, fear, anger, worry regarding T2D risk. The consequences subscale ranges from 6-30. Higher scores on the consequences represent strongly held beliefs about negative consequences of the illness. The personal control subscale ranges from 6-30 and the treatment control subscale ranges from 2-10. Higher scores on the personal control and treatment control represent positive beliefs about the controllability of the illness. The emotional representations scores range from 6-30. Higher score indicates higher levels of worry or anxiety about risk of illness., 6 months|Patient Activation Score, Patient activation is the degree to which patients accept an active role in their healthcare, and have the knowledge, skills and confidence to take care of their health. When scored as a continuous variable, the range is from 0 to 100, with higher numbers indicating greater levels of patient activation., 12 months|Stages of Change, These evidence-based questions are validated and based upon the Transtheoretical Model and assess an individual's readiness to make behavioral change in 5 health behavior domains (dietary intake, exercise, weight loss, smoking cessation, and medication adherence)., 6 months|Depression, as Measured by the Beck Depression Inventory (BDI), The Beck Depression Inventory is a 21-item measure that assesses self-reported symptoms of depression. It has been heavily used in research linking depression to heart disease. Scores range from 0-63, with 0 = minimal depression and 63 = severe depression., 6 months|Unmanaged Stress as Measured by the Perceived Stress Scale (PSS), The PSS is a 10 item survey assessing feelings and thoughts of stress. Scores range from 0-40 with higher scores indicating higher perceived stress., 6 months|Social Isolation, Single item to assess for availability of support person, where No=no support person., 6 months",,Duke University,David Grant U.S. Air Force Medical Center,ALL,"ADULT, OLDER_ADULT",NA,220,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,Pro00039569,2013-07,2017-02-01,2017-02-01,2013-06-24,2018-01-31,2018-04-24,"David Grant Medical Center, Fairfield, California, 94535, United States","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/45/NCT01884545/Prot_SAP_000.pdf"
NCT05115175,Acceptability of Self-Led Mindfulness-Based Intervention,https://clinicaltrials.gov/study/NCT05115175,,COMPLETED,"This study had two primary aims. First, the investigators examined the associations between mindfulness and diabetes-related outcomes. It was hypothesized that at baseline, increased mindfulness would be associated with decreased diabetes distress and more optimal glycemic levels and that all three variables would share similar associations with related constructs including greater self-compassion, lower general stress, better psychosocial health, increased diabetes treatment engagement, and greater diabetes-related quality of life. The association between specific aspects of dispositional mindfulness and diabetes distress was also explored. Second, the investigators examined the acceptability, feasibility, and potential utility of self-led MBSR intervention. It was hypothesized that participation in a self-led MBSR intervention would be feasible and acceptable, evidenced by treatment attrition and participant feedback. It was also hypothesized that participants who received the self-led Mindfulness-based stress reduction (MBSR) intervention would experience increased mindfulness and decreased diabetes distress compared to a waitlist control group.",NO,"Diabetes Mellitus, Type 1",BEHAVIORAL: Mindfulness-Based Stress Reduction,"Change from Baseline in Mindfulness as Assessed by Mindful Attention Awareness Scale-Adolescent (MAAS-A), Assessed difference in dispositional mindfulness in adolescents from pre-intervention to post-intervention. The Mindful Attention Awareness Scale-Adolescent has a single-factor structure with 14 items rated on a 6-point scale (1 = almost always, 6 = almost never). Higher scores indicate higher trait mindfulness., 10 weeks intervention, 20 weeks waitlist|Change from Baseline in Engagement in Self-Compassionate Behavior as Assessed by Self-Compassion Scale (SCS), Participants rated how often they engage in each self-compassionate behavior in specific situations pre- and post-intervention. The Self-Compassion Scale is a 26-item measure rated on a 5-point scale (1 = almost never, 5 = almost always). Higher scores indicate higher self-compassion., 10 weeks intervention, 20 weeks waitlist|Change from Baseline in Diabetes Stress as Assessed by Diabetes Stress Questionnaire (DSQ), Assessed different daily, diabetes-specific stressors from pre-intervention to post-intervention. The Diabetes Stress Questionnaire consists of 65 items and includes eight subscales. Participants rate severity of stress across several diabetes-related scenarios on a 4-point scale (0 = not at all, 3 = very much). Higher scores indicate higher diabetes distress., 10 weeks intervention, 20 weeks waitlist|Change from Baseline in Health-Related Quality of Life as Assessed by Pediatric Quality of Life Inventory (PedsQL) 3.2 Diabetes Module, Assessed diabetes-specific, health-related quality of life in children, adolescents, and young adults from pre-intervention to post-intervention. The Pediatric Quality of Life Inventory 3.2 Diabetes Module consists of 33 items rated on a 5-point scale (0 = never, 4 = almost always). Higher scores indicate greater quality of life., 10 weeks intervention, 20 weeks waitlist|Change from Baseline in Perceived Stress as Assessed by Perceived Stress Scale-10 Item Version (PSS-10), Assessed the severity of broad, stressful situations in adolescents from pre-intervention to post-intervention. Participants rank how often each statement applies to their feelings of stress on a 5-point scale (0 = never, 4 = very often). Negative items are reversed and the sum of all 10 items is calculated. Higher scores indicate higher perceived stress., 10 weeks intervention, 20 weeks waitlist|Change from Baseline in Psychosocial Impairment as Assessed by Pediatric Symptoms Checklist-17 (PSC-17), Assessed psychosocial functioning from pre-intervention to post-intervention. Participants rate how frequently each symptom occurs on a 3-point scale (0 = never, 2 = often). Total scores range from 0-34 with higher scores indicating greater risk of psychosocial impairment., 10 weeks intervention, 20 weeks waitlist|Change from Baseline in Diabetes Treatment Engagement as Assessed by Self Care Inventory (SCI), Assessed to what degree individuals follow health care provider guidelines for diabetes-management behaviors from pre-intervention to post-intervention. The investigators removed the item ""how frequently do you come in for appointments"" from the study as the measure was not used within a physician/ appointment context. After removing the item, the Self Care Inventory consisted of 22 items and is rated on a 5-point scale (1 = never, 5 = always). Higher scores indicate higher diabetes treatment engagement., 10 weeks intervention, 20 weeks waitlist|Change from Baseline in Glycosylated Hemoglobin Percentage, Assessed the difference in glycosylated hemoglobin percentage from pre-intervention to post-intervention., 10 weeks intervention, 20 weeks waitlist|Engagement with the Scaled Mindfulness-Based Intervention as Assessed by Number of Weekly Surveys Completed., Assessed the number of weekly surveys each participant completed during the intervention period. Participants were asked to complete at least 6 out of the 10 weekly surveys during the intervention period to be considered highly engaged., 20 weeks|Feasibility of the Scaled Mindfulness-Based Intervention as Assessed by Participant Feedback, Assessed the acceptability and feasibility of a mindfulness-based intervention for teens with type 1 diabetes by examining participant feedback on reasons for attrition and low engagement. Weekly feedback surveys asked about barriers to engaging in the weekly material., 20 weeks",,,"University of Nevada, Reno",AlterMed Research foundation,,"CHILD, ADULT",NA,29,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,1221205,2019-07-14,2020-04-17,2020-07-17,2021-11-10,,2021-11-10,"University of Nevada, Reno, Reno, Nevada, 89557, United States","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/75/NCT05115175/Prot_SAP_000.pdf|Informed Consent Form, https://storage.googleapis.com/ctgov2-large-docs/75/NCT05115175/ICF_001.pdf"
NCT03192475,The Pitt Retiree Study: A Diabetes Prevention Program for Medicare Eligible Older Adults,https://clinicaltrials.gov/study/NCT03192475,PRS,COMPLETED,"The Pitt Retiree Study (PRS) disseminates a novel, yet practical, diabetes prevention program among Medicare eligible adults in Western Pennsylvania. This study will provide 4, and 12 month outcome data (with a no treatment follow-up assessment at 24 months) to help determine whether a continued contact group telephone intervention is feasible and effective in enhancing health outcomes and physical functional ability in high risk adults (aged 65-80) with obesity and cardiometabolic risk factors .",YES,Obesity|Cardiovascular Risk Factor|Eating Behavior|Diet Modification|Physical Activity|Quality of Life|Mobility Limitation,BEHAVIORAL: GLB plus phone contacts|BEHAVIORAL: GLB plus newsletter contacts,"Change in Bodyweight, Bodyweight of participant., Change from baseline bodyweight at 12-months","Change in Waist Circumference, Waist circumference measured with a spring-loaded tape measure., Change from baseline circumference at 12-months|Change in Fasting Total Cholesterol, Total cholesterol (mg/dl) measured by finger-stick blood sample, Change from baseline level at 12-months|Change in Fasting High-Density Lipoprotein (HDL) Cholesterol, HDL-cholesterol (mg/dl) measured by finger-stick blood sample, Change from baseline level at 12-months|Change in Fasting Low-Density Lipoprotein (LDL) Cholesterol, LDL-cholesterol (mg/dl) measured by finger-stick blood sample, Change from baseline level at 12-months|Change in Fasting Triglycerides, Triglycerides (mg/dl) measured by fasting finger-stick sample, Change from baseline level at 12-months|Change in Fasting Glucose, Fasting glucose (mg/dl) measured by finger-stick sample, Change from baseline level at 12-months|Change in Systolic Blood Pressure, Systolic blood pressure (mmHg) measured by arm cuff digital blood pressure monitor (OMROM HEM90HXC), Change from baseline level at 12-months|Change in Diastolic Blood Pressure (mmHg), Diastolic blood pressure (mmHg) measured by arm cuff digital blood pressure monitor (OMROM HEM90HXC), Change from baseline value at 12 months|Change in Physical Function Performance Battery, Short Physical Performance Battery (SPPB) total score (0-12) includes three function tests (each scored 0-4) and summed.

The subtests are (1) gait speed measured in meters/second on a 4-meter walk route; (2) 3 progressive standing balance tests; (3) 5 chair stands. Higher score indicates better physical function., Change from baseline score at 12-months|Change in Physical Activity Minutes/Week Using All CHAMPS Items, Community Healthy Activities Model Program for Seniors (CHAMPS) physical activity questionnaire for older adults, Change from baseline minutes/week at 12-months|Percentage Participants Achieving 3 or More Days of Moderate Intensity Physical Activities Per Week, Stanford Brief Physical Activity categorical measure:

Queries amount and intensity of typical weekly activities over the past month.

1. most of week spent without any physical activity; sedentary at home; light chores; high intensity activities no more than 1-2 times per month.
2. most days of week spent doing few activities; 1-2 times per week some light-moderate activity like walking or active chores at home.
3. at least 3 times per week reports moderate activity such as brisk walking for 15-20 minutes or more, or at least 45-60 minutes of heavy home and yard chores.
4. at least 3 times per week reports a regular program of moderate-vigorous intensity physical activities, or a regular program of fitness for 30 minutes or more, or active games like handball or tennis, or heavy home and yard chores for 60-minutes or more.

Participants that endorse items 3 or 4 were considered to have achieved 3 or more days of moderate intensity physical activities per week., percentage reporting higher intensity level activities 3 times per week or more at 12 months|Change in Health Related Quality of Life-physical Component Summary Score, Short-form 12-item health status questionnaire produces two scores: a physical component summary score and a mental component summary score. Scores range from 0-100 with higher scores indicating better health related quality of life. Each component score is transformed (standardized) using a mean of 50 and a standard deviation of 10., Change from baseline score at 12-months|Change in Nutrition, Mediterranean Diet Assessment Tool. Total score ranges from 0 - 14. A higher score means higher adherence to a better quality of diet., change from baseline score at 12-months|Change in Mood, Center for Epidemiological Studies Depression Scale (CES-D) (score ranges 0-60; higher score indicates greater depressive symptoms), change from baseline score at 12-months",,University of Pittsburgh,,ALL,OLDER_ADULT,NA,322,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",PRO12050022,2013-01-28,2017-05-26,2017-05-26,2017-06-20,2019-05-09,2019-11-13,,"Informed Consent Form, https://storage.googleapis.com/ctgov2-large-docs/75/NCT03192475/ICF_000.pdf|Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/75/NCT03192475/Prot_SAP_001.pdf"
NCT03369145,"High-fat Overfeeding, Hepatokines and Appetite Regulation",https://clinicaltrials.gov/study/NCT03369145,OVEREAT,COMPLETED,"The present study will investigate the effect of high-fat overfeeding on a group of liver-secreted proteins linked to worsened blood sugar control, as well as proteins involved in appetite control. Participants will consume both a high-fat diet, consisting of 50% extra calories above their daily required intake, and a control diet, consisting of their normal 'habitual' diet, with each diet lasting seven days. The diets will be undertaken in a randomised order, with a period of three weeks separating the two diets. Blood samples will be taken before and after each diet to measure blood sugar control. Further blood samples will also be taken 24 hours and 72 hours into each diet to see how levels of the liver and appetite-regulating proteins change over the course of the seven days.

It is expected that blood sugar control will be worsened by the high-fat diet and this will be accompanied by increases in levels of the liver-secreted proteins and an impaired release of the appetite-regulating proteins into the blood.",NO,Insulin Resistance|Type2 Diabetes Mellitus|Non-Alcoholic Fatty Liver Disease|Obesity,DIETARY_SUPPLEMENT: High-fat diet,"Leukocyte cell-derived chemotaxin 2 (LECT2), Time-course of LECT2 plasma concentrations across the 7-day dietary interventions, Baseline, 1 day, 3 days, 7 days","Fibroblast growth factor 21 (FGF21), Time-course of FGF21 plasma concentrations across the 7-day dietary interventions, Baseline, 1 day, 3 days, 7 days|Fetuin-A, Time-course of Fetuin-A plasma concentrations across the 7-day dietary interventions, Baseline, 1 day, 3 days, 7 days|Acylated ghrelin, Time-course of acylated ghrelin plasma concentrations across the 7-day dietary interventions, Baseline, 1 day, 3 days, 7 days|Peptide YY (PYY), Time-course of PYY plasma concentrations across the 7-day dietary interventions, Baseline, 1 day, 3 days, 7 days|C-Terminal Telopeptide of Type 1 Collagen (CTX), Time-course of CTX plasma concentrations across the 7-day dietary interventions, Baseline, 1 day, 3 days, 7 days|N-Terminal Propeptide of Type 1 Procollagen (P1NP), Time-course of P1NP plasma concentrations across the 7-day dietary interventions, Baseline, 1 day, 3 days, 7 days|Visual Analogue Scale for Subjective Ratings of Appetite, Time-course of subjective ratings of hunger across the 7-day dietary interventions, measured using an appetite visual analogue scale. The scale is divided into subscales of different appetite perceptions including: hunger, fullness, satisfaction and prospective food consumption. Each subscale is rated on a 100mm scale (i.e. from 0 - 100), with a rating of 100 fully supporting the perception and a rating of 0 fully opposing the perception., Baseline, 1 day, 3 days, 7 days|Subjective food preference, Time-course of subjective food preference across the 7-day dietary interventions, measured using the Leeds Food Preference Questionnaire., Baseline, 1 day, 3 days, 7 days|Whole-body insulin sensitivity, Changes in whole-body insulin sensitivity using the Matsuda Index, calculated from plasma glucose and insulin concentrations during the oral glucose tolerance test, Baseline, 7 Days|Homeostasis model assessment of insulin resistance (HOMA-IR), Changes in HOMA-IR (a marker of hepatic insulin resistance) using baseline concentrations of plasma glucose and insulin., Baseline, 1 day, 3 days, 7 days|Adipose tissue insulin resistance (ADIPO-IR), Changes in ADIPO-IR using baseline concentrations of plasma insulin and non-esterified free fatty acids., Baseline, 1 day, 3 days, 7 days|Physical activity and sedentary behaviour, Amounts of sitting time, standing time, light activity and moderate-vigorous activity will be measured across the duration of each diets to compare between the two. This will be Measured using Acitgraph and ActivPAL monitors., 7 days (per diet)|Resting Metabolic Rate, Changes in resting metabolic rate in response to the diets will be measured using indirect calorimetry and estimated using the Haldane transformation., Baseline, 7 Days|Fat Oxidation, Changes in fat oxidation in response to the diets will be measured using indirect calorimetry and estimated using the Haldane transformation., Baseline, 7 Days|Blood pressure, Changes in blood pressure (systolic and diastolic) across the two dietary interventions will be measured using an automated pressure cuff., Baseline, 1 day, 3 days, 7 days|Body weight, Changes in body weight across the two dietary interventions., Baseline, 1 day, 3 days, 7 days|Body fat percentage, Changes in body fat percentage across the two dietary interventions using bioelectrical impedance analysis., Baseline, 7 Days",,Loughborough University,Nottingham Trent University|Nottingham University Hospitals NHS Trust,MALE,ADULT,NA,12,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE,R17-P144,2017-12-11,2018-07-31,2018-07-31,2017-12-11,,2019-02-18,"National Centre for Sport and Exercise Medicine, Loughborough University, Loughborough, Leicestershire, LE11 3TU, United Kingdom|Clifton Campus, Nottingham Trent University, Nottingham, Nottinghamshire, NG1 4FQ, United Kingdom","Study Protocol, https://storage.googleapis.com/ctgov2-large-docs/45/NCT03369145/Prot_000.pdf|Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/45/NCT03369145/SAP_001.pdf|Informed Consent Form, https://storage.googleapis.com/ctgov2-large-docs/45/NCT03369145/ICF_002.pdf"
NCT04621045,Active You: Feasibility of a Unique Physical Activity Program to Prevent Diabetes and Heart Disease,https://clinicaltrials.gov/study/NCT04621045,,COMPLETED,"Individuals who are overweight/obese are more vulnerable to type 2 diabetes (T2D). Current evidence suggests that PA, even without dietary prescription, can be efficacious in preventing T2D. Yet most Americans, especially those who are overweight/obese, are not physically active. Socioenvironmental barriers to physical activity (PA) such as body image concerns and limited access to fitness facilities contribute to the low levels of PA observed in overweight/obese adults. Web-based PA programs have been developed to address these barriers, but the outcomes have been marginal. Qualitative studies suggest that individuals who are overweight/obese prefer PA programs that feature people they can relate to especially in body size, fitness status and age. Previously, the investigators have included these preferences in a technology-based Physical Activity for The Heart (PATH) intervention that leverages open source platforms, such as YouTube, to promote PA in any setting. In this application, the investigators propose to test the feasibility and preliminary efficacy of PATH in promoting PA and reducing cardiometabolic risk in adults who are overweight/obese and at high risk of diabetes. In Aim 1 the investigators will conduct a 12-week randomized clinical trial including 52 adults who are overweight/obese and at high risk of diabetes to assess the feasibility and acceptability of PATH. In Aim 2 investigators will examine the trend in PA and cardiometabolic risk change from baseline to post-intervention. This approach is innovative because it leverages open source technologies to provide low-cost, action-oriented PA resources that match the preferences of adults who are overweight/obese. This contribution will be significant because PATH could offer a convenient, enjoyable and scalable program that features ""similar others"" to promote PA in overweight/obese adults at high risk of diabetes.",NO,Cardiovascular Risk Factor|Prediabetes|Overweight and Obesity|Sedentary Behavior,BEHAVIORAL: The Physical Activity for The Heart (PATH) intervention|BEHAVIORAL: Be Active Your Way Booklet,"Recruitment feasibility, Will be indicated by ability to recruit, screen, and enroll the target sample within 6 months of commencing recruitment, and retention of 80% of the sample., At the end of study approximately 48 weeks after commencement of the study|Feasibility of self-monitoring step count using wrist worn ActiGraph GT9X, will be indicated by the proportion of the sample with 4days per week of valid Actigraph wear time (10hrs) during the entire course of the study., At the end of study approximately 52 weeks after commencement of the study|Acceptability of PATH intervention, Will be indicated by utilization data that will be collected via Web analytics, and a post-intervention survey will assess the intervention acceptability., At the end of study approximately 52 weeks after commencement of the study","Change from baseline in body mass index (BMI) at 12 weeks, BMI will be measured using Fitbit Aria II scale provided to the participant by the study team. The study team will guide the participants on how to measure their BMI and will supervise the measurement via HIPAA compliant Zoom session., Post-intervention at 12 weeks|Change from baseline in body fat percentage at 12 weeks, Body fat percentage will be measured using Fitbit Aria II scale provided to the participant by the study team. The study team will guide the participants on how to measure their body fat and will supervise the measurement via HIPAA compliant Zoom session., Post-intervention at 12 weeks|Change from baseline in waist circumference at 12 weeks, Waist circumference will be measured using Perfect waist tape measure provided to the participant by the study team. The study team will guide the participants on how to take the measurement using a standard video and will be able to observe the outcome of the measurement via HIPAA compliant Zoom session., Post-intervention at 12 weeks|Change from baseline in blood pressure (BP) at 12 weeks, Both diastolic and systolic BP will be reported. The measurement will be done using automated OMRON BP machine provided to the participant by the study team. The study team will guide the participants on how to take blood pressure and will supervise the measurement via HIPAA compliant Zoom session., Post-intervention at 12 weeks|Change from baseline in glycated hemoglobin (HbA1C) at 12 weeks, The sample for HbA1C will be collected by participants at home using the dry blood spot method. The study team will guide the participants on how to take the sample using a standard video and will supervise the collection via HIPAA compliant Zoom session. The sample will be processed by CoreMedica lab using standard protocols, Post-intervention at 12 weeks|Change from baseline in lipids at 12 weeks, The blood sample for lipids (LDL, HDL, and total cholesterol) will be collected by participants at home using the dry blood spot method. The study team will guide the participants on how to take the sample using a standard video and will supervise the collection via HIPAA compliant Zoom session. The sample will be processed by CoreMedica lab using standard protocols., Post-intervention at 12 weeks|Change from baseline in the risk score for diabetes at 12 weeks, The risk score for diabetes will be measured via the American Diabetes Association (ADA) Risk Calculator. The scores range from 0 to 10 with higher scores indicating high risk for developing type 2 diabetes., Post-intervention at 12 weeks|Change from baseline in step count at 12 weeks, Step count will be measured using a wrist worn ActiGraph GT9X link (about half the participants used Fitbit charge 2 due to device defects that we detected with Actigraph GT9X) during the entire study period. The study outcomes will focus on change from baseline to 12 weeks., Post-intervention at 12 weeks|Change from baseline in light physical activity at 12 weeks, Light physical activity will be measured using a waist worn ActiGraph GT3X accelerometer., Post-intervention at 12 weeks|Change from baseline in moderate to vigorous physical activity (MVPA) at 12 weeks, MVPA will be measured using a waist worn ActiGraph GT3X accelerometer., Post-intervention at 12 weeks|Change from baseline in Barriers Exercise Self-efficacy (BARSE) scale at 12 weeks, Participants will be asked to respond to the BARSE scale appraising their exercise self-efficacy. The scale range from 0 to 100, with higher scores indicating increased exercise self-efficacy., Post-intervention at 12 weeks",,University of Pittsburgh,,ALL,"ADULT, OLDER_ADULT",NA,52,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,STUDY19090134,2020-10-27,2022-03-12,2022-03-12,2020-11-09,,2022-10-07,"Primay Health Network, Beaver Falls, Pennsylvania, 15010, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, 15261, United States","Informed Consent Form, https://storage.googleapis.com/ctgov2-large-docs/45/NCT04621045/ICF_000.pdf"
NCT05433415,Black Girls Move Physical Activity and Improving Dietary Intake Among Black Adolescent Daughters,https://clinicaltrials.gov/study/NCT05433415,,RECRUITING,"Black Girls Move is a school-linked daughter/mother physical activity and dietary behavior program, with 9th and 10th grade students. This program is designed to prevent obesity in Black adolescent females and thus aligns with the NIH mission to enhance health, lengthen life, and reduce illness and disability. This project is relevant to public health because it holds the potential to reduce population health disparities impacted by structural racism.",NO,Adolescent Obesity|Diabetes Mellitus,BEHAVIORAL: Black Girls Move,"Change from Actigraph GT3X Device at 12 and 24 weeks, Objective measure of daughter and mother daily steps and activity counts. PA levels operationalized as moderate (1500-2600 counts/30 secs) or vigorous (\>2600 count/30 secs). Device worn for one week during waking hours, Baseline, 12 weeks, and 24 weeks|Change from Block Kids 2004 Food Frequency Questionnaire (BKFFQ) at 12 and 24 weeks, A 72-item self-report measure of daughter dietary behavior over the past week. Participants indicate frequency of consumption of food/beverages on a 6-point scale (none to every day)., Baseline, 12 weeks, and 24 weeks","Change from 3-Day Physical Activity Recall at 12 and 24 weeks moderate/vigorous physical activity per week, A 59-item self-report measure of daughter physical activity. Participants recall 59 physical activity activities in the past 3 days. Each day divided into 34, 30-minute blocks from 7 am to midnight. Activities rated as light, moderate, hard, or very hard., Baseline, 12 weeks, and 24 weeks|Change from The Multidimensional Model of Black Identity - Short Form at 12 and 24 weeks, A 27-item self-report measure of daughter and mother racial identity., Baseline, 12 weeks, and 24 weeks|Change from Child Health Behavior Knowledge Scale at 12 and 24 weeks, A 9-item self-report measure of daughter and mother physical activity knowledge related to cardiovascular benefits of exercise., Baseline, 12 weeks, and 24 weeks|Change from Diet and Health Knowledge Survey at 12 and 24 weeks, A 42-item self-report measure of daughter and mother diet knowledge., Baseline, 12 weeks, and 24 weeks|Change from Physical Activity and Nutrition Self-Efficacy Scale at 12 and 24 weeks, An 11-item self-report measure of daughter self-efficacy for physical activity (3 items) and nutrition (8 items) behaviors., Baseline, 12 weeks, and 24 weeks|Change from Social Support for Physical Activity at 12 and 24 weeks, An 11-item self-report measure of daughter social support for physical activity., Baseline, 12 weeks, and 24 weeks|Change from Social Support Scale at 12 and 24 weeks, A 5-item self-report measure for daughter and mother social support for healthy eating., Baseline, 12 weeks, and 24 weeks|Change from Family Assessment Device (FAD) at 12 and 24 weeks, A 53-item self-report measure of daughter and mother perceptions of family systems., Baseline, 12 weeks, and 24 weeks|Change fron Quality of Mother Interaction at 12 and 24 weeks, A 14-item self-report measure of daughter perceptions of quality of communication with mother, Baseline, 12 weeks, and 24 weeks","Two-Item Hunger VitalSignTM, A 2-item self-report questionnaire evaluating daughter and mother food insecurity in the past 12 months., Baseline|Change from International Physical Activity Questionnaire at 12 and 24 weeks, A 27-item self-report measure of mother physical activity. Activities pertain to job (7), transportation (6), household (6), recreation (6), and sitting (2). Participants indicate frequency (days), duration (hours/minutes), and intensity (moderate to vigorous) over past 7days., Baseline, 12 weeks, and 24 weeks|Change from 2014 Block Food Frequency Questionnaire at 12 and 24 weeks, A 127-item self-report measure of mother dietary behavior. Items similar to BKFFQ with additional items to adjust for fat, protein, carbohydrate, sugar, and whole grain content, Baseline, 12 weeks, and 24 weeks|Change from Self-Efficacy for Walking Scale at 12 and 24 weeks, A 12-item self-report measure of mother self-efficacy for walking., Baseline, 12 weeks, and 24 weeks|Change from Weight Efficacy Lifestyle Questionnaire at 12 and 24 weeks, A 20-item self-report measure of mother dietary self-efficacy., Baseline, 12 weeks, and 24 weeks",Rush University Medical Center,National Institutes of Health (NIH)|University of Illinois at Chicago|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),FEMALE,"CHILD, ADULT",NA,384,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,R01DK132698|R01DK132698,2023-03-06,2024-07,2025-04,2022-06-27,,2023-12-07,"Rush University Medical Center, Chicago, Illinois, 60612, United States","Informed Consent Form, https://storage.googleapis.com/ctgov2-large-docs/15/NCT05433415/ICF_000.pdf"
NCT04183413,Strengthening Primary Healthcare Delivery for Diabetes and Hypertension in Eswatini,https://clinicaltrials.gov/study/NCT04183413,,RECRUITING,"The WHO-PEN@Scale project is a three-arm cluster-randomized trial that is investigating the population-level effects of a healthcare reform in Eswatini, which aims to strengthen primary care for diabetes and hypertension. Prior to the reform, healthcare for diabetes and hypertension was mostly provided through physician-led teams in hospital outpatient departments. The healthcare reform aims to strengthen the provision of nurse-led care for diabetes and hypertension in primary healthcare facilities and community health worker-led care for these conditions in the facilities' catchment areas. The reform will broadly be guided by the World Health Organization's ""Package of Essential Noncommunicable Disease Interventions for Primary Health Care in Low-Resource Settings"" (WHO-PEN). The trial will take place at 84 clusters (a primary healthcare facility and its catchment area) across the country.",NO,Diabetes Mellitus|Hypertension,OTHER: DSD|OTHER: CDP,"Glycemic control (continuous) among adults with diabetes, Mean glycated haemoglobin (HbA1c) among adults aged 40 years and older with diabetes, 12 months|Systolic blood pressure among adults with hypertension, Mean systolic blood pressure among adults aged 40 years and older with hypertension, 12 months","HbA1c among adults with diabetes or prediabetes, Mean glycated haemoglobin (HbA1c) among adults aged 40 years and older with diabetes or prediabetes, 12 months|Glycemic control (binary) among adults with diabetes, The proportion of adults aged 40 years and older with diabetes who have an HbA1c less than 7.0%, 12 months|Glycemic control (binary) among adults with diabetes or prediabetes, The proportion of adults aged 40 years and older with diabetes or prediabetes who have an HbA1c less than 7.0%, 12 months|Awareness of one's diabetes diagnosis, The proportion of adults aged 40 years and older with diabetes who report to have been diagnosed with diabetes prior to the household survey, 12 months|Awareness of one's diabetes or prediabetes diagnosis, The proportion of adults aged 40 years and older with diabetes or prediabetes who report to have been diagnosed with diabetes or prediabetes prior to the household survey, 12 months|Probability of being treated for diabetes among adults with diabetes, The proportion of adults aged 40 years and older with diabetes who report to be taking medication for their diabetes, 12 months|Probability of having been tested for diabetes among adults with diabetes, The proportion of adults aged 40 years and older with diabetes who report to have ever been tested for diabetes, 12 months|Probability of having been tested for diabetes among adults with diabetes or prediabetes, The proportion of adults aged 40 years and older with diabetes or prediabetes who report to have ever been tested for diabetes, 12 months|Probability of smoking among adults with diabetes, prediabetes, or hypertension, The proportion of adults aged 40 years and older with diabetes, prediabetes, or hypertension who report to be a current smoker, 12 months|Time spent doing moderate- or vigorous-intensity exercise among adults with diabetes, prediabetes, or hypertension, The mean number of minutes in a typical week spent doing moderate- or vigorous-intensity exercise among adults aged 40 years and older with diabetes, 12 months|Systolic blood pressure among adults with diabetes, Mean systolic blood pressure among adults aged 40 years and older with diabetes, 12 months|Systolic blood pressure among adults with diabetes or prediabetes, Mean systolic blood pressure among adults aged 40 years and older with diabetes or prediabetes, 12 months|Diastolic blood pressure among adults with diabetes, Mean diastolic blood pressure among adults aged 40 years and older with diabetes, 12 months|Diastolic blood pressure among adults with diabetes or prediabetes, Mean diastolic blood pressure among adults aged 40 years and older with diabetes or prediabetes, 12 months|Hypertension control (binary) among adults with hypertension, The proportion of adults aged 40 years and older with hypertension who have a systolic blood pressure \<140 mm Hg and a diastolic blood pressure \<90 mm Hg, 12 months|Diastolic blood pressure among adults with hypertension, Mean diastolic blood pressure among adults aged 40 years and older with hypertension, 12 months|Awareness of one's hypertension diagnosis, The proportion of adults aged 40 years and older with hypertension who report to have been diagnosed with hypertension prior to the household survey, 12 months|Probability of being treated for hypertension among adults with hypertension, The proportion of adults aged 40 years and older with hypertension who report to be taking blood-pressure-lowering medication, 12 months|Probability of having been tested for hypertension among adults with hypertension, The proportion of adults aged 40 years and older with hypertension who report to have ever had their blood pressure measured, 12 months|Frequency of drinking alcohol in the past 12 months among adults with diabetes, prediabetes, or hypertension, The proportion of adults aged 40 years and older with diabetes, prediabetes, or hypertension who report to having drunk daily, 5-6 days per week, 3-4 days per week, 1-2 days per week, 1-3 days per month, less than once a month, or never over the past 12 months., 12 months|21. Knowledge on diabetes and hypertension among adults with diabetes, prediabetes, or hypertension, The proportion of adults aged 40 years and older with diabetes, prediabetes, or hypertension who correctly responded to each individual question on diabetes and hypertension related knowledge., 12 months",,University Hospital Heidelberg,"Amsterdam Institute for Global Health and Development|Swiss Tropical & Public Health Institute|Clinton Health Access Initiative, Eswatini|University of Gttingen|University of Eswatini|SWABCHA, Eswatini|Diabetes Swaziland",ALL,"ADULT, OLDER_ADULT",NA,3500,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,WHO-PEN@Scale,2021-11-01,2022-12-16,2022-12-16,2019-12-03,,2022-12-15,"Clinton Health Access Initiative, Mbabane, Swaziland","Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/13/NCT04183413/SAP_000.pdf"
NCT05404711,Continuous Glucose Monitors (CGM) for Type 2 Diabetes (T2D) Risk Evaluation,https://clinicaltrials.gov/study/NCT05404711,,COMPLETED,"The purpose of this research study is to determine whether continuous glucose monitors (CGM) are a safe, effective, and acceptable way to evaluate type 2 diabetes risk in youth as compared to the standard 2-hour oral glucose tolerance test (OGTT).

This study will involve wearing a CGM, wearing a physical activity tracker, responding to surveys, and completing at-home glucose and mixed food challenge while wearing the CGM. Subjects will also be asked to complete an interview by phone or videoconference after wearing the CGM.",NO,Overweight and Obesity|PreDiabetes|Insulin Resistance,DEVICE: CGM,"Feasibility of CGM use to determine Type 2 Diabetes Risk, Completeness of CGM data ( 80% of days with data), 10 days","Sensitivity of at-home CGM-measured glucose challenge, Sensitivity of CGM-glucose 2 hours after at-home glucose beverage ingestion to predict OGTT-2h140 mg/dL, 2 Hours|Specificity of at-home CGM-measured glucose challenge, Specificity of CGM-glucose 2 hours after at-home glucose beverage ingestion to predict OGTT-2h140 mg/dL, 2 Hours|Positive predictive value of at-home, CGM-measured glucose challenge, Positive predictive value of CGM-glucose 2 hours after at-home glucose beverage ingestion to predict OGTT-2h140 mg/dL, 2 Hours|Negative predictive value of at-home, CGM-measured glucose challenge, Negative predictive value of CGM-glucose 2 hours after at-home glucose beverage ingestion to predict OGTT-2h140 mg/dL, 2 Hours|Acceptability of CGM use for at-home T2D risk evaluation in youth, Interview-based, 30 minutes",,"Mary Ellen Vajravelu, MD",,ALL,"CHILD, ADULT",NA,40,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,STUDY22030082,2022-10-11,2023-11-21,2023-12-14,2022-06-03,,2023-12-21,"Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, 15224, United States","Informed Consent Form, https://storage.googleapis.com/ctgov2-large-docs/11/NCT05404711/ICF_000.pdf"
NCT03712501,Influence of Prior Walking on Postprandial Metabolism and Endothelial Function.,https://clinicaltrials.gov/study/NCT03712501,,COMPLETED,"The present study will investigate the effect of prior walking on postprandial metabolism and endothelial function in healthy South Asian and White European women.

Participants will complete two, 2-day trials in a random, crossover design separated by at least 3 weeks to control for the menstrual cycle phase.

On day 1, participants will either rest or complete a 60 minute walk at 60% maximal oxygen uptake. On day 2, participants will arrive at 08:00 having fasted overnight and a baseline venous blood sample and endothelial function measurement will be taken. Participants will consume a high-fat breakfast and lunch and 12 subsequent venous blood samples will be taken throughout the day at standardised intervals to measure a variety of coronary heart disease risk markers. A second endothelial function measurement will be completed 2 hours after the breakfast. Blood pressure will be measured every hour.

It is expected that the South Asian participants will have impaired metabolism and endothelial function compared to their European counterparts but the bout of exercise performed on day 1 will mitigate these responses.",NO,"Diabetes Mellitus, Type 2|Cardiovascular Diseases|Endothelial Dysfunction|Insulin Resistance|Oxidative Stress",BEHAVIORAL: Exercise,"Triacylglycerol, Fasting on day 1 and 2. Time-course of plasma triacylglycerol concentrations in response to exercise and/or feeding on day 2., Day 1 fasting. Day 2 fasting, 1.5h, 1.75h, 2h, 3h, 4h, 5h, 5.5h, 5.75h, 6h, 7h, 8h and 9h.","Endothelial function, Changes in endothelial function via flow-mediated dilatation in response to feeding and exercise., Day 1 fasting and 8.75h. Day 2 fasting and 3.5h.|Blood pressure, Changes in blood pressure (systolic and diastolic)., Day 1 fasting. Day 2 fasting and 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h and 9h.|Glucose, Fasting on day 1 and 2. Time-course of plasma glucose concentrations in response to exercise and/or feeding on day 2., Day 1 fasting. Day 2 fasting, 1.5h, 1.75h, 2h, 3h, 4h, 5h, 5.5h, 5.75h, 6h, 7h, 8h and 9h|Total cholesterol, Fasting plasma total cholesterol on day 1 and day 2 of both trials., Day 1 fasting. Day 2 fasting.|Insulin, Fasting on day 1 and 2. Time-course of plasma insulin concentrations in response to exercise and/or feeding on day 2., Day 1 fasting. Day 2 fasting, 1.5h, 2h, 4h, 5h, 5.5h, 7h, 8h.|High-density lipoprotein cholesterol, Fasting high-density lipoprotein cholesterol on day 1 and 2 of both trials., Day 1 fasting. Day 2 fasting.|Low-density lipoprotein cholesterol, Fasting low-density lipoprotein cholesterol on day 1 and 2 of both trials., Day 1 fasting. Day 2 fasting.|Non-esterified fatty acids, Fasting on day 1 and 2. Time-course of plasma non-esterified fatty acid concentrations in response to exercise and/or feeding on day 2., Day 1 fasting. Day 2 fasting, 1.5h, 2h, 4h, 5h, 5.5h, 7h and 9h.|Interleukin-6, Fasting on day 1 and 2. Time-course of plasma interleukin-6 concentrations in response to exercise and/or feeding on day 2., Day 1 fasting. Day 2 fasting, 3h, 6h and 8h.|C-Reactive protein, Fasting on day 1 and 2. Time-course of plasma C-Reactive protein concentrations in response to exercise and/or feeding on day 2., Day 1 fasting. Day 2 fasting, 3h, 6h and 8h.|Peroxiredoxin-4, Fasting on day 1 and 2. Time-course of plasma peroxiredoxin-4 concentrations across day 2 of both trials., Day 1 fasting. Day 2 fasting, 3h, 6h and 8h.|Superoxide dismutase 3, Fasting on day 1 and 2. Time-course of plasma Superoxide dismutase 3 concentrations across day 2 of both trials, Day 1 fasting. Day 2 fasting, 3h, 6h and 8h.",,Loughborough University,"University Hospitals, Leicester",FEMALE,ADULT,NA,24,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: PREVENTION,R16-P188,2017-10-01,2018-12-30,2018-12-30,2018-10-19,,2019-05-14,"National Centre for Sport and Exercise Medicine, Loughborough University, Loughborough, LE11 3TU, United Kingdom","Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/01/NCT03712501/SAP_000.pdf"
NCT06022601,Post Delivery Intervention in Women With Previous Gestational Diabetes Mellitus to Improve Glycaemia,https://clinicaltrials.gov/study/NCT06022601,Post-GDM-DNA,RECRUITING,"STUDY SUMMARY

TITLE Post-delivery intervention in women with previous gestational diabetes mellitus for weight loss, glycaemia and cardiovascular health DESIGN Feasibility study Allocation: RCT AIMS To determine the feasibility of a post-delivery intervention to improve glycemia and cardiovascular function and promote weight loss in women who have had gestational diabetes.

OUTCOME MEASURES Primary outcome; Effect of intervention on HbA1c: difference in HbA1c between intervention arm and control arm measured at 12 weeks.

Secondary Outcomes;

* Adherence to intervention;
* Willingness to be randomised to post-delivery intervention;
* Process measures to evaluate patient experience of study and intervention;
* Participants' preferred time to commence the study, within the start date allowance of 6 weeks - 6 month post-delivery.
* Between-arm differences and within-arm differences to evaluate:

  * Effect of intervention on HbA1c at 12 and 24 weeks
  * Effect of intervention on weight and BMI at 12 and 24 weeks
  * Effect of intervention on systolic and diastolic blood pressure at 12 and 24 weeks
  * Effect of intervention on lipid profile (total cholesterol, HDL, LDL) at 12 and 24 weeks
  * Effect of intervention on physical activity at 12 and 24 weeks POPULATION We will recruit 50 women aged 18-45 with previous gestational diabetes and randomise them to 1 of 2 arms to commence study at 6 weeks - 6 months post-delivery. Women starting the study at 13 weeks post-delivery will have their routine post-delivery HbA1c act as baseline HBA1c.

ELIGIBILITY Pregnant women with gestational diabetes (women will be given the option to start the study between 6 weeks and 6 months post-delivery) or women who have given birth in the last 12 months and had gestational diabetes during that pregnancy; aged 18-45; and access to a smartphone with an operating system of iOS 9.0 or above, or Android 5.0 or above.

DURATION Study duration: 1/4/21-1/9/22. Participant duration: 24 weeks",NO,Gestational Diabetes,DEVICE: DNA Nudge,"HbA1c, Glycaemia, 12 weeks","HbA1c, Glycaemia, 24 weeks|Weight, kg, 12 weeks|Weight, kg, 24 weeks|Systolic and diastolic Blood pressure, mmHg, 12 weeks|Systolic and Diastolic Blood pressure, mmHg, 24 weeks",,Imperial College Healthcare NHS Trust,,FEMALE,"ADULT, OLDER_ADULT",NA,50,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,292085,2023-03-01,2024-09-30,2024-09-30,2023-09-05,,2023-09-05,"Imperial College Healthcare NHS Trust, London, W12 0HS, United Kingdom","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/01/NCT06022601/Prot_SAP_000.pdf"
NCT05298111,"Acute Effect of MMT Peel Powder on Glycemic Response, Satiety, and Food Intake in Adults at Risk for Type 2 Diabetes",https://clinicaltrials.gov/study/NCT05298111,,COMPLETED,"Open-label, randomised, placebo-controlled, crossover study with two intervention arms. The study was conducted in 30 respondents and the primary objective is to show an improved glycemic response after Melon Manis Terengganu (MMT) peel powder consumption in people at risk of type 2 diabetes.",NO,At Risk of Type 2 Diabetes Mellitus,OTHER: Formulation 3|OTHER: Control,"Changes in fasting and postprandial blood glucose, Blood glucose were measured using glucometer (Accu Chek Performa, New South Wales, Australia) from finger-prick blood samples according to the standard operating procedure at baseline (0 min), 30, 60, 90 and 120 minutes., Day 1 and 4 of both study visits","Changes in perceived satiety, Perceived satiety measurements were rated using a 10-cm visual analogue scale (VAS) which consisted of hunger (How hungry are you?), fullness (How full are you?), desire to eat (How strong is your desire to eat?), prospective food consumption (How much would you be able to eat right now?) and thirstiness (How thirsty are you?) (Tey, Salleh, Henry, \& Forde, 2017). The scale ranged from 0 (not at all) to 10 (very much) measured at baseline (0 min), 30, 60, 90 and 120 minutes., Day 1 and 4 of both study visits|Changes in food intake, The respondents were asked to record all the food or drink they had consumed including sauces, soup and gravies using household measures once they woke up in the morning until they went to sleep at night., Day 1 and 4 of both study visits","Changes in body weight (kg), Body weight was taken at every study visit., Day 1 and 4 of both study visits|Changes in height (m), Height was taken at every study visit., Day 1 and 4 of both study visits|Changes in body mass index (BMI) (kg/m^2), BMI was calculated using formula = body weight (kg)/height (m)\^2, Day 1 and 4 of both study visits|Changes in % body fat, % body fat was taken at every study visit., Day 1 and 4 of both study visits|Changes in waist circumference (cm), Waist circumference was taken at every study visit., Day 1 and 4 of both study visits|Changes in blood pressure, Blood pressure was measured using an Omron automatic digital blood pressure monitor (Omron HEM-7221) in a seated position at all visits after 5 min of sitting., Day 1 and 4 of both study visits|Habitual food intake, The respondents were instructed to complete a semi-quantitative Food Frequency Questionnaire (FFQ) which was adapted from the Malaysian Adult Nutrition Survey (MANS) (Institute for Public Health, 2014)., Day 0 before the first study visit start date|Habitual physical activity, The physical activity of the respondents was measured by using the International Physical Activity Questionnaire-Short Version (IPAQ-SF) in Malay language that had been pilot tested and pre validated in National Health and Morbidity Survey 2011 (Teh et al., 2014), Day 0 before the first study visit start date",Universiti Sultan Zainal Abidin,National University of Malaysia|Universiti Sains Malaysia,ALL,ADULT,NA,36,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE,RCTOYQ,2021-10-01,2021-11-03,2021-11-03,2022-03-28,,2022-03-28,"Food Preparation and Therapeutic Diet Lab, Faculty of Health Sciences, Universiti Sultan Zainal Abidin, Gong Badak Campus, Kuala Terengganu, Terengganu, 21300, Malaysia","Informed Consent Form, https://storage.googleapis.com/ctgov2-large-docs/11/NCT05298111/ICF_000.pdf"
NCT02673203,Investigation Into the Effects of Blood Glucose Levels Upon Eating Behavior in Lean and Obese Non-diabetic and Diabetic Subjects,https://clinicaltrials.gov/study/NCT02673203,,COMPLETED,To investigate whether the daily glucose profiles as assessed by continuous glucose monitoring for 1 week of normal weight and obese individuals relate to hunger levels and food intake.,YES,Diabetes,DEVICE: Continuous Glucose Monitoring System (CGMS)|BEHAVIORAL: Food log,"Rate of Changing Glucose Level, The CGM sensor measures the glucose levels from the interstitial tissue. Presented is the rate of changing glucose level (mg/dl/min)., 3-5 days|Glucose Peak, The CGM sensor measures the glucose levels from the interstitial tissue. Presented is the glucose peak (mg/dl)., 3-5 days|Glucose Nadir, The CGM sensor measures the glucose levels from the interstitial tissue. Presented is the glucose nadir (mg/dl)., 3-5 days","Difference in Glucose Peak and Nadir, The CGM sensor measures the glucose levels from the interstitial tissue. Presented is the difference in glucose peak and nadir (mg/dl)., 3-5 days|Average Daily Hunger Rating, Average daily hunger was measured using a self-report scale. Hunger is measured on a scale from 1-10. 10 is the most hungry, 1 is the least hungry., 3-5 days|Nutirion Intake: Energy, Data were collected through food journals. Energy and macronutrient composition were calculated from self-reported food records based on Nutrition Data System for Research (NDS-R). Presented is the average daily energy intake (kcal/day)., 3-5 days|Nutirion Intake: Carbohydrate, Data were collected through food journals. Energy and macronutrient composition were calculated from self-reported food records based on Nutrition Data System for Research (NDS-R). Presented is the average daily carbohydrate intake (g/day)., 3-5 days|Nutirion Intake: Fat, Data were collected through food journals. Energy and macronutrient composition were calculated from self-reported food records based on Nutrition Data System for Research (NDS-R). Presented is the average daily fat intake (g/day)., 3-5 days|Nutirion Intake: Protein, Data were collected through food journals. Energy and macronutrient composition were calculated from self-reported food records based on Nutrition Data System for Research (NDS-R). Presented is the average daily protein intake (g/day)., 3-5 days",,Yale University,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),ALL,"ADULT, OLDER_ADULT",NA,31,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,1503015469|1K23DK098286-01A1,2016-02,2017-12-14,2017-12-14,2016-02-03,2020-01-13,2022-05-05,"Yale New Haven Hospital, New Haven, Connecticut, 06519-1362, United States|Yale University School of Medicine, New Haven, Connecticut, 06520, United States","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/03/NCT02673203/Prot_SAP_000.pdf"
NCT03394456,Technology to Improve the Health of Resource-poor Hispanics With Diabetes,https://clinicaltrials.gov/study/NCT03394456,,COMPLETED,"This study evaluates the efficacy and implementation of a telehealth-supported, integrated diabetes group visit program led by Community Health Workers (CHWs). Primary study relates to efficacy and a secondary study addresses mentored implementation.",NO,"Diabetes Mellitus, Type 2",OTHER: diabetes program|OTHER: telehealth training and support for Community Health Workers,"Glycemic control, Hemoglobin A1c (%), At baseline and every 6-months until study completion","Adherence to preventive care guidelines, As measured by placement on a statin, annual urine micro albumin, target A1c, weight loss (if applicable), retinal eye examination, blood pressure targets, serum B12 measurements, vaccinations., pre/post diabetes group visits|Survey, The survey totaled 12 questions and assessed participant satisfaction, mental relaxation, faith/spirituality, and open-ended comments. Questions were ranked as followed: 1-3 (4-point Likert Scale), 4-7 (10-point Likert Scale), 8-11 (open-ended, descriptive), 12 (days of exercise/week). The Use of Mental Stress Management/Relaxation Techniques questionnaire and our pilot study survey templates were used to evaluate patient group visit and CHW satisfaction. We defined acceptability as high (3.5-4/4 or 8-10/10), moderate (2-3.4/4 or 4-7/10), and low (1-1.9/4 or 1-3/10) and totaled the items to create an overall score., at the beginning and end of each cohort (baseline, six-months)|Diabetes-related health, As measured by the Self Management Resource Center Surveys: Diabetes Medications (a 4-question yes/no survey to assess patient medication adherence and understanding of their medications), Self-rated Health (a 1-question ranked on a 5-point scale (1 is excellent, 5 is poor) to determine the patient's view of their health), at the beginning and end of each cohort (baseline, six-months)|Body Mass Index (BMI), Body Mass Index (BMI) (weight in kg/height in m\^2), At baseline and every 6-month until study completion|Blood Pressure, Blood Pressure (mmHg), At baseline and every 6-month until study completion|Barriers to care, We obtain barriers to care data from the CHW-patient mobile health (mHealth) records and chart review, and group into three categories: obtaining medications, appointment access, clinic eligibility. mHealth records were sent to the study physician through a secure, encrypted site on a weekly basis., weekly to bimonthly from baseline to 12-months|longitudinal outcomes, conduct a chart review to determine long-term (until 24-months post group visits) clinical outcomes including blood pressure (mmHg), from the time group visits end and as long as month-24 after|longitudinal outcomes, conduct a chart review to determine long-term (until 24-months post group visits) clinical outcomes including HbA1c (%), from the time group visits end and as long as month-24 after|longitudinal outcomes, conduct a chart review to determine long-term (until 24-months post group visits) clinical outcomes including BMI (kg/m\^2), from the time group visits end and as long as month-24 after","Feasibility and acceptability of telehealth patient, clinician encounters during diabetes group visits, As measured by the Telehealth Usability Questionnaire(21-question survey where 1 is strongly disagree and 5 is strongly agree), At six months after group visits for wait list control Cohort 2|Feasibility and acceptability of telehealth support for community health workers 2, The Diabetes Knowledge Test (University of Michigan, 2015; 23 questions; where a total score of 0 indicates the least and 23 indicates the most diabetes knowledge based on this test), At baseline and six months during Cohort 1 intervention group|Feasibility and acceptability of telemedicine support for community health workers, As measured by a six-month 4-question survey (four open-ended questions i.e., what CHWs liked, disliked, general comments) and a 10-question multiple choice posttest that covers content they were taught the last six months (Vaughan et al, 2018), After each cohort (every six months)|Feasibility and acceptability of telemedicine support for community health workers, As measured by the Telehealth Usability Questionnaire(21-question survey where 1 is strongly disagree and 5 is strongly agree), After Cohort 1|CHW knowledge, As measured by pre- /post-tests. TEST-1 (n=21 questions) and TEST-2 (n=19 questions). Tests were multiple choice with 3-5 answer option and were original to this study., During Cohort 2 at baseline (TEST-1 pretest), 6- (TEST-1 posttest, TEST-2 pretest) and 12-months (TEST-2 posttest)|CHW knowledge, This will be accomplished by the 24-question Starr County Diabetes Knowledge Test, which has shown validity and reliability in English and Spanish. Each of the 24-question has three answer choices. This will be pre/posttest format., During the secondary study, at baseline and 6-months (pre/posttest)|Access to care, As measured by the amount of contact participants had with the clinic during the intervention, from baseline to 12-months",Baylor College of Medicine,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),ALL,"ADULT, OLDER_ADULT",NA,265,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,H-40322|K23DK110341|H-40322,2018-01-13,2022-08-30,2022-08-30,2018-01-09,,2022-09-28,"Baylor College of Medicine, Houston, Texas, 77030, United States","Informed Consent Form, https://storage.googleapis.com/ctgov2-large-docs/56/NCT03394456/ICF_000.pdf"
NCT03406975,Multicenter Endoscopic Sleeve Gastrectomy (ESG) Trial (MERIT Trial),https://clinicaltrials.gov/study/NCT03406975,,COMPLETED,"Endoscopic Sleeve Gastroplasty (ESG) is an endoscopic minimally invasive weight loss procedure where a commercially available, FDA approved, full-thickness endoscopic suturing device (Overstitch; Apollo Endosurgery, Austin, TX) is used to reduce the stomach volume by 80% through the creation of a restrictive endoscopic sleeve. This is accomplished by a series of endoscopically placed full-thickness sutures through the gastric wall, extending from the antrum to the gastroesophageal junction.

Up to 200 participants at 9 locations in the United States will participate in this study.

The ESG procedure has been performed clinically since 2013 in the United States. The investigators are completing this study to compare how effective the ESG is for achieving long-term weight loss when compared to lifestyle modification only, as well as to evaluate the long-term safety and durability of the procedure and its impact on quality of life. Results of this research may help support having this procedure covered by health insurance plans for future patients.",YES,"Obesity|Hypertension|Diabetes Mellitus, Type 2",DEVICE: Overstitch Endoscopic Suture System|BEHAVIORAL: Lifestyle Intervention,"Percentage of Excess Weight Loss (EWL), Percentage of excess weight loss in participants at 12 months from randomization. Calculated as (weight loss/baseline excess weight) x 100, where weight loss is defined as follow-up weight minus the initial weight, and baseline excess weight is defined as index weight minus ideal weight X (X=25 kg/m), 12 months","Number of Participants With 25% EWL, Total number of participants with 25% excess weight loss at 12 months from randomization, 12 months|Number of Participants Off Or With Reduction in Antihypertensive Medications, Total number participants off or with reduction in antihypertensive medications, 12 months|Change in Blood Pressure, Change in blood pressure measured in units of millimeters of mercury (mmHg), Baseline, 12 months|Change in Blood Pressure for ESG Intervention From Baseline to 24 Months, Change in blood pressure for participants that received ESG intervention measured in units of millimeters of mercury (mmHg), Baseline, 24 months|Number of Participants Off or With Reduction in Diabetes Medications, Total number of participants off or with reduction in diabetes medications, 12 months|Change in HgbA1c, Change in HgbA1c levels, Baseline, 12 months|Change in HgbA1c for ESG Intervention From Baseline to 24 Months, Change in HgbA1c levels for participants that received the ESG intervention, Baseline, 24 months|Percentage of Total Body Weight Loss (TBWL), Percentage of total body weight loss in participants, 12 months|Number of Participants to Achieve 5% TBWL, Total number of participants to achieve 5% total body weight loss, 12 months|Number of Participants to Achieve 10% TBWL, Total number of participants to achieve 10% total body weight loss, 12 months|Esophagitis at Repeat Endoscopy, Total number of participants to have esophagitis at repeat endoscopy, 12 months|Change in Impact of Weight on Quality of Life-Lite (IWQOL-Lite), Changes in impact of weight on quality of life score assessed using self-reported IWQOL-lite questionnaire consisting of five domains: physical function (11 items, score range from 11-55 with higher scores indicating more negative outcome), self-esteem (7 items, score range from 7-35 with higher scores indicating more negative outcome), sexual life (4 items, score range from 4-20 with higher scores indicating more negative outcome), public distress (5 items, score range from 5-25 with higher scores indicating more negative outcome), and work (4 items, score range from 4-20 with higher scores indicating more negative outcome)., Baseline, 12 months|Changes in Health Status Survey Scores, Changes in subject's view of health assessed using self-reported SF-36 Health Status Survey consisting of 8 scaled scores: physical function (10-items, score range from 0-100 with higher scores indicating more positive outcome), role limitations due to physical health (4-items, score range from 0-100 with higher scores indicating more positive outcome), role limitations due to emotional problems (3-item, score range from 0-100 with higher scores indicating more positive outcome), energy/fatigue (4-items, score range from 0-100 with higher scores indicating more positive outcome), emotional well-being (5-items, score range from 0-100 with higher scores indicating more positive outcome), social functioning (2-items, score range from 0-100 with higher scores indicating more positive outcome), pain (2-items, score range from 0-100 with higher scores indicating more positive outcome), general health (5-items, score range from 0-100 with higher scores indicating more positive outcome), Baseline, 12 months|Number of Participants With Major Depression or Severe Major Depression at Baseline, Number of participants to identify with major or severe major depression measured using the self-reported Patient Health Questionnaire (PHQ-9). The PHQ-9 is self-reported 9-item questionnaire to assess degree of depression severity with total score range from 0-27 categories were defined as followed: minimal, score \< 10; major depression, 10  score \< 20; severe major depression, x  20, Baseline|Number of Participants With Major Depression or Severe Major Depression at 12 Months, Number of participants to identify with major or severe major depression measured using the self-reported Patient Health Questionnaire (PHQ-9). The PHQ-9 is self-reported 9-item questionnaire to assess degree of depression severity with total score range from 0-27 categories were defined as followed: minimal, score \< 10; major depression, 10  score \< 20; severe major depression, x  20, 12 months|Change in Eating Behaviors, Change in eating behaviors evaluated using the self-reported Three Factor Eating Questionnaire (TFEQ) consisting of 3 domains: cognitive restraint (6-items, score range from 0-100 with higher score indicating more restraint), uncontrolled eating (9-items, score range from 0-100 with lower score indicating more control), and emotional eating (3-items, score range 0-100 with higher score indicating eating with negative emotions), Baseline, 12 months",,Mayo Clinic,"University of Texas|Johns Hopkins University|Brigham and Women's Hospital|NorthShore University HealthSystem|University of Chicago|Orlando Health, Inc.|Cornell University|Avera McKennan Hospital & University Health Center",ALL,"ADULT, OLDER_ADULT",NA,208,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER,17-007934,2017-12-20,2020-10-29,2021-10-15,2018-01-23,2022-08-24,2022-10-18,"Orlando Health, Orlando, Florida, 32806, United States|University of Chicago, Chicago, Illinois, 60637, United States|NorthShore University Health System, Evanston, Illinois, 60201, United States|Johns Hopkins University, Baltimore, Maryland, 21224, United States|Brigham and Women's Hospital, Boston, Massachusetts, 02115, United States|Mayo Clinic in Rochester, Rochester, Minnesota, 55905, United States|Cornell University, New York, New York, 10065, United States|Avera McKennan Hospital & University Health Center, Sioux Falls, South Dakota, 57105, United States|University of Texas, Houston, Texas, 77401, United States","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/75/NCT03406975/Prot_SAP_000.pdf"
NCT02678390,Medium Chain Triglycerides and Aerobic Exercise on Ketone Production in Women With or Without Prediabetes,https://clinicaltrials.gov/study/NCT02678390,MCT+AE,COMPLETED,"The aim of this study is to compare the effect on ketone production of dietary an MCT supplement combined or not with physical exercise in two groups of women (N=10/group), healthy adults and patients with prediabetes. After an evaluation of the metabolism (a 4-hour visit with multiple blood samples) at the beginning of the study, all the participants are taken for one-week the MCT supplement alone follow by a one-week period of taking the MCT supplement in combination with physical exercise. At the end of each period of time, the 4-hour visit for the evaluation of the metabolism is repeated.",YES,Prediabetic State,DIETARY_SUPPLEMENT: MCT|DIETARY_SUPPLEMENT: MCT+ aerobic exercise|DIETARY_SUPPLEMENT: Aerobic exercise|DIETARY_SUPPLEMENT: Control day,"Plasma Ketone Concentrations, Acetoacetate (umol/L) and beta-hydroxybutyrate (umol/L); Called Ketones (mol/L) when combine together The area under the curve (AUC) was calculated according to the trapezoidal method from 0 to 4 h during the visits (interventions) CTL = Metabolic study day (Day 1) MCT = Metabolic study day after 5 days of supplementation (Day 5) AE= Metabolic Study day after acute aerobic exercise (Day 6) AE + MCT = Metabolic Study day after 5 days of aerobic exercise and mct supplementation (Day 11), 5 days","Plasma Glucose Concentrations, Glucose (mmol/L) measured in the plasma The area under the curve (AUC) was calculated according to the trapezoidal method from 0 to 4 h during the visits (interventions) CTL = Metabolic study day (Day 1) MCT = Metabolic study day after 5 days of supplementation (Day 5) AE= Metabolic Study day after acute aerobic exercise (Day 6) AE + MCT = Metabolic Study day after 5 days of aerobic exercise and mct supplementation (Day 11), 5 days|Plasma Triglyceride Concentrations, Triglycerides (mmol/L) measured in the plasma The area under the curve (AUC) was calculated according to the trapezoidal method from 0 to 4 h during the visits (interventions) CTL = Metabolic study day (Day 1) MCT = Metabolic study day after 5 days of supplementation (Day 5) AE= Metabolic Study day after acute aerobic exercise (Day 6) AE + MCT = Metabolic Study day after 5 days of aerobic exercise and mct supplementation (Day 11), 5 days|Plasma Free Fatty Acid Concentrations, Free fatty acids (mmol/L) measured in the plasma The area under the curve (AUC) was calculated according to the trapezoidal method from 0 to 4 h during the visits (interventions) CTL = Metabolic study day (Day 1) MCT = Metabolic study day after 5 days of supplementation (Day 5) AE= Metabolic Study day after acute aerobic exercise (Day 6) AE + MCT = Metabolic Study day after 5 days of aerobic exercise and mct supplementation (Day 11), 5 days|Plasma Insulin Concentrations, Insulin (nmol/L) measured in the plasma The area under the curve (AUC) was calculated according to the trapezoidal method from 0 to 4 h during the visits (interventions) CTL = Metabolic study day (Day 1) MCT = Metabolic study day after 5 days of supplementation (Day 5) AE= Metabolic Study day after acute aerobic exercise (Day 6) AE + MCT = Metabolic Study day after 5 days of aerobic exercise and mct supplementation (Day 11), 5 days",,Universit de Sherbrooke,,FEMALE,"ADULT, OLDER_ADULT",NA,20,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2015-508,2015-09,2017-09,2017-09,2016-02-09,2019-01-31,2020-04-07,"Research Centre on Aging - CSSS-IUGS - CIUSSS de l'Estrie - CHUS, Sherbrooke, Quebec, J1H 4C4, Canada","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/90/NCT02678390/Prot_SAP_000.pdf"
NCT03502304,Concurrent Training and Prediabetes Control,https://clinicaltrials.gov/study/NCT03502304,,COMPLETED,"Despite exercise training decrease blood fasting glicaemy in 'average' terms, there is a wide inter-individual variability after exercise training explored mainly in adults but not in adults with prediabetes comorbidities. Thus, is yet unknown the effects and influence of the concurrent training (CT) eliciting responders (R) and non-responders (NR) cases (i.e., percentage of subjects who experienced a non-change/worsened response after training in some metabolic outcomes).",NO,Metabolic Disturbance,BEHAVIORAL: Endurance training plus resistant training,"Fasting glucose, Change from Baseline in fasting glucose, Baseline and 20-weeks immediately after the interventions ends|Lipoproteins, Change from baseline in lipoproteins, Baseline and 20-weeks immediately after the interventions ends","Body mass, Change from Baseline in body mass, Baseline and 20-weeks immediately after the interventions ends|Waist circumference, Change from Baseline in waist circumference, Baseline and 20-weeks immediately after the interventions ends|Fat mass, Change from Baseline in fat mass, Baseline and 20-weeks immediately after the interventions ends|Lean mass, Change from Baseline in lean mass, Baseline and 20-weeks immediately after the interventions ends|Heart rate at rest, Change from Baseline in heart rate at rest, Baseline and 20-weeks immediately after the interventions ends|Six minutes walking test, Change from Baseline in six minutes walking test, Baseline and 20-weeks immediately after the interventions ends",,Universidad Santo Tomas,Universidad de Los Lagos|Healthcare Center Tomas Rojas|Universidad del Rosario,FEMALE,ADULT,NA,28,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: PREVENTION,9042018,2017-06-10,2018-04-09,2018-04-09,2018-04-18,,2018-05-31,"Cristian Alvarez, Los Lagos, Osorno, 000000000, Chile","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/04/NCT03502304/Prot_SAP_000.pdf"
NCT03689530,Using Peer Support to Aid in Prevention and Treatment in Prediabetes,https://clinicaltrials.gov/study/NCT03689530,UPSTART,COMPLETED,"An estimated 86 million adults in the United States have prediabetes, and low-income Latino and African American adults have disproportionately high rates compared to non-Hispanic adults. Structured lifestyle interventions can prevent or delay type 2 diabetes in these at-risk populations and now are widely offered at community organizations and health systems. Yet, uptake of and engagement in available formal programs is very low. Low-income adults in particular face multiple barriers to navigating, engaging in, and sustaining involvement in available programs and lifestyle behaviors found to decrease progression to diabetes. It is critically important to develop and evaluate innovative approaches to increase uptake, engagement, and maintenance of gains in diabetes prevention activities. Peer support has been shown in the investigators' and others' effectiveness trials to be a sustainable, effective approach for positive behavior change and improved outcomes in adults with diabetes and other chronic conditions. The study team's pilot work suggests such approaches are feasible and acceptable among low-income Latino and African American patients with prediabetes to prevent chronic disease and better navigate their health care systems to obtain healthy lifestyle counseling and support. However, such peer support models among Latino, African American, and other low-income adults with prediabetes have not yet been rigorously evaluated. Accordingly, the study will conduct a parallel, two-arm randomized controlled trial in primary care centers in two different health systems that serve multi-ethnic communities with a high concentration of Latinos and African Americans and diverse socio-economic backgrounds. The study will compare enhanced usual care (providing referrals to diabetes prevention programs and resources) with a model of a structured behavioral change intervention supplementing enhanced referral to programs and resources with peer support to help link adults with prediabetes to existing health system and community diabetes prevention programs, to support their engagement in formal programs, maintain achieved gains, and support participants to initiate and sustain healthy behaviors to prevent diabetes.",YES,PreDiabetes,BEHAVIORAL: Peer Support|BEHAVIORAL: Enhanced Usual Care,"Change in Glycosylated Hemoglobin A1c (HbA1c) at 6 Months, An A1C test measures the percentage of red blood cells that have glucose-coated hemoglobin. This percentage indicates average blood sugar levels over the last 2-3 months. Higher percentages indicate higher levels of blood sugar levels, and an A1c between 5.7% and 6.4% is considered in the prediabetes range. The negative numbers for change over time indicate an improvement because they show a drop in percentages from the baseline percentages., baseline to 6 months|Change in Body Weight at 6 Months, body weight in kilograms, baseline to 6 months","Change in Glycosylated Hemoglobin A1c (HbA1c) at 12 Months, An A1C test measures the percentage of red blood cells that have glucose-coated hemoglobin. This percentage indicates average blood sugar levels over the last 2-3 months. Higher percentages indicate higher levels of blood sugar levels, and an A1c between 5.7% and 6.4% is considered in the prediabetes range. The negative numbers for change over time indicate an improvement because they show a drop in percentages from the baseline percentages., baseline through 12 months|Change in Body Weight at 12 Months, body weight in kilograms, baseline through 12 months|Change in Whether Participant Enrolled in a Formal Program to Prevent Diabetes, one item with yes/no response. Results indicate percentage of participants who responded ""yes."", baseline through 12 months|Change in Number of Sessions Participant Attended in a Formal Program to Prevent Diabetes, one item that asks participant to report number of sessions attended, baseline through 12 months|Change in Frequency and Duration Participant Engages in Moderate to Vigorous Physical Activity as Shown by Minutes Per Week, This combined measure is based on participant-reported frequency and duration of moderate to vigorous physical activity, measured in minutes per week. Frequency and duration were initially registered separately.

Two questions were used to calculated minutes of physical activity per week, asked in both the baseline and 12 months surveys:

Q1. On average, how many days per week do you engage in moderate-to-vigorous physical activity? A1: 0-7, integer response only Q2: On average on those days, how many minutes do you engage in physical activity as this level? A2: open numeric response

A1\*A2 = minutes per week (Physical Activity value)

Minutes of physical activity per week reported in 12 month survey - minutes of physical activity per week in baseline survey = change in minutes per week of physical activity, baseline through 12 months|Change in the Number of Times Drinking Regular Soda or Pop That Contains Sugar, Recorded frequency of consumption in the last 30 days. Participants could report times per day, times per week, or times over past 30 days. These reports were converted to the number of times over past 30 days participants drank regular soda or pop that contained sugar., baseline through 12 months|Change in Patient Activation as Measured by the Patient Activation Measure 13 (PAM-13), PAM-13 is a 13-item scale that measures participant beliefs, perceived knowledge, and confidence for engaging in behaviors related to the participant's health condition. PAM-13 has a 0-100 scale, where a low score indicates low activation (disengaged and overwhelmed) and a high score indicates high activation (patient considers self their own advocate). The difference between the score at 12 months and the score at baseline was calculated., baseline through 12 months|Change in Participant's Perceived Confidence in Their Ability to Take Steps to Prevent Diabetes Using the Williams Perceived Competence Scale, Williams Perceived Competence Scale comprises 4 items measuring the participants' perception of their own ability to take steps to prevent diabetes. Responses for each individual question range from 1 (not at all true) to 7 (very true). The responses to all 4 items were averaged (range: 1-7), with higher scores on the scale indicating higher perceived competence in preventing diabetes., baseline through 12 months|Change in Autonomous Motivation to Prevent Diabetes Using the Treatment Self-Regulation Questionnaire (TSRQ - Autonomous), The Treatment Self-Regulation Questionnaire (TSRQ) consisted of 11 items that measured the participants' perceptions of how true various reasons to take steps to help prevent diabetes may be to the participants.

The TSRQ was split into two measures: autonomous and controlled. The autonomous measure consisted of 4 items that measured participants' autonomous (or internal) perceptions of how true various reasons to take steps to help prevent diabetes may be to the participants.

Responses for each individual question range from 1 (not at all true) to 7 (very true). The responses to all 4-items are averaged (range: 1-7). Higher scores indicate participants agree with more internal reasons for preventing diabetes (ex: wanting to take responsibility for my own health)., baseline through 12 months|Change in the Participant's Level of Social Support Related to Improving Their Own Health Behaviors Using the Change in Health-Specific Social Support Scale, The Health-Specific Social Support Scale consisted of 12 items that asked participants to indicate their level of agreement on a 6-point Likert scale (""Strongly disagree"" \[1\] to ""Strongly agree"" \[6\]) with statements regarding accessibility of any contact they had with people in the past 3 months who were specifically also at risk for developing diabetes and could provide social support in attempts to prevent diabetes via healthy lifestyle changes. Scores for negative statements were reversed, and the total score was the sum of all scores. Total scores can range from 12 (minimum) to 72 (maximum). A higher score indicated a better outcome because it indicated a higher level of reported social support., baseline through 12 months|The Role a Participant's Peer Supporter Played in Assisting Them to Set and Reach Their Goals Using the Goal Setting and Intervention Tailoring Subscale of the Patient Assessment of Chronic Illness Care (PACIC) at 6 Months, The goal setting and intervention tailoring subscale of the Patient Assessment of Chronic Illness Care (PACIC) consisted of 5 questions that ask the participant to state how often their peer supporter engaged in supportive behaviors regarding setting and achieving goals in order to make healthy lifestyle changes. Each question had a range of 1 (None of the time) to 5 (Always). Averaged scores range from 1 (minimum) to 5 (maximum). A higher score indicated a better outcome because it indicated that the peer perceived their partner to be more supportive., 6 months|The Role a Participant's Peer Supporter Played in Assisting Them to Set and Reach Their Goals Using the Goal Setting and Intervention Tailoring Subscale of the Patient Assessment of Chronic Illness Care (PACIC) at 12 Months, The goal setting and intervention tailoring subscale of the Patient Assessment of Chronic Illness Care (PACIC) consisted of 5 questions that ask the participant to state how often their peer supporter engaged in supportive behaviors regarding setting and achieving goals in order to make healthy lifestyle changes. Each question had a range of 1 (None of the time) to 5 (Always). Averaged scores range from 1 (minimum) to 5 (maximum). A higher score indicated a better outcome because it indicated that the peer perceived their partner to be more supportive., 12 months|Participant's Perceived Autonomy Support From Their Peer Supporter Using the Health Care Climate Questionnaire (HCCQ, Long Form) at 6 Months, The Health Care Climate Questionnaire (HCCQ, long form) consisted of 15 items that asked the participant to rank their agreement with statements that indicated degree of autonomy support (Strongly Disagree \[1\] to Strongly Agree \[7\]). Averaged scores ranged from 1 (minimum) to 7 (maximum). A higher the score indicated a better outcome because it indicated that the peer perceived their partner to be more autonomy supportive., 6 months|Participant's Perceived Autonomy Support From Their Peer Supporter Using the Health Care Climate Questionnaire (HCCQ, Long Form) at 12 Months, The Health Care Climate Questionnaire (HCCQ, long form) consisted of 15 items that asked the participants to rank their agreement with statements that indicated degree of autonomy support (Strongly Disagree \[1\] to Strongly Agree \[7\]). Total scores ranged from 1 (minimum) to 7 (maximum). A higher score indicated a better outcome because it indicated that the peer perceived their partner to be more autonomy supportive., 12 months|Change in the Number of Times Drinking Sugary Drinks Besides Pop or Soda, Recorded frequency of consumption in the last 30 days. Participants could report times per day, times per week, or times over past 30 days. These reports were converted to the number of times over past 30 days participants drank sugary drinks besides pop or soda., baseline through 12 months|Change in the Number of Times Eating Fruit, Recorded frequency of consumption in the last 30 days - participants could report times per day, times per week, or times over past 30 days, which was converted to times over past 30 days, baseline through 12 months|Change in the Number of Times Eating Vegetables, One measure that recorded frequency of consumption in the last 30 days - participants could report times per day, times per week, or times over past 30 days, which was converted to times over past 30 days, baseline through 12 months|Change in the Number of Times Eating Meals Cooked With Olive Oil, One measure that recorded frequency of consumption in the last 30 days - participants could report times per day, times per week, or times over past 30 days, which was converted to times over past 30 days, baseline through 12 months|Change in the Number of Times Eating Sweets or Desserts, One measure that recorded frequency of consumption in the last 30 days - participants could report times per day, times per week, or times over past 30 days, which was converted to times over past 30 days, baseline through 12 months|Change in the Number of Times Eating Whole Grain Breads, Whole Grain Pasta, or Brown Rice, One measure that recorded frequency of consumption in the last 30 days - participants could report times per day, times per week, or times over past 30 days, which was converted to times over past 30 days, baseline through 12 months|Change in the Number of Times Eating Breads, Pasta, Rolls, or Rice Made From White, Refined Grains, One measure that recorded frequency of consumption in the last 30 days - participants could report times per day, times per week, or times over past 30 days, which was converted to times over past 30 days, baseline through 12 months|Change in Controlled Motivation to Prevent Diabetes Using the Treatment Self-Regulation Questionnaire (TSRQ - Controlled), The Treatment Self-Regulation Questionnaire (TSRQ) consists of 11 items that measure participants' perceptions of how true various reasons to take steps to help prevent diabetes may be to the participants.

The TSRQ is split into two measures: autonomous and controlled. The controlled measure consists of 7 items that measure participants' controlled (or external) perceptions of how true various reasons to take steps to help prevent diabetes may be to the participants.

Responses for each individual question range from 1 (not at all true) to 7 (very true). The responses to all 7-items are averaged (range: 1-7). Higher scores indicate participants agree with more external behaviors or reasons for preventing diabetes (ex: feeling pressure to do so from others)., baseline through 12 months",,University of Michigan,Kaiser Foundation Research Institute|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),ALL,"ADULT, OLDER_ADULT",NA,450,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,HUM00135745|1R18DK113403-01,2018-10-02,2021-10-25,2022-04-15,2018-09-28,2022-10-27,2023-03-03,"Kaiser Permanente Northern California, Oakland, California, 94611, United States|University of Michigan, Ann Arbor, Michigan, 48109-2800, United States","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/30/NCT03689530/Prot_SAP_000.pdf"
NCT02552355,Milk Protein Feeding After Aerobic Exercise in Older Adults With Pre-diabetes Taking the Biguanide Metformin,https://clinicaltrials.gov/study/NCT02552355,,COMPLETED,"The investigators propose that post-exercise milk protein feeding will enhance the mitochondrial protein synthesis (biogenesis) response to an exercise-training program. In addition, the investigators propose that this stimulatory effect of protein feeding will overcome the potential blunting effect of metformin on exercise responses. The investigators will investigate these outcomes over a 12-week exercise-training program in older adults with pre-diabetes with or without metformin treatment.",YES,Physical Activity,DRUG: Metformin|DRUG: Placebo|DIETARY_SUPPLEMENT: Carbohydrate Beverage|DIETARY_SUPPLEMENT: Protein Beverage,"Mitochondrial Function, Oxygen consumption was assessed via high-resolution mitochondrial respirometry in permeabilized skeletal muscle. This outcome was assessed via 2 different protocols; Protocol 1 was a substrate-uncoupler-inhibitor titration (SUIT) and Protocol 2 was an adenosine diphosphate (ADP) titration. These data are reported as the percent change from baseline compared to 12 weeks., Baseline and 12 weeks|Protein Synthesis, Incorporation of deuterium into proteins to calculate cumulative synthesis rates. Protein synthesis was measured in sub cellular fractions of skeletal muscle including mixed, cytoplasmic and mitochondrial enriched fractions. These data are reported as the mean at 12 weeks., 12 weeks|Body Composition, Dual energy x-ray absorptiometry was used to assess fat-free and fat mass. These data are reported as the mean at baseline (pre) and mean at 12 weeks (post)., Baseline and 12 weeks|Insulin Sensitivity, Oral glucose tolerance test was used to measure whole-body insulin sensitivity. These data are reported as the mean at baseline (pre) and the mean at 12 weeks (post)., Baseline and 12 weeks|Peak Aerobic Capacity, Indirect calorimetry was used to measure peak oxygen consumption during a maximal, graded exercise test. These data are reported as the percent change from baseline compared to 12 weeks., Baseline and 12 weeks|DNA Synthesis, Incorporation of Deuterium Oxide into DNA will be measured before and after the 12 week interventions., Baseline and 12 weeks|Glucose Tolerance, Oral glucose tolerance test was used to measure glucose tolerance. These data are reported as the mean at baseline (pre) and the mean at 12 weeks (post)., Baseline and 12 weeks","Intracellular Signaling Proteins, Protein content of intracellular signaling proteins that are implicated in mitochondrial biogenesis, mitochondrial function and insulin sensitivity were measured by Western blotting. Densitometry results are reported as a ratio of protein divided by total amount of protein expressed. All proteins of interest are expressed as phosphorylated relative to total. These data are reported as the percent change from baseline compared to 12 weeks., Baseline and 12 weeks|Glucose Profiles From Real-Time Continuous Glucose Monitoring, Data derived from Continuous Glucose Monitoring was used to calculate mean glucose and mean average glucose excursions (MAGE). These data are reported as the percent change at baseline (pre), 6-8 weeks (Mid), and 12 weeks (post) ., Baseline, Weeks 6-8, 12 weeks",,Colorado State University,,ALL,"ADULT, OLDER_ADULT",PHASE2,56,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",15-8573H,2015-08,2017-08,2017-08,2015-09-17,2018-11-29,2019-04-30,"Colorado State University, Dept. of Health and Exercise Science, Fort Collins, Colorado, 80523-1582, United States","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/55/NCT02552355/Prot_SAP_000.pdf|Informed Consent Form, https://storage.googleapis.com/ctgov2-large-docs/55/NCT02552355/ICF_001.pdf"
NCT03675165,Can You Reduce Diabetes Symptomatology by Becoming Your 'Best Possible Self': The Role of Stress and Resilience,https://clinicaltrials.gov/study/NCT03675165,,COMPLETED,The purpose of this study is to examine how the 'Best Possible Self' (BPS) intervention influences diabetes symptomatology over a four week period by assessing stress and resilience as mediatory effects. Half of the participants will receive the BPS straight away while the other half will be put on a waiting list and will act as the control group.,NO,"Diabetes Mellitus, Type 2",BEHAVIORAL: Best Possible Self,"Diabetes Symptomatology (assessed using the Diabetes Symptoms Checklist - Revised), Subscales assess the existence of, and the distress caused by, fatigue, cognitive, pain, sensory, cardiology, ophthalmology, hypoglycaemia, and hyperglycaemia symptoms individually. For each sub-scale, participants can score between 0 and 5, with a lower score meaning fewer symptoms and less distress caused by that subset of symptoms. Subscales do not come together to create a total symptomatology score., Four Weeks",,"Self-Reported Stress (assessed using the Perceived Stress Scale), Mediatory Effect. Individual scores are added up and can range from 0-40. A higher score means that the individuals perceives themselves to be more stressed., Four weeks|Self-Reported Resilience (assessed using the Six-Item Brief Resilience Scale), Mediatory Effect. Responses are added up to give a score between 6 and 30. The total sum is then divided by 6 (the number of questions). A higher score indicates a higher level of resilience., Four Weeks|Diabetes Risk (calculated using the Canadian Diabetes Risk Questionnaire), Control Variable. A total risk score is assessed by summing up the scores of each of the 12 questions. Scores range from 0-87. A lower score indicates less risk. Participants with a score of \< 21 are low risk, participants with a score of 21 - 32 are medium risk, and participants with a score of \>32 are high risk., Four Weeks",Liverpool John Moores University,,ALL,"ADULT, OLDER_ADULT",NA,110,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",18/NSP/067,2018-08-28,2019-03-20,2019-03-20,2018-09-18,,2021-02-23,"Liverpool John Moores University, Liverpool, Merseyside, L3 5AF, United Kingdom","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/65/NCT03675165/Prot_SAP_000.pdf|Informed Consent Form, https://storage.googleapis.com/ctgov2-large-docs/65/NCT03675165/ICF_001.pdf"
NCT02068885,Framingham State Food Study,https://clinicaltrials.gov/study/NCT02068885,(FS)2,COMPLETED,"This study will evaluate the effects of dietary composition on energy expenditure and chronic disease risk factors, while also exploring physiological mechanisms underlying these effects.",YES,Obesity|Diabetes|Cardiovascular Disease,BEHAVIORAL: Feeding study,"Total Energy Expenditure, Assessed by Indirect Calorimetry Using Stable Isotopes, Total energy expenditure (TEE), assessed by indirect calorimetry using stable isotopes

Total calories burned: Participants each drank about a cup of water containing special tracers which are measurable when they pass out of the body through urine. They provided a urine sample before they drank the water and then about every other day for the next two (2) weeks.

Change: average (midpoint of test phase, end of test phase) - start of trial, Start of Trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance","Resting Energy Expenditure, Assessed by Indirect Calorimetry Using Respiratory Gas Exchange, Resting energy expenditure, assessed by indirect calorimetry using respiratory gas exchange Calories burned while resting: Participants lied down with head and neck under a clear plastic ""bubble,"" breathing room air. Gases in expired air were collected.

Change: average (midpoint of test phase, end of test phase) - start of trial, Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Physical Activity, Assessed by Accelerometry, Actigraph Accelerometer Change: average (midpoint of test phase, end of test phase) - start of trial An Actigraph Accelerometer measures movement, similar to a pedometer. Data are reported as counts (divided by 1,000) per day. Each participant wore the the accelerometer on the right hip for 7 days at each time point., Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Skeletal Muscle Work Efficiency, Efficiency is expressed as percentage ratio of power generated during cycle ergometry (with conversion of Watts to kcal/min using a factor of 0.01433) to energy expenditure above resting.

Change: end of test phase - start of trial., Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Leptin (Start of Trial), Leptin levels were log transformed for analysis. For reporting, the adjusted means and 95% Confidence Intervals were retransformed to the original units (exp(mean log)exp(mean log)(exp(SE log)-1)).

Changes (see Outcome 6) are expressed in percentage units (100%(exp(change in log)-1)): average (midpoint of test phase, end of test phase) - start of trial, Start of trial (time of randomization, post-weight loss)|Leptin (% Change), Leptin levels were log transformed for analysis. Change (expressed in percentage units, 100%(exp(change in log)-1)): average (midpoint of test phase, end of test phase) - start of trial, Change through 20 weeks' weight loss maintenance|Ghrelin (Start of Trial), Ghrelin levels were log transformed for analysis. For reporting, the adjusted means and 95% Confidence Intervals were retransformed to the original units (exp(mean log)exp(mean log)(exp(SE log)-1)).

Changes (see Outcome 8) are expressed in percentage units (100%(exp(change in log)-1)): average (midpoint of test phase, end of test phase) - start of trial, Start of trial (time of randomization, post-weight loss)|Ghrelin (% Change), Ghrelin levels were log transformed for analysis. Change (expressed in percentage units, 100%(exp(change in log)-1)): average (midpoint of test phase, end of test phase) - start of trial, Change through 20 weeks' weight loss maintenance|1,5-Anhydroglucitol, Biomeasure of carbohydrate intake Change, 10 weeks: midpoint of test phase - start of trial Change, 20 weeks: end of test phase - start of trial, Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Glycemic Control, Assessed by HgA1c, Change, 10 weeks: midpoint of test phase - start of trial. Change, 20 weeks: end of test phase - start of trial., Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Triglycerides, Triglyceride levels were log transformed for analysis. For reporting, the adjusted means and 95% Confidence Intervals were retransformed to the original units Change, 10 weeks: midpoint of test phase - start of trial Change, 20 weeks: end of test phase - start of trial, Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Body Composition (DXA), Body fat, presented as a % of total mass

Participants each had a special scan (x-ray) to measure their amount of body fat. The special x-ray is called ""dual-energy x-ray absorptiometry"" (DXA). They were asked to lie still on a table for x-ray pictures.

Change: end of test phase - start of trial, Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Glucose, Glucose level, fasting blood draw Change: end of test phase - start of trial, Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Change in Lipoprotein Particle Subfraction Distribution, Lipoprotein insulin resistance (LPIR) score was calculated from triglyceride-rich, high-density, and low-density lipoprotein particle (TRL-P, HDL-P, LDL-P) sizes and subfraction concentrations (large/very large TRL-P, large HDL-P, small LDL-P). LPIR score is quantified on a scale of 0-100. Higher scores indicate worse outcome.

Change: end of test phase - start of trial, Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Total Cholesterol, Change: end of test phase - start of trial, Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|HDL-Cholesterol, High-density lipoprotein cholesterol Change, 10 weeks: midpoint of test phase - start of trial. Change, 20 weeks: end of test phase - start of trial., Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Non-HDL-Cholesterol, Calculated by subtracting HDL-cholesterol from total cholesterol. Change: end of test phase - start of trial, Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|LDL-Cholesterol, Low-density-lipoprotein cholesterol Change: end of test phase - start of trial, Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Adiponectin (Start of Trial), Total and high molecular weight adiponectin Adiponectin levels were log transformed for analysis. For reporting, the adjusted means and 95% Confidence Intervals were retransformed to the original units (exp(mean log)exp(mean log)(exp(SE log)-1)).

Changes (see Outcome 20) are expressed in percentage units (100%(exp(change in log)-1)): end of test phase - start of trial, Start of trial (time of randomization, post-weight loss)|Adiponectin (% Change), Adiponeptin levels were log transformed for analysis. Change (expressed in percentage units, 100%(exp(change in log)-1)): end of test phase - start of trial, Change through 20 weeks' weight loss maintenance|C-reactive Protein (Start of Trial), C-reactive protein, marker of inflammation C-reactive protein levels were log transformed for analysis. For reporting, the adjusted means and 95% Confidence Intervals were retransformed to the original units (exp(mean log)exp(mean log)(exp(SE log)-1)).

Changes (see Outcome 22) are expressed in percentage units (100%(exp(change in log)-1)): end of test phase - start of trial, Start of trial (time of randomization, post-weight loss)|C-reactive Protein (% Change), C-reactive protein, marker of inflammation C-reactive protein levels were log transformed for analysis. Change (expressed in percentage units, 100%(exp(change in log)-1)): end of test phase - start of trial, Change through 20 weeks' weight loss maintenance|IL-6 (Start of Trial), Interleukin-6, marker of inflammation Interleukin-6 levels were log transformed for analysis. For reporting, the adjusted means and 95% Confidence Intervals were retransformed to the original units (exp(mean log)exp(mean log)(exp(SE log)-1)).

Changes (see Outcome 24) are expressed in percentage units (100%(exp(change in log)-1)): end of test phase - start of trial, Start of trial (time of randomization, post-weight loss)|IL-6 (% Change), Interleukin-6, marker of inflammation Interleukin-6 levels were log transformed for analysis. Change (expressed in percentage units, 100%(exp(change in log)-1)): end of test phase - start of trial, Change through 20 weeks' weight loss maintenance|Blood Pressure, Systolic and diastolic blood pressure Change: end of test phase - start of trial, Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Plasminogen Activator Inhibitor-1 (Start of Trial), Plasminogen activator inhibitor-1 levels were log transformed for analysis. For reporting, the adjusted means and 95% Confidence Intervals were retransformed to the original units (exp(mean log)exp(mean log)(exp(SE log)-1)).

Changes (see Outcome 27) are expressed in percentage units (100%(exp(change in log)-1)): end of test phase - start of trial, Start of trial (time of randomization, post-weight loss)|Plasminogen Activator Inhibitor-1 (% Change), Plasminogen activator inhibitor-1 levels were log transformed for analysis. Change (expressed in percentage units, 100%(exp(change in log)-1)): end of test phase - start of trial, Change through 20 weeks' weight loss maintenance|Fibrinogen, Change: end of test phase - start of trial, Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Insulin Secretion Determined as Blood Insulin Concentration 30 Minutes After Oral Glucose (Start of Trial), Insulin level 30 minutes after consuming 75 grams of glucose, Start of trial (time of randomization, post-weight loss)|Thyroxine (T4), thyroid function test, Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Free T4, free thyroxine, thyroid function test, Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Thyroid Stimulating Hormone, Produced by the pituitary gland in the brain. Tells the thyroid gland to make thyroid hormones., Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Reverse T3, thyroid function test, inactive form of triiodothyronine (T3) Lifespan Bio kit was used for analysis. The range of this kit is 250 to 5000 pg/mL, which varies from other commercially available kits (about 10-fold greater values)., Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Urinary Cortisol Excretion, cortisol (stress hormone) excreted in the urine over a 24-hour period, Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Urinary Catecholamine - Adrenaline, catecholamine excreted in the urine over 24 hours, also known as epinephrine, Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Urinary Catecholamine - Dopamine, catecholamine excreted in the urine over 24 hours, Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Urinary Catecholamine - Noradrenaline, catecholamine excreted in the urine over 24 hours, also known as norepinephrine, Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Insulin Sensitivity (Hepatic), Assessed by Frequently-sampled Oral Glucose Tolerance Test, Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Insulin Sensitivity (Systemic), Assessed by Frequently-sampled Oral Glucose Tolerance Test, Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Non-esterified Fatty Acids, Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Serum Ketones/Ketoacids, Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Lactate, Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Metabolic Fuel Concentration in Serum (Glucose, Nonesterified Fatty Acids, Ketones/Ketoacids, Lactate), Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Insulin-like Growth Factor 1 (IGF-1), Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|IGF Binding Proteins, Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Testosterone, Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Estradiol, Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Luteinizing Hormone, Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Follicle Stimulating Hormone, Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Body Weight Change During ad Libitum Feeding, Ad libitum feeding period (weeks 21 and 22 following randomization)|Gut Microbiome Profile, Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Serum Metabolomics Profile, Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Change in Cognitive Function Related to Memory, California Verbal Learning Test - Second Edition \[CVLT-II\] and Digit Span Test, Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Change in Cognitive Function Related to Processing Speed and Executive Function, Trail Making Test Parts A and B \[TMT-A, TMT-B\], Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Change in Self-reported Sleep Quality, Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Change in Self-reported Depression Measure, Beck Depression Inventory-II \[BDI-II\], Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Change in Self-reported Mood/Anxiety, Mood and Anxiety Symptom Questionnaire \[MASQ\], Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Change in Self-reported Food Addiction Score, Yale Food Addiction Scale \[YFAS\], Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Change in Self-reported Emotional Eating Score, Emotional Eating Scale \[EES\], Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Change in Self-reported Binge Eating Score, Binge Eating Scale \[BES\], Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance","Effect Modification by Insulin Secretion of Metabolic Responses to Diet, Effect modifier: Insulin level 30 minutes into an standard OGTT (Insulin-30) Outcome: Total Energy Expenditure Tertiles: Pre-weight-loss Insulin-30 (Low, Moderate, High) Change: average (midpoint of test phase, end of test phase) - start of trial, Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Effect Modification by Insulin Resistance of Metabolic Responses to Diet, Start of (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance|Effect Modification by Amylase Gene Copy Number, Start of trial (time of randomization, post-weight loss) through 20 weeks' weight loss maintenance",Boston Children's Hospital,Framingham State University|Baylor College of Medicine|Nutrition Science Initiative|New Balance Foundation|Many Voices Foundation|Blue Cross Blue Shield,ALL,"ADULT, OLDER_ADULT",NA,234,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,IRB-P00009571,2014-08-17,2017-05,2017-05,2014-02-21,2020-07-24,2022-07-25,"Framingham State University, Framingham, Massachusetts, 01702, United States","Study Protocol, https://storage.googleapis.com/ctgov2-large-docs/85/NCT02068885/Prot_001.pdf|Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/85/NCT02068885/SAP_000.pdf"
NCT03113916,De Por Vida: A Diabetes Risk Reduction Intervention for Hispanic Women,https://clinicaltrials.gov/study/NCT03113916,,COMPLETED,"This pragmatic randomized clinical trial will assess the efficacy, cost, and sustainability of a culturally tailored weight-loss program targeting obese Hispanic women with pre-diabetes or T2D. The intervention will be integrated into patient care at a Federally Qualified Health Center serving over 30,000 low-income patients, and will be delivered by trained clinic staff, with minimal support from research staff. After the effectiveness clinical trial, two cohorts of clinic patients will receive the intervention in a sustainability test.",YES,Diabetes|Weight Loss|PreDiabetes|Obesity,BEHAVIORAL: Behavioural Lifestyle Intervention,"Weight in Kilograms, Comparison of body weight trajectories in kilograms between the intervention and usual-care control groups., Baseline, 6, 12, and 18 months|Waist Circumference in Centimeters, Comparison of waist circumference trajectories in centimeters between the intervention and usual-care control groups., Baseline, 6, 12, and 18 months","Hemoglobin HbA1c % (Transformed Using the Inverse Cube, or 1/HbAlc%^3), Comparison of hemoglobin HbA1c trajectories between the intervention and usual-care control groups.

Because of the severe kurtosis and skewness present in this outcome, a transformation (using the inverse cube, or 1/HbAlc%\^3) was undertaken to better meet the assumptions of the analysis. Thus, the trajectory differences between arms were formally tested using the inverse cube of HbA1c, and back transforming the least square mean estimates from this model will not result in the least square means in the original metric. We performed a sensitivity analysis using the untransformed HbA1c, and that model exhibited poorer model fit. We can present the crude, observed means, or the least square means from the model using the untransformed HbA1c if it is of greater priority to have more direct interpretability of the HbA1c values than using the model that better meets the statistical assumptions., Baseline, 6, 12 and 18 months from enrollment|Fasting Blood Glucose (Fbg; Transformed Using the Inverse Square, or 1/Fbg in mg/dl^2 ), Comparison of fasting blood glucose trajectories between the intervention and usual-care control groups.

Because of the severe kurtosis and skewness present in this outcome, a transformation (using the inverse square, or 1/fasting blood glucose in mg/dl\^2) was undertaken to better meet the assumptions of the analysis. Thus, the trajectory differences between arms were formally tested using the inverse square of fasting blood glucose, and back transforming the least square mean estimates from this model will not result in the least square means in the original metric. We performed a sensitivity analysis using the untransformed fasting blood glucose, and that model exhibited poorer model fit. We can present the crude, observed means, or the least square means from the model using the untransformed fasting blood glucose if it is of greater priority to have more direct interpretability of the fasting blood glucose values than using the model that better meets the statistical assumptions., Baseline, 6, 12, and 18 months|Total Cholesterol, Comparison of total cholesterol trajectories between the intervention and usual-care control groups., Baseline, 6, 12, and 18 months|Number of Fruit Servings Per Day (Transformed Using the Natural Log), Comparison of number fruit servings per day trajectories between the intervention and usual-care control groups.

Because of the severe kurtosis and skewness present in this outcome, a transformation (using the natural log) was undertaken to better meet the assumptions of the analysis. Thus, the trajectory differences between arms were formally tested using the log of the number of fruit servings per day, and back transforming the least square mean estimates from this model will not result in the least square means in the original metric. We performed a sensitivity analysis using the untransformed number of fruit servings per day, and that model exhibited poorer model fit. We can present the crude, observed means, or the least square means from the model using the untransformed number of fruit servings per day if it is of greater priority to have more direct interpretability of the # of fruit servings per day values than using the model that better meets the statistical assumptions., Baseline, 6, 12, and 18 months|Number of Kilocalories, Comparison of the number of kilocalories trajectories between the intervention and usual-care control groups., Baseline, 6, 12, and 18 months|Sugar Intake in Grams, Comparison of the sugar intake in grams trajectories between the intervention and usual-care control groups., Baseline, 6, 12, and 18 months|Dietary Fiber Intake in Grams (Transformed Using the Natural Log), Comparison of the dietary fiber intake in grams trajectories between the intervention and usual-care control groups.

Because of the severe kurtosis and skewness present in this outcome, a transformation (using the natural log) was undertaken to better meet the assumptions of the analysis. Thus, the trajectory differences between arms were formally tested using the log of the dietary fiber intake in grams and back transforming the least square mean estimates from this model will not result in the least square means in the original metric. We performed a sensitivity analysis using the untransformed dietary fiber intake in grams, and that model exhibited poorer model fit. We can present the crude, observed means, or the least square means from the model using the untransformed dietary fiber intake in grams if it is of greater priority to have more direct interpretability of the dietary fiber intake in grams values than using the model that better meets the statistical assumptions., Baseline, 6, 12, and 18 months|Saturated Fat Intake as Percentage of Total Energy Intake, Comparison of the saturated fat intake as percentage of total energy intake trajectories between the intervention and usual-care control groups., Baseline, 6, 12, and 18 months|Number of Vegetable Servings Per Day (Transformed Using the Natural Log), Comparison of the dietary intake of the number of vegetable servings per day trajectories between the intervention and usual-care control groups.

Because of the severe kurtosis and skewness present in this outcome, a transformation (using the natural log) was undertaken to better meet the assumptions of the analysis. Thus, the trajectory differences between arms were formally tested using the log of the number of vegetable servings per day, and back transforming the least square mean estimates from this model will not result in the least square means in the original metric. We performed a sensitivity analysis using the untransformed outcome, and that model exhibited poorer model fit. We can present the crude, observed means, or the least square means from the model using the untransformed number of vegetable servings per day if it is of greater priority to have more direct interpretability of the outcome values than using the model that better meets the statistical assumptions., Baseline, 6, 12, and 18 months","Average Program Cost Per Participant, Average cost per participant of the De Por Vida intervention and enhanced usual care, 12 months|Recruit Participants for Sustainability Phase, Number of participants recruited, Post-intervention for 12 months",Kaiser Permanente,Arizona State University,FEMALE,"ADULT, OLDER_ADULT",NA,195,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",5R01DK099277-04,2014-06-23,2018-03-05,2018-03-05,2017-04-14,2020-02-18,2020-09-23,,"Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/16/NCT03113916/Prot_SAP_000.pdf"
NCT03675360,Low-Carbohydrate Dietary Pattern on Glycemic Outcomes Trial,https://clinicaltrials.gov/study/NCT03675360,ADEPT,COMPLETED,The proposed randomized controlled trial will test the effect of a low-carbohydrate diet on hemoglobin A1c among individuals with elevated hemoglobin A1c that are within the range of prediabetes or diabetes. Results may provide evidence about the role of carbohydrate restriction in individuals with or at high risk of type 2 diabetes.,YES,Diabetes|PreDiabetes|Metabolic Disease|Hyperglycemia|Diet Modification|Glucose Intolerance|Glucose Metabolism Disorders (Including Diabetes Mellitus)|Endocrine System Diseases,BEHAVIORAL: Low-Carbohydrate Diet,"Change in Hemoglobin A1c, 6-month change in Hemoglobin A1c comparing low-carbohydrate arm with usual diet arm, Baseline and six months","Change in Fasting Plasma Glucose, 6-month change in fasting plasma glucose comparing low-carbohydrate arm with usual diet arm, Baseline and six months|Change in Systolic Blood Pressure, 6-month change in systolic blood pressure comparing low-carbohydrate arm with usual diet arm, Baseline and six months|Change in Total-to-HDL-cholesterol Ratio, 6-month change in total-to-HDL-cholesterol ratio comparing low-carbohydrate arm with usual diet arm, Baseline and six months|Change in Body Weight, 6-month change in body weight comparing low-carbohydrate arm with usual diet arm, Baseline and six months","Change in Insulin, 6-month change in fasting insulin comparing low-carbohydrate arm with usual diet arm, Baseline and six months|Change in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR), 6-month change in HOMA-IR comparing low-carbohydrate arm with usual diet arm. HOMA-IR was calculated as fasting insulin (IU/mL) x fasting glucose (mmol/L)/22.5., Baseline and six months|Change in Diastolic Blood Pressure, 6-month change in diastolic blood pressure comparing low-carbohydrate arm with usual diet arm, Baseline and six months|Change in Waist Circumference, 6-month change in waist circumference comparing low-carbohydrate arm with usual diet arm, Baseline and six months|Change in Estimated Atherosclerotic Cardiovascular Disease Risk, 6-month change in estimated 10-year atherosclerotic cardiovascular disease risk comparing low-carbohydrate arm with usual diet arm.

The estimated 10-year cardiovascular disease risk was assessed by 2013 American College of Cardiology/American Heart Association Atherosclerotic Cardiovascular Disease Risk Score, known as the Pooled Cohort Equations. The Pooled Cohort Equations estimate the 10-year primary risk of ASCVD (atherosclerotic cardiovascular disease) among patients without pre-existing cardiovascular disease who are between 40 and 79 years of age. Variables included in the risk score include: gender, age, race, total cholesterol, HDL cholesterol, systolic blood pressure, treatment for blood pressure, diabetes, and smoking status.

Reference: Goff DC, Lloyd-Jones DM et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: A report of the American college of cardiology/American heart association task force on practice guidelines. Vol. 129, Circulation. 2014., Baseline and six months",Tulane University School of Public Health and Tropical Medicine,National Institute of General Medical Sciences (NIGMS),ALL,"ADULT, OLDER_ADULT",NA,150,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2018-053|P20GM109036,2018-09-25,2021-06-21,2021-06-21,2018-09-18,2022-11-28,2023-03-01,"Tulane Office of Health Research, New Orleans, Louisiana, 70112, United States","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/60/NCT03675360/Prot_SAP_000.pdf"
NCT03483129,15-minute Individual Consultation to Improve Blood Glucose Control in Pre-diabetes,https://clinicaltrials.gov/study/NCT03483129,,COMPLETED,"This research will assess the feasibility of conducting a randomised control trial to evaluate the effectiveness of a 15-minute one-to-one consultation to improve blood glucose control in pre-diabetes. The consultation will take the form of a 15-minute one-to-one consultation between a health-care practitioner and the patient in a primary care setting. Patients with a glycated haemoglobin (HbA1c) of between 42 and 47 mmolmol-1 will be identified in general practise and will be eligible to participate. They will attend testing sessions at baseline (before the consultation), and at three months and six months post consultation. Body mass index (BMI), waist and hip girth, blood pressure and body composition will be recorded and blood analysed for HbA1c, cholesterol and dietary components. For a three-week period following each visit, urine will be collected, a 5-ml sample on nine occasions, and physical activity will be recorded in a sub group of participants. Urine will be analysed by flow infusion electrospray mass spectrometry (FIE-MS) to determine the metabolic content, providing an indication of the diet over the three-week sampling period. The research objectives are to assess the effectiveness of recruitment strategy and willingness of patients to engage in, and adhere to, the research process; to determine the impact of consultation on health outcome measures, including HbA1c, and to establish participant and practitioner perspectives of the consultation.",NO,Pre-Diabetes,BEHAVIORAL: Consultation,"Percentage of eligible patients recruited into the study assessed by study attendance and surgery patient records, Quantify the percentage (%) of patients enrolled in the study based on letters of invitation sent to eligible participants from their surgery, Baseline","Change in HbA1c assessed by blood Hba1c assessment, To determine the impact of the consultation on changes in HbA1c (mmol), Change assessed between baseline and 3 months, baseline and 6 months, 3 months and 6 months|Change in BMI assessed by aggregation of height and weight, To determine the impact of the consultation on changes in BMI (kg/m2). Data on height (cm) and weight (kg) aggregated to report BMI., Change assessed between baseline and 3 months, baseline and 6 months, 3 months and 6 months|Change in waist circumference assessed by anthropometric measurement, To determine the impact of the consultation on changes in waist circumference (cm), Change assessed between baseline and 3 months, baseline and 6 months, 3 months and 6 months|Change in hip circumference assessed by anthropometric measurement, To determine the impact of the consultation on changes in hip circumference (cm), Change assessed between baseline and 3 months, baseline and 6 months, 3 months and 6 months|Change in fat percentage assessed by bioelectrical impedance analysis, To determine the impact of the consultation on changes in fat percentage (%), Change assessed between baseline and 3 months, baseline and 6 months, 3 months and 6 months|Change in HDL assessed by blood lipid assessment, To determine the impact of the consultation on changes in HDL (mmol), Change assessed between baseline and 3 months, baseline and 6 months, 3 months and 6 months|Change in LDL assessed by blood lipid assessment, To determine the impact of the consultation on changes in LDL (mmol), Change assessed between baseline and 3 months, baseline and 6 months, 3 months and 6 months|Change in Cholesterol assessed by blood lipid assessment, To determine the impact of the consultation on changes in cholesterol (mmol), Change assessed between baseline and 3 months, baseline and 6 months, 3 months and 6 months|Change in physical activity level assessed by Actigraph and Physical Activity Questionnaire, To determine the impact of the consultation on changes in physical activity (met minutes), Change assessed between baseline and 3 months, baseline and 6 months, 3 months and 6 months|Change in the urinary concentration of metabolites of high health importance assessed by FIE-MS, To determine the impact of the consultation on changes in the concentration urinary of metabolites (M/mM) of high health importance, Change assessed between baseline and 3 months, baseline and 6 months, 3 months and 6 months",,Aberystwyth University,Hywel Dda Health Board,ALL,"ADULT, OLDER_ADULT",NA,23,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,239910,2018-04-25,2019-01-23,2019-01-23,2018-03-30,,2020-02-05,"Carwyn James Building, Aberystwyth, Ceredigion, SY23 3FD, United Kingdom","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/29/NCT03483129/Prot_SAP_000.pdf"
NCT01862029,Effects of Roflumilast on Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals,https://clinicaltrials.gov/study/NCT01862029,,COMPLETED,"Background:

- Roflumilast is a drug used to treat chronic obstructive pulmonary disease (COPD). It is designed to help reduce lung inflammation. However, during testing, roflumilast also appeared to reduce high blood sugar levels in people with COPD and type 2 diabetes. Other tests showed that roflumilast also improved blood sugar levels in people who only had type 2 diabetes. Researchers want to see how roflumilast affects insulin and blood sugar levels in overweight or obese people who are not diabetic, but who have high blood sugar levels.

Objectives:

- To see how well roflumilast improves blood sugar and insulin levels in prediabetic overweight or obese individuals.

Eligibility:

- Individuals between 30 to 65 years old who are overweight or obese (body mass index of 24.9 to 39.9 kg/m2) and have elevated blood sugar levels.

Design:

* This study will last approximately 8 weeks. Participants will have approximately five study visits over about 7 weeks. Two of these visits will be overnight inpatient stays.
* Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. They will also have a 3-day diet and exercise assessment with a dietitian.
* In Week 1, participants will have a special diet for 2 days to keep their regular weight. They will then have a 2-day inpatient stay. During their stay, they will have multiple tests, including blood sugar tests and full body scans. They may provide a fat and muscle tissue biopsy sample. They will then receive the study drug to take during the study.
* In Week 2, participants will repeat the diet study from the screening visit. They will receive a different dose of the study drug.
* In Week 3, participants will review their diet results and have blood and urine tests.
* In Week 5, participants will repeat the diet and exercise study from the screening visit.
* In Week 6, participants will repeat the inpatient studies and tests from Week 1.

In the last week, participants will have a final follow-up visit.",YES,Obesity,DRUG: Roflumilast,"Change in Insulin Sensitivity- Pre-roflumilast, Our primary outcome measure is the change in peripheral insulin sensitivity. The hyperinsulinemic euglycemic clamp procedure's M value, which was obtained before the subjects began roflumilast, was used to assess the primary outcome., Baseline|Change in Insulin Sensitivity - Post-roflumilast, Our primary outcome measure is the change in peripheral insulin sensitivity. The hyperinsulinemic euglycemic clamp procedure's M value, which was obtained post-roflumilast, was used for this primary outcome assessment., 6 weeks",,,"National Heart, Lung, and Blood Institute (NHLBI)",,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,24,NIH,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,130123|13-H-0123,2013-05-22,2017-07-25,2017-07-25,2013-05-24,2018-07-26,2018-09-04,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/29/NCT01862029/Prot_SAP_000.pdf"
NCT02320253,REAL HEALTH-Diabetes: Reach Ahead for Lifestyle and Health-Diabetes,https://clinicaltrials.gov/study/NCT02320253,,COMPLETED,"The goal of this project is to translate the Look AHEAD intensive lifestyle intervention for type 2 diabetes and obesity into usual care at community health centers, comparing an in-person group program (IP), a telephone conference call (TCC) group program, and referral to medical nutrition therapy (MNT), the current standard of care.",YES,Type 2 Diabetes Mellitus|Obesity,BEHAVIORAL: In Person Group (IP)|BEHAVIORAL: Telephone Conference Call Group (TCC)|BEHAVIORAL: Medical Nutrition Therapy (MNT),"Percent Weight Change From Baseline, Percent weight change form baseline; negative values indicate weight loss., Baseline, 6, 12, 24, and 36 months.","Hemoglobin A1c: Change From Baseline, Change in percentage of glycated hemoglobin. Negative values indicate HbA1c reduction (improvement) from baseline., 6, 12, 24 months|Systolic Blood Pressure: Change From Baseline, Blood pressure is reported as change in systolic blood pressure only. Negative values indicate improvement., 6, 12, 24, months.|Triglyceride Levels: Change From Baseline, Triglycerides are measured in mg/dl. Negative values indicate improved triglyceride levels compared to baseline., 6, 12, 24 months|Diet Self-efficacy: Change From Baseline, Diet Self-Efficacy Scale is scored 1-5 with higher scores denoting greater self confidence in managing diet and positive values denoting improved self-confidence in managing diet. Hickey ML, Owen SV, Froman RD. Instrument development: cardiac diet and exercise self-efficacy. Nursing research. 1992;41(6):347-351, 6, 12, 24, and 36 months.|Fat-related Diet Behavior: Change From Baseline., Fat-related diet behavior was scored on a scale of 1 to 5, in which lower scores indicate lower fat dietary habits. Negative values indicate a shift to lower-fat diet behavior.

Kristal AR, Shattuck AL, Henry HJ. Patterns of dietary behavior associated with selecting diets low in fat: reliability and validity of a behavioral approach to dietary assessment. J Am Diet Assoc. 1990;90(2):214-220.

Glasgow RE, Perry JD, Toobert DJ, Hollis JF. Brief assessments of dietary behavior in field settings. Addictive behaviors. 1996;21(2):239-247, Baseline, 6, 12, 24, and 36 months.|Dietary Restraint: Change From Baseline, Dietary restraint was measured by the Dutch Eating Behavior Questionnaire with higher scores (1-5) denoting greater self-regulation of dietary behaviors and positive values denoting improved dietary restraint. Van Strien T, Frijters JER, Defares PB. The Dutch Eating Behavior Questionnaire (DEBQ) for assessment of restrained, emotional, and external eating behavior. International Journal of Eating Disorders. 1986;5(2):295-315., Baseline, 6, 12, 24, and 36 months.|Diabetes Distress: Change From Baseline, Diabetes distress was measured with the Problem Areas in Diabetes Scale. The scale ranges from 0 to 100, in which higher scores indicate greater emotional distress, with a score of 40 marking the threshold for severe emotional distress. Negative values indicate reduction in diabetes-related distress.

Welch GW, Jacobson AM, Polonsky WH. The Problem Areas in Diabetes Scale. An evaluation of its clinical utility. Diabetes Care. 1997;20(5):760-766, Baseline, 6, 12, 24, and 36 months.|Depression Score: Change From Baseline., The PHQ-8 measures depressed mood, with higher scores representing a higher degree of depressed mood and negative values indicating improvement. The range of scores is 0 to 24. Kroenke K, Strine TW, Spitzer RL, Williams JB, Berry JT, Mokdad AH. The PHQ-8 as a measure of current depression in the general population. J Affect Disord. 2009;114(1-3):163-173., Baseline, 6, 12, 24, and 36 months.","Health Economics, Total cost of intervention at 12 months taking into account intervention cost and savings from medication dose reduction. Incremental cost effectiveness and probabilistic sensitivity analyses and further details are reported in: Delahanty LM, Levy DE, Chang Y, Porneala BC, Goldman V, McCarthy J, Bissett L, Rodriguez AR, Chase B, LaRocca R, Wheeler A, Wexler DJ. Effectiveness of Lifestyle Intervention for Type 2 Diabetes in Primary Care: the REAL HEALTH-Diabetes Randomized Clinical Trial. J Gen Intern Med. 2020 Sep;35(9):2637-2646. doi: 10.1007/s11606-019-05629-9. Epub 2020 Jan 21. PMID: 31965526; PMCID: PMC7458982., 12 months",Massachusetts General Hospital,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),ALL,"ADULT, OLDER_ADULT",NA,211,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2014P002074|1R18DK102737-01A1,2014-11,2020-09,2021-07,2014-12-19,2021-07-26,2021-09-20,"Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Charlestown HealthCare Center, Charlestown, Massachusetts, 02129, United States|Chelsea HealthCare Center, Chelsea, Massachusetts, 02150, United States|Revere HealthCare Center, Revere, Massachusetts, 02151, United States","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/53/NCT02320253/Prot_SAP_000.pdf"
NCT03077360,Skeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on Insulin Resistance in Humans,https://clinicaltrials.gov/study/NCT03077360,,COMPLETED,"The rationale for the proposed research is that elucidating changes in localized diacylglycerol (DAG) and sphingolipid species that predict insulin sensitivity will reveal specific localized lipids to target in therapeutics for type 2 diabetes. To attain the overall objective, the investigators propose three specific aims: 1. Identify the influence of sarcolemmal DAG and sphingolipids on cell signaling and insulin sensitivity before and after insulin sensitizing lifestyle interventions. Strong preliminary data shape the hypothesis that sarcolemmal 1,2-disaturated DAG and C18:0 ceramide species will decrease after insulin sensitizing lifestyle interventions, leading to less Protein kinase C (PKC) and Protein phosphatase 2A (PP2A) activation, and enhanced insulin signaling. Skeletal muscle DAG and sphingolipid isomers, species, localization, and de novo synthesis will be measured before and after diet-induced weight loss or exercise training interventions in obese men and women. Insulin sensitivity will be measured using insulin clamps, and muscle lipids using Liquid Chromatography Mass Spectrometry (LC/MS). 2. Determine the impact of mitochondrial/ER (endoplasmic reticulum) DAG and sphingolipids on mitochondrial function and ER stress in vivo, before and after insulin sensitizing lifestyle interventions. The investigators hypothesize, again based on preliminary data, that mitochondrial/ER sphingolipids will decrease, yet DAG will increase after insulin sensitizing lifestyle interventions, and each will associate with increased insulin sensitivity. Changes in sphingolipids will relate to increased mitochondrial function, less ER stress, reactive oxygen species (ROS), and acyl-carnitine formation, while changes in DAG will relate to increased mitochondrial content and dynamics. 3. Identify the effect of exogenous DAG and sphingolipids on mitochondrial function in vitro, before and after insulin sensitizing lifestyle interventions. The working hypothesis is that DAG and sphingolipids will reduce mitochondrial respiration and increase ROS and acyl-carnitine content, but will be attenuated after endurance exercise training. The proposed research is innovative because it represents a substantive departure from the status quo by addressing cellular compartmentalization of bioactive lipids. The investigators contribution will be significant by identifying key species and locations of DAG and sphingolipids promoting insulin resistance, as well as mechanisms explaining accumulation that could be modified by insulin sensitizing therapeutic interventions.",YES,"Diabetes Mellitus, Type 2|Pre-diabetes|Obesity",BEHAVIORAL: Lifestyle,"Percent Change in Insulin Sensitivity Compared to Baseline Measurement., Hyperinsulinemic/euglycemic clamp measured as glucose infusion rate in mg/kg/min., Baseline and 12 weeks|Percent Change in Localized Muscle Lipids Compared to Baseline, We measured changes in sarcolemmal, mitochondrial, nuclear and cytosolic lipids measured in pmol/ug protein after compared to before the interventions, Baseline and 12 weeks|Percent Change in Body Weight Compared to Baseline Measurement, This is the percent change in body weight for each group after the 12 week intervention., Baseline, 3 Months",,,"University of Colorado, Denver",National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),ALL,ADULT,NA,62,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,16-1404|5R01DK111559,2017-02-01,2020-11-19,2020-11-19,2017-03-10,2022-01-06,2022-06-21,"University of Colorado, Aurora, Colorado, 80045, United States","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/60/NCT03077360/Prot_SAP_000.pdf|Informed Consent Form, https://storage.googleapis.com/ctgov2-large-docs/60/NCT03077360/ICF_001.pdf"
NCT02569060,Feeding America Intervention Trial for Health--Diabetes Mellitus,https://clinicaltrials.gov/study/NCT02569060,FAITH-DM,COMPLETED,"The Feeding America Intervention Trial for Health-Diabetes Mellitus (FAITH-DM) is a randomized, controlled study of the implementation of a diabetes intervention in food pantry settings.",NO,Diabetes Mellitus,OTHER: Testing and Monitoring of Blood Glucose Levels|OTHER: Primary care coordination|OTHER: Diabetes-appropriate food packages|BEHAVIORAL: Diabetes self-management education,"Change from Baseline HbA1c at 6 Months, Point-of-care HbA1c testing with the PTS Diagnostics A1CNow+ System, 6 months","Change from Baseline Dietary Intake, Brief fruit \& vegetable dietary screener, 6 months and 12 months|Change from Baseline Health Care Utilization, Communication with primary care provider requesting dates of service, service levels, and diagnosis codes, 6 months and 12 months|Change from Baseline Diabetes Distress, Self-reported distress as assessed by the 2-item emotional burden sub-score of the Diabetes Distress Scale, 6 months and 12 months|Change from Baseline Hypoglycemic events, Self-reported hypoglycemic events over the previous 4 weeks, both any events and number of events, and self-reported severe hypoglycemic episodes, both any events and number of events, 6 months and 12 months|Change from Baseline Depressive symptoms, PHQ-8 (a subset of PHQ-9 scores without assessment of suicidality), 6 months and 12 months|Change from Baseline Medication Adherence, Morisky Medication Adherence Scale (4 items), 6 months and 12 months|Food vs medicine trade-offs, Three self-reported questions, 6 months and 12 months|Change from Baseline Food security status, 6-item version of the USDA's Core Food Security Survey Module, 6 months and 12 months|Change from Baseline Food stability, Two items assessing adequacy of food resources to last the entire month, 6 months and 12 months","Change from Baseline Diabetes Self-Efficacy, 8-item scale of diabetes-specific self-efficacy, 6 months and 12 months|Change from Baseline Diabetes Self-Care, Self-reported assessment of 5 self-care behaviors: medications, exercise, diet, blood sugar monitoring, and foot care, 6 months and 12 months","University of California, San Francisco",Feeding America|Laura and John Arnold Foundation|Urban Institute,ALL,"ADULT, OLDER_ADULT",NA,568,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,A125548,2015-10,2017-10-31,2017-10-31,2015-10-06,,2020-05-18,"Alameda County Community Food Bank, Oakland, California, 94614, United States|University of California San Francisco, San Francisco, California, 94143, United States|Gleaners Community Food Bank of Southeastern Michigan, Detroit, Michigan, 48207, United States|Houston Food Bank, Houston, Texas, 77029, United States","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/60/NCT02569060/Prot_SAP_000.pdf"
NCT04171648,Effect of Dry Roasted Peanuts and Boiled Peanuts on Glycemic Control,https://clinicaltrials.gov/study/NCT04171648,,TERMINATED,"Research on glycemic control related to nuts or whole snack foods has focused primarily on tree nuts. Different processing and cooking methods have not been comprehensively analyzed to observe the effect on nutrient quality, bioavailability, or digestive absorption in peanuts. There is little to no research surrounding the nutrition of boiled peanuts so it may be of interest to compare boiled to roasted peanuts in terms of glycemic control. Peanuts have been shown to have a similar beneficial effect on glycemic control while being more financially accessible than almonds. Glycemic control could be improved based on the low glycemic index, high fiber, lipid, and or protein content of peanuts. The acute trial (phase 1) will investigate the impact of preprandial peanut consumption on glycemic response. The participants will complete an oral glucose tolerance test for both roasted and boiled peanuts. The long term study (phase 2\&3) consists of participants consuming one serving per day of boiled or roasted peanuts in a four week crossover trial to observe any long term impact of daily peanut snacking on glycemic control. (Wash out weeks occurring between all trials.) At the conclusion of phase 2 \& 3 an oral glucose tolerance test will be executed. The subjects will self record a exercise/step count and diet dairy, weight and waist to hip ratio will be measured weekly. The study will aim for a male and/or female healthy population from 18-65 years of age at NCSU.",NO,Diabetes Mellitus|Glycemic Control,OTHER: Roasted Peanut Treatment|OTHER: Boiled Peanut Treatment,"Change from Baseline Blood Glucose Response (Glycemic Response), The blood glucose response will be measured during each oral glucose tolerance test. These tests will happen periodically through out the study to determine if there is any correlation and or significant difference in glycemic response between consuming boiled or roasted peanuts (acute and chronic consumption). The metric is the blood glucose concentration measured by a blood glucose monitor by finger prick 10 times over a two hour period after consuming a standardized 50 gram glucose beverage. The 10 blood glucose measurements are synthesized into one measurement to display a pattern of blood glucose concentrations called the glycemic response.

Please refer to Study Description -Detailed Description for a more thorough explanation., [week 1 - phase 1 - three measurements mon/wed/fri] [week 2 - wash out week] [week 3 & week 4- phase 2 - one measurement at the end of week 4] [week 5 - wash out week] [week 6 & week 7 - phase 3 - one measurement at end of week 7]","weight change, Weight of each participant will be measured to determine any weight loss or gain during the study., Once week one, once week 4, once week 8.|waist to hip ratio, Waist to hip ration of each participant will be measured to further define any weight change during the study., Once week one, once week 4, once week 7.",,North Carolina State University,,ALL,"ADULT, OLDER_ADULT",NA,24,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: PREVENTION,19049,2020-03-02,2020-03-17,2020-03-18,2019-11-21,,2020-10-05,"North Carolina State University, Raleigh, North Carolina, 27607, United States","Informed Consent Form, https://storage.googleapis.com/ctgov2-large-docs/48/NCT04171648/ICF_000.pdf"
NCT03938233,Diabetes Self Management Education Programme in Thailand,https://clinicaltrials.gov/study/NCT03938233,DSMET,UNKNOWN,"Type 2 diabetes is amongst the foremost challenges facing policy makers in Thailand, accounting for considerable death, disability and healthcare expenditure. Under Thailand's strong primary health system, medical management of diabetes is widely available. However, control of blood glucose and other cardiovascular disease risk factors, and regular screening for early detection of complications remain low due to a lack of services for education and counselling to support behavioural changes necessary for good self-management of the condition. A substantial literature documents the effectiveness of Diabetes Self-Management Education (DSME) programs for improving diabetes outcomes, although little high-quality data are available in Thailand, and traditional delivery models (health-professional led one-to-one or small-group sessions) are unlikely to be scalable in Thailand given current human resource and budgetary constraints. Thus, a low-cost DSME program will be developed with a scalable delivery model for roll-out within the Thai primary care system. The intervention will be based on behaviour-change and social support theories, delivered in monthly group meetings by lay health workers or nurses, and aided by a suite of short films to introduce key topics and stimulate discussion. 21 primary care units will be randomised to offer to those with diabetes diagnosed within the first three years. DSME will be delivered by lay health workers, nurses (for comparative effectiveness), or usual care. After 12 months, glycaemic control and cardiovascular risk scores will be compared between the three arms. Cost-effectiveness will be assessed, also process and policy evaluations to produce best-buy recommendations for the Thai Ministry of Public Health.",NO,"Diabetes Mellitus, Type 2",BEHAVIORAL: A low-cost DSME program and scalable delivery model for roll-out within the Thai primary care system,"Hemoglobin A1c levels (HbA1c), HbA1c will measures the average blood glucose (sugar) levels months, 12 months|Total cardiovascular risk, The cardiovascular risk will be estimated by Systemic Coronary Risk Evaluation. (SCORE) model. This is a range from 120 to 180 measuring systolic blood pressure (mmHq)., 12 months","EQ-5D, Quality of Life measure that will also assess cost-effectiveness. Includes five quality of life question on mobility, self-care, usual activity, pain, anxiety / depression and a scale of 0 to 100 on how the person is feeling on that day.

Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The respondent is asked to indicate his/her health state by ticking in the box against the most appropriate statement in each of the 5 dimensions. This decision results in a 1-digit number expressing the level selected for that dimension. The digits for 5 dimensions can be combined in a 5-digit number describing the respondent's health state., 12 months|Hospital Anxiety and Depression scale (HADS), HADS measures depression and anxiety which will address psychological change. Scale is from 0 to 3.

Scale defined as:

Definitely 0 Usually 1 Sometimes 2 Not often 3 Not at all Total score of 21.

Scoring:

Total score:

0-7 = Normal 8-10 = Borderline abnormal (borderline case) 11-21 = Abnormal (case), 12 months|Perceived Stress Questionnaire (PSQ), PSQ will assess stress and ability to self-management. 30 questions on how the person is feeling with a scale from 1 to 4.

0 = Never 1 = Almost Never 2 = Sometimes 3 = Fairly Often 4 = Very Often Scores ranging from 0-13 would be considered low stress. Scores ranging from 14-26 would be considered moderate stress. Scores ranging from 27-40 would be considered high perceived stress., 12 months|Summary of Diabetes Self-Care Activities Assessment (SDSCA), Diabetes self-care activities questionnaire focuses on general diet, diabetes-specific diet, physical activity, blood-glucose testing, foot care, and smoking. With a scale of 0 to 7 with no cut of points. Higher score indicate higher self care activities., 12 months|International Physical Activity Questionnaire, The assessment of physical activity comprises a set of 4 questionnaires. Long (5 activity domains asked independently) and short (4 generic items) versions.There are two forms of output from scoring the IPAQ. Results can be reported in categories (low activity levels, moderate activity levels or high activity levels) or as a continuous variable (MET minutes a week). MET minutes represent the amount of energy expended carrying out physical activity.

Expressed as MET-min per week:

MET level x minutes of activity x events per week

Sample Calculation:

MET levels MET-min/week for 30 min episodes, 5 times/week Walking = 3.3 METs 3.3\*30\*5 = 495 MET-min/week Moderate Intensity = 4.0 METs 4.0\*30\*5 = 600 MET-min/week Vigorous Intensity = 8.0 METs 8.0\*30\*5 = 1,200 MET-min/week

___________________________ TOTAL = 2,295 MET-min/week Total MET-min/week = (Walk METs\*min\*days) + (Mod METs\*min\*days) + Vig METs\*min\*days), 12 months|Body mass index (BMI), Height and weight (used to derive BMI), 12 months","Smoking, Assessing the number of cigarettes smoked through four set questions. Do you currently use tobacco? 0 1 Yes, on a regular basis Number per day: ____________ 02 Yes, but only once in a while 03 Not anymore, I quit 04 No, I have never used tobacco, 12 months",London School of Hygiene and Tropical Medicine,Medical Research Council|Chiang Mai University,ALL,"ADULT, OLDER_ADULT",NA,693,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH,1,2020-03-01,2022-09-01,2023-03-01,2019-05-06,,2020-01-18,,"Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/33/NCT03938233/Prot_SAP_000.pdf|Informed Consent Form, https://storage.googleapis.com/ctgov2-large-docs/33/NCT03938233/ICF_001.pdf"
NCT03854656,Effect of Time-restricted Eating on Behaviour and Metabolism in Overweight Individuals at High Risk of Type 2 Diabetes,https://clinicaltrials.gov/study/NCT03854656,RESET,COMPLETED,The aim of the present study is to investigate effects of 12 weeks time-restricted eating on behaviour and metabolism in individuals with overweight or obesity at high risk of type 2 diabetes.,NO,Overweight and Obesity|PreDiabetes,OTHER: Time-restricted eating,"Change in body weight (kg), Measured in fasted state on a digital scale, Change from baseline to the end of the intervention (after 12 weeks)","Body weight (kg), Measured on a digital scale, Changes from baseline. Fasted state at all four visits (Baseline and after 6, 12, and 26 weeks)|Body mass index (kg/m^2), Calculated from body weight (kg) and height (m), Changes from baseline. Fasted state at all four visits (Baseline and after 6, 12, and 26 weeks)|Fat mass (kg), Measured by Dual-energy X-ray Absorptiometry, Changes from baseline. Fasted state at all four visits (Baseline and after 6, 12, and 26 weeks)|Fat free mass (kg), Measured by Dual-energy X-ray Absorptiometry, Changes from baseline. Fasted state at all four visits (Baseline and after 6, 12, and 26 weeks)|Fat percentage (%), Measured by Dual-energy X-ray Absorptiometry, Changes from baseline. Fasted state at all four visits (Baseline and after 6, 12, and 26 weeks)|Waist circumference (cm), Measured using tape measure, Changes from baseline. Fasted state at all four visits (Baseline and after 6, 12, and 26 weeks)|Hip circumference (cm), Measured using tape measure, Changes from baseline. Fasted state at all four visits (Baseline and after 6, 12, and 26 weeks)|HbA1c (mmol/mol and %), Assessed from blood samples at all visits, Changes from baseline. All four visits (Baseline and after 6, 12, and 26 weeks)|Systolic blood pressure (mmHg), Measured under resting and fasting conditions, Changes from baseline. Measured at all four visits (Baseline and after 6, 12, and 26 weeks)|Diastolic blood pressure (mmHg), Measured under resting and fasting conditions, Changes from baseline. Measured at all four visits (Baseline and after 6, 12, and 26 weeks)|Heart rate (bpm), Measured under resting and fasting conditions during measurements of blood pressure and in the supine position by a handheld ECG measuring device (Vagus), Changes from baseline. Measured at all four visits (Baseline and after 6, 12, and 26 weeks)|Resting energy expenditure (kcal/day), Measured by indirect calorimetry under resting and fasting conditions, Changes from baseline. Measured at visits at baseline and after 12 weeks|Substrate oxidation (respiratory exchange ratio), Measured by indirect calorimetry under resting and fasting conditions, Changes from baseline. Measured at visits at baseline and after 12 weeks|Metabolites, Fasting and postprandial (after a standard mixed breakfast meal) concentrations of metabolites including but not limited to: glucose, lipids, cholesterol, free-fatty acids, and amino acids, Changes from baseline. Measured in the blood in the fasted state at all four visits (Baseline and after 6, 12, and 26 weeks) and during a mixed meal test (4 hours) at baseline and end of the intervention (after 12 weeks)|Hormones, Fasting and postprandial (after a standard mixed breakfast meal) concentrations of hormones related to regulation of appetite, glucose and lipid metabolism (including but not limited to: insulin, glucagon, ghrelin, glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and peptide YY (PYY), leptin, fibroblast growth factor 19 (FGF-19), fibroblast growth factor 21 (FGF-21), growth differentiation factor 15 (GDF-15))., Changes from baseline. Measured in the blood in the fasted state at all four visits (Baseline and after 6, 12, and 26 weeks) and during a mixed meal test (4 hours) at baseline and end of the intervention (after 12 weeks)|Circulating proteins that associate with low-grade inflammation and lipid metabolism, Fasting levels of circulating proteins that associate with low-grade inflammation and lipid metabolism. Such proteins are captured by mass-spectrometry driven analyses of the plasma proteome i.e. proteins circulating in the blood, Changes from baseline. Fasted state at all four visits (Baseline and after 6, 12, and 26 weeks)|Respiratory and glycolytic capacities of isolated peripheral blood mononuclear cells (PBMCs), Measured using the Seahorse method, which measures mitochondrial respiration, Changes from baseline. Fasted state at all four visits (Baseline and after 6, 12, and 26 weeks) and during a mixed meal test at baseline and end of the intervention (after 12 weeks)|Heart rate response to standing up from the supine position, Measured by a handheld ECG measuring device (Vagus)., Changes from baseline. Measured at visits at baseline and end of the intervention (after 12 weeks)|Heart rate response to inhalation and exhalation, Measured by a handheld ECG measuring device (Vagus)., Changes from baseline. Measured at visits at baseline and end of the intervention (after 12 weeks)|Heart rate response to forced exhalation during rest (valsalva maneuver), Measured by a handheld ECG measuring device (Vagus)., Changes from baseline. Measured at visits at baseline and end of the intervention (after 12 weeks)|Gastric emptying time (hours and minutes), Measured using the SmartPill technique. The SmartPill is ingested together with a standard mixed breakfast meal, Changes from baseline. Time after consumption of the standard mixed meal at baseline and end of the intervention (after 12 weeks).|Small bowel transit time (hours and minutes), Measured using the SmartPill technique. The SmartPill is ingested together with a standard mixed breakfast meal, Changes from baseline. Time after consumption of the standard mixed meal at baseline and end of the intervention (after 12 weeks).|Large bowel transit time (hours and minutes), Measured using the SmartPill technique. The SmartPill is ingested together with a standard mixed breakfast meal, Changes from baseline. Time after consumption of the standard mixed meal at baseline and end of the intervention (after 12 weeks).|Total gastrointestinal transit time (hours and minutes), Measured using the SmartPill technique. The SmartPill is ingested together with a standard mixed breakfast meal, Changes from baseline. Time after consumption of the standard mixed meal at baseline and end of the intervention (after 12 weeks).|Motility index, Calculated based on amplitudes and number of contractions measured using the SmartPill technique. The SmartPill is ingested together with a standard mixed breakfast meal, Changes from baseline. Time after consumption of the standard mixed meal at baseline and end of the intervention (after 12 weeks).|Attention measured using eye tracking, Eye tracking metrics including gaze duration bias, gaze direction bias, fixations, saccades, pupil size/dilation, distance to screen, ocular vergence and blinks to measure attention in response to looking at food pictures during the computerized Leeds Food Preference Questionnaire, Changes from baseline. Fasted state at all four visits (Baseline and after 6, 12, and 26 weeks) and during a mixed meal test at baseline and end of the intervention (after 12 weeks)|Emotions measured using facial expression analyses, Facial expression analyses using computer-vision algorithms (AFFDEX) to measure emotions in response to looking at food pictures during the computerized Leeds Food Preference Questionnaire, Changes from baseline. Fasted state at all four visits (baseline and after 6, 12, and 26 weeks) and during a mixed meal test at baseline and end of the intervention (after 12 weeks)|Arousal measured using galvanic skin response, Changes in conductivity of the skin (galvanic skin response) in response to looking at food pictures during the computerized Leeds Food Preference Questionnaire, Changes from baseline. Fasted state at all four visits (Baseline and after 6, 12, and 26 weeks) and during a mixed meal test at baseline and end of the intervention (after 12 weeks)|Food choice, Food choice of food items from four combined food categories (high-fat savoury, high-fat sweet, low-fat savoury and low-fat sweet foods) examined from the computerized Leeds Food Preference Questionnaire. Food choice is determined based on frequency of selection made within each food category. The scores range from 0-48 i.e. 0 = foods within a specific food category have not been selected at all to 48 = foods within a specific food category have been selected 48 times, Changes from baseline. Fasted state at all four visits (Baseline and after 6, 12, and 26 weeks) and during a mixed meal test at baseline and end of the intervention (after 12 weeks)|Implicit wanting, Implicit wanting of food items from four combined food categories (high-fat savoury, high-fat sweet, low-fat savoury and low-fat sweet foods) examined from the computerized Leeds Food Preference Questionnaire. Implicit wanting is assessed based on food choice and response time for selected and non-selected food items as well as mean response time., Changes from baseline. Fasted state at all four visits (Baseline and after 6, 12, and 26 weeks) and during a mixed meal test at baseline and end of the intervention (after 12 weeks)|Explicit liking, Explicit liking of 16 food items from four combined food categories (high-fat savoury, high-fat sweet, low-fat savoury and low-fat sweet foods) examined from the computerized Leeds Food Preference Questionnaire. Explicit liking is rated using visual analogue scales and the range is 0-100. Each end represents the extremes e.g. Question: ""how pleasant would it be to taste this food right now?"" Answer: ""not at all"" (rated 0 on the 0-100 scale) to ""extremely"" (rated 100 on the 0-100 scale), Changes from baseline. Fasted state at all four visits (Baseline and after 6, 12, and 26 weeks) and during a mixed meal test at baseline and end of the intervention (after 12 weeks)|Explicit wanting, Explicit wanting of 16 food items from four combined food categories (high-fat savoury, high-fat sweet, low-fat savoury and low-fat sweet foods) examined from the computerized Leeds Food Preference Questionnaire. Explicit wanting is rated using visual analogue scales and the range is 0-100. Each end represents the extremes e.g. Question: ""how much do you want some of this food now?"" Answer: ""not at all"" (rated 0 on the 0-100 scale) to ""extremely"" (rated 100 on the 0-100 scale)., Changes from baseline. Fasted state at all four visits (Baseline and after 6, 12, and 26 weeks) and during a mixed meal test at baseline and end of the intervention (after 12 weeks)|Insulin sensitivity (indices), Including but not limited to the Matsuda index, At all four visits (Baseline and after 6, 12, and 26 weeks)|Insulin resistance (indices), Including but not limited to Homeostaic Model Assessment for Insulin Resistance (HOMA-IR), At all four visits (Baseline and after 6, 12, and 26 weeks)|Subjective appetite, Rated using visual analogue scales and includes sensations of: Hunger, fullness, satiety, prospective food consumption, wellbeing, nausea, thirst, desire to eat meat, salty, and sweet. The scale range is 0-100 and each end represent the extremes e.g. hunger rating: ""I am not hungry at all"" to ""I have nerver been this hungry before""., Changes from baseline. Fasted state at all four visits (Baseline and after 6, 12, and 26 weeks) and during a mixed meal test at baseline and end of the intervention (after 12 weeks)|Mean amplitude of glycaemic excursions (MAGE), Measured using continous glucose monitoring, Changes from baseline. Measured 7 days after the test days at baseline and after 6 and 12 weeks|Continuous overall net glycaemic action (CONGA), Measured using continous glucose monitoring, Changes from baseline. Measured 7 days after the test days at baseline and after 6 and 12 weeks|Daily time spent above different glucose concentrations (e.g. >6.1 mmol/L, >7.0 mmol/L, >7.8 mmol/L, and >11.1 mmol/L), Measured using continous glucose monitoring., Changes from baseline. Measured 7 days after the test days at baseline and after 6 and 12 weeks|Mean glucose concentrations, Measured using continous glucose monitoring., Changes from baseline. Measured 7 days after the test days at baseline and after 6 and 12 weeks|Standard deviation of glucose concentrations, Measured using continous glucose monitoring., Changes from baseline. Measured 7 days after the test days at baseline and after 6 and 12 weeks|Variation coefficients of glucose concentrations, Measured using continous glucose monitoring., Changes from baseline. Measured 7 days after the test days at baseline and after 6 and 12 weeks|Physical activity (time spent at different intensities), Sedentary time, light, moderate and vigorous intensity physical activity. Assessed from 24 h/day accelerometry, Changes from baseline. Measured 7 days after the test days at baseline and after 6 and 12 weeks|Physical activity (counts/min), Assessed from 24 h/day accelerometry, Changes from baseline. Measured 7 days after the test days at baseline and after 6 and 12 weeks|Physical activity energy expenditure (kcal/day), Assessed from 24 h/day accelerometry, Changes from baseline. Measured 7 days after the test days at baseline and after 6 and 12 weeks|Physical activity (MET hours), Assessed from 24 h/day accelerometry, Changes from baseline. Measured 7 days after the test days at baseline and after 6 and 12 weeks|Timing of physical activity (hh:mm), Assessed from activity logs and 24 h/day accelerometry, Changes from baseline. Measured 7 days after the test days at baseline and after 6 and 12 weeks|Energy intake (kcal/day), Assessed from diet records, Changes from baseline. Registered 3 days after the test days at baseline and after 6 and 12 weeks|Macronutrient intake (energy percentage), Assessed from diet records, Changes from baseline. Registered 3 days after the test days at baseline and after 6 and 12 weeks|Timing of dietary intake (hh:mm), Assessed from diet records, Changes from baseline. Registered 3 days after the test days at baseline and after 6 and 12 weeks|Sleep timing (hh:mm), Including bedtime, sleep onset, wake-up, time out of bed, sleep midpoint. Assessed from sleep logs and 24 h/day accelerometry, Changes from baseline. Registered and measured for 7 days after the test days at baseline and after 6 and 12 weeks|Sleep duration (min), Assessed from sleep logs and 24 h/day accelerometry, Changes from baseline. Registered and measured for 7 days after the test days at baseline and after 6 and 12 weeks|Sleep variability (min), Variability in bedtime, wake-up, sleep duration and sleep midpoint. Assessed from sleep logs and 24 h/day accelerometry, Changes from baseline. Registered and measured for 7 days after the test days at baseline and after 6 and 12 weeks|Sleep onset latency (min), Assessed from sleep logs and 24 h/day accelerometry, Changes from baseline. Registered and measured for 7 days after the test days at baseline and after 6 and 12 weeks|Sleep efficiency (%), Assessed from 24 h/day accelerometry, Changes from baseline. Measured for 7 days after the test days at baseline and after 6 and 12 weeks|Wakefulness (min), Assessed from 24 h/day accelerometry, Changes from baseline. Measured for 7 days after the test days at baseline and after 6 and 12 weeks|Self-reported gastrointestinal symptoms (part 1), Assessed from the questionnaires the Gastrointestinal Symptom Rating Scale (GSRS). Rated on 7-point likert scales. Range: 1 = absence of symptoms to 7 = very severe symptoms., Changes from baseline. Assessed at all four visits (Baseline and after 6, 12, and 26 weeks)|Self-reported gastrointestinal symptoms (part 2), Assessed from the Gastrointestinal Symptom Score (PAGI-SYM). Rated on 6-point likert scales. Range: 1 = absence of symptoms to 6 = very severe symptoms., Changes from baseline. Assessed at all four visits (Baseline and after 6, 12, and 26 weeks)|Self-reported gastrointestinal symptoms (part 3), Number of symptoms. Assessed from logs., Changes from baseline. Registered 7 days after the test days at baseline and after 12 weeks|Self-reported autonomic symptoms, Assessed from the questionnaire COMPASS31, Changes from baseline. Assessed at all four visits (Baseline and after 6, 12, and 26 weeks)|Self-reported control over eating, Assessed from the questionnaire Control over Eating Questionnaire, Changes from baseline. Assessed at all four visits (Baseline and after 6, 12, and 26 weeks)|Self-reported sleepiness, Assessed from the questionnaire the Epworth Sleepiness Scale, Changes from baseline. Assessed at all four visits (Baseline and after 6, 12, and 26 weeks)|Self-reported sleep quality, Assessed from the questionnaire Pittsburgh Sleep Quality Index, Changes from baseline. Assessed at all four visits (Baseline and after 6, 12, and 26 weeks)|Self-reported chronotype, Assessed from the Munich Chronotype Questionnaire, Changes from baseline. Assessed at all four visits (Baseline and after 6, 12, and 26 weeks)|Self-reported physical activity, Assessed from questionnaire International Physical Activity Questionnaire, Changes from baseline. Assessed at all four visits (Baseline and after 6, 12, and 26 weeks)|Self-reported overall health and wellbeing, Assessed from the questionnaire Self-reported health (SF-36 health survey), Changes from baseline. Assessed at all four visits (Baseline and after 6, 12, and 26 weeks)|Self-reported eating behavior, Assessed from The Dutch Eating Behavior Questionnaire, Changes from baseline. Assessed at all four visits (Baseline and after 6, 12, and 26 weeks)|Self-reported night eating, Assessed from The Night Eating Questionnaire, Changes from baseline. Assessed at all four visits (Baseline and after 6, 12, and 26 weeks)|Daily eating/drinking window (hh:min), Time of first and last meal/beverage, Registrered every day (13 weeks intervention and 13 weeks follow-up period)|Microbiome content and diversity, Determined from stool samples. Bacterial DNA and RNA will be purified from the stool samples and changes in the microbiome composition and function will be estimated based on sequencing of the microbiomes' DNA and RNA. Includes but is not limited to the Firmicute/Bacteroidete ratio., Changes from baseline. Collected before or during test days at visits at baseline and after 12 weeks|Motivation for participation (qualitative methods), Themes and aspects related to motivation for participation will be assessed based on interviews with the participants including completers and potential drop-outs., Visits at baseline and after 12 and 26 weeks. Potential drop-outs will be interviewed at the specific time point.|Feasibility of the intervention (qualitative methods), Themes and aspects related to feasibility of the intervention will be assessed based on interviews with the participants including completers and potential drop-outs., Visits at baseline and after 12 and 26 weeks. Potential drop-outs will be interviewed at the specific time point.|Satisfaction with the intervention (qualitative methods), Themes and aspects related to satisfaction with the intervention will be assessed based on interviews with the participants including completers and potential drop-outs., Visits at baseline and after 12 and 26 weeks. Potential drop-outs will be interviewed at the specific time point.",,Kristine Frch,University of Copenhagen|Aalborg University Hospital|IMotions A/S|University of Leeds|Salk Institute for Biological Studies,ALL,"ADULT, OLDER_ADULT",NA,100,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,NNF17OC0027822,2019-02-25,2022-03-02,2022-03-02,2019-02-26,,2022-03-18,"Steno Diabetes Center Copenhagen, Gentofte, DK-2810, Denmark","Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/56/NCT03854656/SAP_000.pdf"
NCT03146156,Lifestyle Intervention in Preparation for Pregnancy (LIPP),https://clinicaltrials.gov/study/NCT03146156,,ACTIVE_NOT_RECRUITING,"Studies evaluating lifestyle intervention in obese women during pregnancy have reported limited success in decreasing excessive gestational weight gain, and have failed to achieve the key outcome of breaking the obesity cycle and reducing neonatal adiposity or birth weight. Although some investigators advocate weight loss during pregnancy in obese women, these recommendations were based on extrapolation of retrospective epidemiological data. Of concern, we reported increased small for gestational age babies and decreased lean body mass in neonates of obese women with weight loss or inadequate gestational weight gain. Based on our research, optimal outcomes from lifestyle interventions are likely to be temporal and therefore must be initiated prior to conception to first improve maternal metabolic function, and subsequently, placental/fetal growth. Several large retrospective cohort studies support our hypothesis. For example, women who lost weight between pregnancies had fewer large for gestational age babies in contrast to women who increased interpregnancy weight. In addition, prospective randomized controlled trials have shown that postpartum weight loss is achievable without adverse maternal or neonatal outcomes, these studies include women who breastfed. Based on these observations, we propose a randomized control trial to determine the effect of lifestyle intervention initiated prior to a planned pregnancy on improving neonatal metabolism and adiposity. Our overarching hypothesis is that the maternal pre-pregnancy metabolic condition determines the obesogenic in-utero environment, which affects programming of placental mitochondrial function and metabolic pathways, promoting lipid accumulation and neonatal adiposity. Our rationale is based on the need to establish the most effective time to introduce an intervention that will break the obesity cycle in mothers and their children. Understanding how pregravid metabolic conditioning improves maternal physiology, and cellular and molecular function in pregnancy will provide the empirical data to support the intervention. We have a highly successful record of recruiting women who are planning a pregnancy, obtaining compliance in longitudinal studies, and in long-term follow-up of mothers and their offspring. Lifestyle intervention will be initiated prior to conception to decrease maternal body fat, inflammation, insulin resistance, and ?-cell dysfunction. Our transdisciplinary team has the required expertise in lifestyle interventions management of obesity, and in human physiology that is needed to determine the effects of these interventions on maternal metabolism and fetalplacental growth and function. We will recruit 200 women to pursue the following specific aims:

Specific Aim 1: To investigate the physiological significance of lifestyle intervention in preparation for pregnancy (LIPP) on maternal and neonatal metabolism and adiposity.

Specific Aim 2: To determine the molecular effects whereby lifestyle intervention initiated before pregnancy can improve placental mitochondrial lipid oxidation and accumulation.",NO,"Obesity|Lifestyle-related Condition|Macrosomia, Fetal",BEHAVIORAL: Lifestyle Intervention,"Neonatal adiposity comparison between intervention and usual care group, Neonatal anthropometry and air densitometry (pea pod), 48 to 72 hours after delivery","Maternal metabolic status, body composition, insulin sensitivity and insulin response, from baseline to 6 month post-partum and then during pregnancy at 12 to 16 weeks gestation and 34 to 36 weeks gestation.",,Tufts Medical Center,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Pennington Biomedical Research Center|The Cleveland Clinic|MetroHealth Medical Center|Brigham and Women's Hospital,FEMALE,ADULT,NA,200,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,IRB16-00553|R01HD088061,2017-03-21,2024-12-01,2024-12-01,2017-05-09,,2024-02-06,"Pennington Biomedical Research Center, Baton Rouge, Louisiana, 70808, United States|Tufts Medical Center, Boston, Massachusetts, 02111, United States|Brigham and Women's Hospital, Boston, Massachusetts, 02115, United States|MetroHealth Medical Center, Cleveland, Ohio, 44109, United States","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/56/NCT03146156/Prot_SAP_000.pdf"
NCT02688218,Exercise Detection Study,https://clinicaltrials.gov/study/NCT02688218,,COMPLETED,"The risk of hypoglycemia in individuals with type 1 diabetes increases considerably during exercise. As a result, many patients with type 1 diabetes experience fear of and reluctance to pursue physical activity, in order to avoid the discomforting symptoms associated with hypoglycemia. The bi-hormonal artificial pancreas, a device used for automatic delivery of insulin and glucagon subcutaneously to subjects with type 1 diabetes, is paving the way to revolutionize the management of this disease. The investigator's group has recently completed a study of the bi-hormonal artificial pancreas system during exercise, suggesting reduced hypoglycemia around the exercise period. In order to prepare for a future home study, the ability to detect, grade, and classify physical activity so as to appropriately adjust system parameters is vital in helping to prevent exercise induced hypoglycemia in the home setting.

This study is designed to collect 3-axis accelerometry data and heart rate data during a variety of different home activities, as well as during formal exercise in both healthy subjects and subjects with type 1 diabetes. Additionally, the investigators will observe the change in glucose levels before and after exercise in subjects with type 1 diabetes.",YES,Type 1 Diabetes,BEHAVIORAL: Aerobic Exercise|BEHAVIORAL: Resistance Exercise,"Mean Change in Sensor Glucose in Subjects With Type 1 Diabetes, The mean change in sensor glucose before and after both exercise periods (aerobic and resistance) during the study visit, obtained from Dexcom G4 sensors in the subjects with type 1 diabetes., 4 hours",,,Oregon Health and Science University,,ALL,ADULT,NA,30,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: DIAGNOSTIC,15452,2016-02,2018-02-02,2018-02-02,2016-02-23,2019-01-24,2019-07-29,"Oregon Health and Science University, Portland, Oregon, 97239, United States","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/18/NCT02688218/Prot_SAP_000.pdf"
NCT03463941,Peer Support Dyads in Churches,https://clinicaltrials.gov/study/NCT03463941,,COMPLETED,The purpose of this study is to explore how working with a partner can influence participation in a church wellness program. There are many different types of church wellness programs. Church members are more likely to participate and achieve goals in these programs when they have peer support. The researcher would like to know what African American men and women think about working with a support partner. This information will help researchers design better church wellness programs. The participants are being asked to take part in this research because the investigators believe that it is helpful to share feelings and thoughts about experiences working with a partner to achieve health goals. This knowledge will be used to create church wellness programs that will help African American men and women prevent disease and live healthier lives.,YES,Peer Support and Chronic Disease|Obesity|Type II Diabetes|Cardiovascular Disease|Cancer,BEHAVIORAL: Peer Support Dyad Intervention,"Feasibility as Measured by Retention, Retention will be calculated from the number of participants who continue to Phase II out of the number who complete Phase I (\>50% attendance), and the attrition rate., Baseline to week 18|Number of Participants Who Agreed That Program Component Was Acceptable, Measured by ten item feasibility survey, scored based on 5-point Likert scale administered at week 18, the last week of the program. Feasibility was measured on a scale of 1-5, where 1=strongly disagree that program component was acceptable or feasible, and 5=strongly agree that program component was acceptable or feasible), Measured at Week 18|Health Educators' Perceptions of Feasibility as Measured by Semi-structured Interviews, Reported as number of health educators who found the program to be feasible., Measured at Week 18","Goal Attainment as Measured by BMI (Body Mass Index), Mixed models will be used to assess changes in participant BMI pre and post intervention., Week 18|Goal Attainment as Measured by Weight in Pounds, A mixed model using intraclass correlation will be used used to assess changes in participant weight pre and post intervention., Week 18|Goal Attainment as Measured by Number of Participants Consuming 7 or More Fruits and Vegetables Per Day, A mixed model using intraclass correlation will be used to assess changes in participant fruit and vegetable intake pre and post intervention., Week 18|Goal Attainment as Measured by Days Per Week That Participants Exercised for 30 Minutes or More, A mixed model using intraclass correlation will be used to assess changes in physical activity at weeks 1 and 18 pre and post intervention., Week 18",,Duke University,National Institute of Nursing Research (NINR),ALL,"ADULT, OLDER_ADULT",NA,80,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,Pro00091547|1F31NR017813-01,2019-01-05,2019-07-31,2019-07-31,2018-03-13,2020-07-20,2020-09-02,"Faithful Families Program, Raleigh, North Carolina, 27695, United States","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/41/NCT03463941/Prot_SAP_000.pdf"
NCT05356884,Adolescent-mediated Family Diabetes Intervention: American Samoa,https://clinicaltrials.gov/study/NCT05356884,,ACTIVE_NOT_RECRUITING,"The goal of this project is to test the feasibility, acceptability, and preliminary efficacy of an adolescent-mediated intervention designed to improve the glycemic control and self-care practices of a parent/grandparent. The preliminary impact of the intervention on adult glycemic control (HbA1c) and self-care behaviors, as well as adolescent risk factors, will be explored with the goal of informing future programs that can be scaled to reduce diabetes burden and eliminate health disparities among at risk, ethnic minority groups.",NO,"Diabetes Mellitus, Type 2",BEHAVIORAL: Diabetes Intervention|BEHAVIORAL: Leadership & Life Skills,"Change in Adult Glycemic Control (HbA1c) 0-6 months, Glycated hemoglobin (marker of long term glycemic control), 0 - 6 months|Change in Adult Glycemic Control (HbA1c) 0-12 months, Glycated hemoglobin (marker of long term glycemic control), 0 - 12 months|Change in Adult Glycemic Control (HbA1c) 6-12 months, Glycated hemoglobin (marker of long term glycemic control), 6 - 12 months|Change in Adult Body Mass Index (BMI) 0-6 months, Body mass index (measure of weight control), 0 - 6 months|Change in Adult Body Mass Index (BMI) 0-12 months, Body mass index (measure of weight control), 0 - 12 months|Change in Adult Body Mass Index (BMI) 6-12 months, Body mass index (measure of weight control), 6 - 12 months|Change in Adult Blood Pressure (BP) 0 - 6 months, Blood Pressure (marker of hypertension risk), 0 - 6 months|Change in Adult Blood Pressure (BP) 0 - 12 months, Blood Pressure (marker of hypertension risk), 0 - 12 months|Change in Adult Blood Pressure (BP) 6 - 12 months, Blood Pressure (marker of hypertension risk), 6 - 12 months|Change in Adult Waist Circumference (WC) 0 - 6 months, Waist circumference (measure of weight control), 0 - 6 months|Change in Adult Waist Circumference (WC) 0 - 12 months, Waist circumference (measure of weight control), 0 - 12 months|Change in Adult Waist Circumference (WC) 6 - 12 months, Waist circumference (measure of weight control), 6 - 12 months","Change in Adolescent Glycemic Control (HbA1c) 0 - 6 months, Glycated hemoglobin (marker of long term glycemic control), 0 - 6 months|Change in Adolescent Glycemic Control (HbA1c) 0 - 12 months, Glycated hemoglobin (marker of long term glycemic control), 0 - 12 months|Change in Adolescent Glycemic Control (HbA1c) 6 - 12 months, Glycated hemoglobin (marker of long term glycemic control), 6 - 12 months|Change in Adolescent Body Mass Index (BMI) 0 - 6 months, Body mass index (measure of weight control), 0 - 6 months|Change in Adolescent Body Mass Index (BMI) 0 - 12 months, Body mass index (measure of weight control), 0 - 12 months|Change in Adolescent Body Mass Index (BMI) 6 - 12 months, Body mass index (measure of weight control), 6 - 12 months|Change in Adolescent Blood Pressure (BP) 0 - 6 months, Blood Pressure (marker of hypertension risk), 0 - 6 months|Change in Adolescent Blood Pressure (BP) 0 - 12 months, Blood Pressure (marker of hypertension risk), 0 - 12 months|Change in Adolescent Blood Pressure (BP) 6 - 12 months, Blood Pressure (marker of hypertension risk), 6 - 12 months|Change in Adolescent Waist Circumference (WC) 0 - 6 months, Waist circumference (measure of weight control), 0 - 6 months|Change in Adolescent Waist Circumference (WC) 0 - 12 months, Waist circumference (measure of weight control), 0 - 12 months|Change in Adolescent Waist Circumference (WC) 6 - 12 months, Waist circumference (measure of weight control), 6 - 12 months",,Yale University,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),ALL,"CHILD, ADULT, OLDER_ADULT",NA,340,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2000031325|1R01DK128277-01A1,2022-07-07,2024-08-31,2024-08-31,2022-05-02,,2024-02-16,"OLaGA Research Center, Pago Pago, American Samoa","Informed Consent Form, https://storage.googleapis.com/ctgov2-large-docs/84/NCT05356884/ICF_000.pdf"
NCT02407132,Family Model of Diabetes Self-Management Education in the Marshallese Community,https://clinicaltrials.gov/study/NCT02407132,,COMPLETED,"The investigators will conduct a comparative effectiveness evaluation using a randomized control trial design of a culturally adapted family model of Diabetes Self-Management Education (Adapted DSME) compared with Standard DSME within the Marshallese population. The family model will cover the same concepts as the standard format. However, the family model will incorporate culturally-adapted education and recommendations aimed at engaging family members in the management of the primary participant's diabetes, and family members will be invited to fully participate in the study. By contrast, the standard model provides diabetes self- management education to the diabetic participant only, and the participant's family members do not participate in the classes or any other part of the study. Biometric and survey data will be collected pre-intervention, post-intervention, 6 months post-intervention, and 12 months post-intervention. A qualitative debriefing session will be held for each family between the final DSME session and the 6 month post-intervention to obtain qualitative data regarding the participant's perceptions of the intervention and implementation process.",YES,Diabetes,BEHAVIORAL: Adapted DSME|BEHAVIORAL: Standard DSME,"Glycemic Control, Measured by Change in Adjusted Mean HbA1c (%) From Baseline to Immediate Post-intervention, 6 Months Post-intervention, and 12 Months Post-intervention., A Siemens analyzer (point of care) was utilized to calculate HbA1c levels for each participant. The primary outcome measure was change in adjusted mean HbA1c (%) from baseline to immediate post-intervention, 6 months post-intervention, and 12 months post-intervention. Analyses were adjusted for baseline sex, age, education, marital status, employment status, use of diabetes medication, and households containing multiple participants. The mean HbA1c values presented here have been adjusted, whereas the mean HbA1c values presented in the Baseline Data section are unadjusted., Baseline, Immediate post-intervention, 6 months post-intervention, 12 months post-intervention","Change in Mean BMI From Baseline to Immediate Post-intervention, 6 Months Post-intervention, and 12 Months Post-intervention, Participant weight (without shoes) was measured in light clothing to the nearest 0.5 lb (0.2 kg) using a calibrated digital scale. Height (without shoes) was measured to the nearest 0.5 cm using a stadiometer. Weight and height were used to compute a continuous measure of BMI (kg/m)., Baseline, Immediate post-intervention; 6 months post-intervention; 12 months post-intervention|Change in Mean Total Cholesterol (mg/dL) From Baseline to Immediate Post-intervention, 6 Months Post-intervention, and 12 Months Post-intervention., Through finger prick blood collection, point of care tests were used to test fasting lipids using a commercial lipid panel kit and Cholestech LDX analyzer. Analyses were adjusted for baseline sex, age, education, marital status, employment status, use of diabetes medication, and households containing multiple participants., Baseline, Immediate post-intervention, 6 months post-intervention, 12 months post-intervention|Change in Mean High-density Lipoproteins (HDL) From Baseline to Immediate Post-intervention, 6 Months Post-intervention, and 12 Months Post-intervention., A commercial lipid panel kit and Cholestech LDX analyzer were used to assess HDL levels. The outcome measure was change in mean HDL from baseline to immediate post-intervention, 6 months post-intervention, and 12 months post-intervention. Analyses were adjusted for baseline sex, age, education, marital status, employment status, use of diabetes medication, and households containing multiple participants., Baseline, Immediate post-intervention, 6 months post-intervention, 12 months post-intervention|Change in Probability of Performing Diabetes Self-care Behaviors From Baseline to 12 Months Post-intervention: Check Blood Glucose Daily, This measure assesses whether or not each participant reported checking her/his blood glucose at least daily at baseline and 12 months post-intervention. This measure of participant-reported current level of diabetes self-care was assessed through an item from the Behavioral Risk Factor Surveillance System (BRFSS) Diabetes Module. (Because three of the diabetes self-care behaviors we assessed are expected to occur annually (e.g., annual doctor visit), analyses of self-care behaviors focus on change from baseline to 12 months post-intervention to allow for a year to elapse between time points.), Baseline, 12 months post-intervention|Change in Probability of Performing Diabetes Self-care Behaviors From Baseline to 12 Months Post-intervention: Seen Doctor or Other Health Professional in Past 12 Months for Diabetes, This measure assesses whether or not each participant reported seeing a doctor, nurse, or other health professional for her/his diabetes within the past 12 months at baseline and 12 months post-intervention. This measure of participant-reported current level of diabetes self-care was assessed through an item from the Behavioral Risk Factor Surveillance System (BRFSS) Diabetes Module. (Because three of the diabetes self-care behaviors we assessed are expected to occur annually (e.g., annual doctor visit), analyses of self-care behaviors focus on change from baseline to 12 months post-intervention to allow for a year to elapse between time points.), Baseline, 12 months post-intervention|Change in Probability of Performing Diabetes Self-care Behaviors From Baseline to 12 Months Post-intervention: Foot Exam by Doctor or Other Health Professional in Past 12 Months, This measure assesses whether or not each participant reported having a health professional check her/his feet for any sores or irritations in the past 12 months at baseline and 12 months post-intervention. This measure of participant-reported current level of diabetes self-care was assessed through an item from the Behavioral Risk Factor Surveillance System (BRFSS) Diabetes Module. (Because three of the diabetes self-care behaviors we assessed are expected to occur annually (e.g., annual doctor visit), analyses of self-care behaviors focus on change from baseline to 12 months post-intervention to allow for a year to elapse between time points.), Baseline, 12 Months Post-Intervention|Change in Probability of Performing Diabetes Self-care Behaviors From Baseline to 12 Months Post-intervention: Eye Exam in Past 12 Months, This measure assesses whether or not each participant reported having an eye exam in which the pupils were dilated in the past 12 months at baseline and 12 months post-intervention. This measure of participant-reported current level of diabetes self-care was assessed through an item from the Behavioral Risk Factor Surveillance System (BRFSS) Diabetes Module. (Because three of the diabetes self-care behaviors we assessed are expected to occur annually (e.g., annual doctor visit), analyses of self-care behaviors focus on change from baseline to 12 months post-intervention to allow for a year to elapse between time points.), Baseline, 12 Months Post-Intervention|Change in Probability of Performing Diabetes Self-care Behaviors From Baseline to 12 Months Post-intervention: Maintain a Normal Weight, This measure assesses whether or not each participant had a normal weight at baseline and 12 months post-intervention as indicated by body mass index (i.e., body mass index between 18.5 to 24.9). Participant weight (without shoes) was measured in light clothing to the nearest 0.5 lb (0.2 kg) using a calibrated digital scale. Height (without shoes) was measured to the nearest 0.5 cm using a stadiometer. Weight and height were used to compute a continuous measure of BMI (kg/m). (Because three of the diabetes self-care behaviors we assessed are expected to occur annually (e.g., annual doctor visit), analyses of self-care behaviors focus on change from baseline to 12 months post-intervention to allow for a year to elapse between time points.), Baseline, 12 Months Post-Intervention|Change in Probability of Performing Diabetes Self-care Behaviors From Baseline to 12 Months Post-intervention: Engage in Recommended Level of Physical Activity, This measure assesses whether or not each participant reported engaging in 60 minutes or more of vigorous activity per week or 150 minutes or more of moderate activity per week at baseline and 12 months post-intervention. This measure was lightly adapted from the measure of physical activity used here: L. Jiang, S. Chen, B. Zhang, J. Beals, C.M. Mitchell, S.M. Manson, et al. Longitudinal patterns of stages of change for exercise and lifestyle intervention outcomes: an application of latent class analysis with distal outcomes. Prev. Sci., 17 (2016), pp. 398-409. (Because three of the diabetes self-care behaviors we assessed are expected to occur annually (e.g., annual doctor visit), analyses of self-care behaviors focus on change from baseline to 12 months post-intervention to allow for a year to elapse between time points.), Baseline, 12 Months Post-Intervention|Change in Mean Fasting Glucose From Baseline to Immediate Post-intervention, 6 Months Post-intervention, and 12 Months Post-intervention, Informally and in response to a survey item, many participants reported that they had not adhered to instructions to fast before data collection. For this reason, we were unable to collect valid measures for fasting glucose, low-density lipoproteins (LDL), and triglycerides., Baseline, Immediate Post-Intervention, 6 Months Post-Intervention, 12 Months Post-Intervention|Change in Mean Low-density Lipoproteins (LDL) From Baseline to Immediate Post-intervention, 6 Months Post-intervention, and 12 Months Post-intervention, Informally and in response to a survey item, many participants reported that they had not adhered to instructions to fast before data collection. For this reason, we were unable to collect valid measures for fasting glucose, low-density lipoproteins (LDL), and triglycerides., Baseline, Immediate Post-Intervention, 6 Months Post-Intervention, 12 Months Post-Intervention|Change in Mean Triglycerides From Baseline to Immediate Post-intervention, 6 Months Post-intervention, and 12 Months Post-intervention, Informally and in response to a survey item, many participants reported that they had not adhered to instructions to fast before data collection. For this reason, we were unable to collect valid measures for fasting glucose, low-density lipoproteins (LDL), and triglycerides., Baseline, Immediate Post-Intervention, 6 Months Post-Intervention, 12 Months Post-Intervention",,University of Arkansas,Patient-Centered Outcomes Research Institute,ALL,"ADULT, OLDER_ADULT",NA,221,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,203482,2015-06,2018-04-30,2018-04-30,2015-04-02,2018-06-07,2019-06-20,"University of Arkansas for Medical Sciences Northwest, Fayetteville, Arkansas, 72703, United States","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/32/NCT02407132/Prot_SAP_000.pdf"
NCT04474795,Clinic to Community Connections - Broader Distribution,https://clinicaltrials.gov/study/NCT04474795,,COMPLETED,"This study addresses education needs in gestational diabetes care and followup at the staff and patient levels.

In the initial phase, nurses and community health workers will complete specific training modules on gestational diabetes developed for this study. The effectiveness of the education modules will be evaluated through pre/post surveys of participants assessing diabetes knowledge, attitudes, and self-efficacy.",YES,Gestational Diabetes|Gestational Diabetes Mellitus in Pregnancy,BEHAVIORAL: Staff -Educational training,"Staff - Self-efficacy to Provide Diabetes Education Questionnaire (Newly Developed), Pre-Post change in staff participants' perceived self-efficacy to provide diabetes education (Mean score min:1 max 10) high score=more confident, Baseline and upon module completion (approximately 3 months)","Staff - Diabetes Knowledge Test, Change in diabetes knowledge measured by multiple choice test (% correct out of 21 items) high score =better knowledge, Baseline and upon module completion (approximately 3 months)|Staff - Diabetes Attitudes (Diabetes Attitudes Scale-3 (DAS-3)), Change in diabetes attitudes measured by 3 subscales of DAS-3 (Mean score min 1, max 5) high score=better attitudes, Baseline and upon module completion (approximately 3 months)|Staff - Intention to Recommend Diabetes Prevention Activities Questionnaire (Newly Developed), Change in staff's intention to recommend postpartum diabetes screening measured by a survey developed for this study (mean score; min 1, max 5) higher score= increased intention to perform action, Baseline and upon module completion (approximately 3 months)","Staff-General Self Efficacy Scale (Schwarzer), General Self Efficacy measure (for use in validation of the Self-Efficacy for Providing Diabetes Education Scale) Sum Score (min: 10, max: 40); higher score=more confidence, Baseline|Staff-Provider Teaching Motivation Questionnaire Intrinsic Motivation Subscale, Measure of teaching motivation (for use in validation of the Self-Efficacy for Providing Diabetes Education Scale) Mean score (min: 0, max 4) higher score=more intrinsic motivation, Baseline",Washington University School of Medicine,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Longer Life Foundation,ALL,"ADULT, OLDER_ADULT",NA,85,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,202007060|1K23HD096204-01A1,2020-06-18,2022-08-22,2022-08-22,2020-07-17,2023-01-30,2023-02-27,"Affinia Healthcare, Saint Louis, Missouri, 63107, United States","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/95/NCT04474795/Prot_SAP_000.pdf"
NCT02028195,Effectiveness and Cost-effectiveness of the Check Your Health Preventive Programme,https://clinicaltrials.gov/study/NCT02028195,,UNKNOWN,"Check your health is a prevention intervention designed to create awareness and action on health condition with focus at physical activity at a population-level to 30-49 years of age. It consists of a behavioural and clinical examination followed by either (I) referral to a health promoting consultation in general practice (II) targeted behavioural programmes at the local Health Centre or (III ) no need for follow-up; stratified after risk-profile. The CORE trial (Check your health) aim to investigate effectiveness on health and social outcomes of the preventive health check and to establish the cost-effectiveness according to life years gained; direct costs and total health costs. A pragmatic cluster randomised controlled trial has been established to meet the aims and in total 10.600 individuals from 35 practices have been randomized in to two groups that will be invited in 2013-14 and 2017-18 respectively. The group offered the preventive health check in 2013-14 will constitute the intervention group and the group examined in 2017 - 18 the control group. A follow up of the intervention group in 2017 - 18 will provide data for the intention to treat analysis revealing the effect. Outcome measures are level of physical activity, risk of getting cardiovascular disease, sick leave and labor market attachment.",NO,Health Promotion|Cardiovascular Disease|Physical Inactivity|Selfreported Quality of Health|Mental Health,OTHER: Health check,"Physical activity, Physical activity level will be measured by 1) self-reported physical activity (days/week with minimum 30 minutes moderate physical activity) and 2) physical fitness, measured by Aastrands submaximal bike-test., 4 years|Modelled cardiovascular risk, Cardiovascular risk will be measured as a modelled risk of developing cardiovascular disease within 10 years and includes information on age, gender, smoking status, systolic blood pressure and total cholesterol., 4 years|Health related quality of life, Health related quality of life measured by The Medical Outcome Study Short Form 12 Health Survey (SF12), 4 years|Functional capacity, Functional capacity will be measured as affiliation to the labor market (work participation in the last year)and sick leave \> 3 weeks., 4 years",,"Health economy assessment, The economic benefits of the interventions will be assessed by comparing mean direct and total costs (direct and productivity costs), and expected life years gained (LYG) in the intervention group with the control group (within a period of four., 4 years",University of Aarhus,"Tryg Danmark|Randers Municipality, Denmark|Region MidtJylland Denmark",ALL,ADULT,NA,11000,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,Tryg 7-11-0500,2013-05,2018-12,2019-12,2014-01-07,,2018-10-01,"Department of Public Health, Aarhus, 8000, Denmark","Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/95/NCT02028195/SAP_001.pdf"
NCT02835495,Healthy Living Partnerships to Prevent Diabetes in Veterans Pilot Study,https://clinicaltrials.gov/study/NCT02835495,HELP Vets,COMPLETED,Diabetes and obesity are both major public health concerns and the prevalence of diabetes is even higher in the patient population of the Veterans Administration. This planning project is designed to adapt a successful weight-loss program for delivery through an existing outpatient clinic to reach local Veterans at risk for developing diabetes. The information gathered as a part of this project will be used to plan a larger trial designed to improve the health of Veterans by offering them a diabetes prevention program through their usual source of healthcare.,YES,Pre-diabetes|Obesity,BEHAVIORAL: HELP Vets Intervention|BEHAVIORAL: Individual Education Program,"Recruitment of Study Participants, To characterize the ability to recruit Veterans to participate in this pilot study, the proportion of Veterans screened who are eligible to participate and the proportion of eligible participants who agree to participate will be calculated. The rate of referrals to the program by providers in the local community-based outpatient clinic will also be monitored., 6 months|Retention of Study Participants, To characterize the ability to retain Veterans in this pilot study, the percentage of participants who complete the study (attendance at the 6-month assessment visit) as a measure of overall study retention will be calculated., 6 months|Adherence to the Lifestyle Weight Loss Intervention, The proportion of intervention sessions attended will be calculated., 6 months",,"Weight, The means and standard deviations at 6 months will be calculated., 6 months|Systolic Blood Pressure, The means and standard deviations at 6 months will be calculated., 6 months|Diastolic Blood Pressure, The means and standard deviations at 6 months will be calculated., 6 months|Proportion of Participants for Whom Fasting Glucose is Available at 6-months Post-randomization, In order to assess the feasibility of collecting this data from the medical record, the proportion of participants for whom this data is available at 6-months post-randomization (+/- 90 days) will be reported., 6 months|Proportion of Participants for Whom Cholesterol (Lipid Panel) is Available at 6-months Post-randomization, In order to assess the feasibility of collecting this data from the medical record, the proportion of participants for whom this data is available at 6-months post-randomization (+/- 90 days) will be reported., 6 months|Fasting Glucose, The means and standard deviations at 6 months will be calculated., 6 months|Cholesterol (Lipid Panel), The means and standard deviations at 6 months will be calculated., 6 months",Wake Forest University Health Sciences,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|US Department of Veterans Affairs,ALL,"ADULT, OLDER_ADULT",NA,118,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,IRB00033688|R34DK108100,2017-11-15,2019-08-30,2019-08-30,2016-07-18,2020-09-02,2020-09-24,"W.G. ""Bill"" Hefner VA Medical Center, Salisbury, North Carolina, 28144, United States|Wake Forest School of Medicine, Winston-Salem, North Carolina, 27157, United States","Informed Consent Form, https://storage.googleapis.com/ctgov2-large-docs/95/NCT02835495/ICF_000.pdf|Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/95/NCT02835495/Prot_SAP_001.pdf"
NCT03917576,Heart Rate During Exercise in Type 2 Diabetes,https://clinicaltrials.gov/study/NCT03917576,HRinT2DM,COMPLETED,"Exercise training is a cornerstone for the prevention and treatment of metabolic disorders and associated cardiometabolic complications such as type 2 diabetes mellitus (T2D) and hypertension. Similar to the beneficial health effects after performing conventional continuous exercise modalities, high intensity interval training (HIIT) has been reported as an effective alternative exercise-modality to improve glucose homeostasis in both prediabetes subjects and individuals with T2D diagnosed. In this regard, although multiple HIIT-based interventions commonly report acute and long term benefits on body composition, cardiorespiratory fitness and insulin sensitivity in metabolically compromised subjects, little is known about the acute cardiovascular response (i.e., at heart rate level) during HIIT in subjects with different glucose control.

HIIT is described as performing brief periods of exercise at vigorous or maximal intensity, interspersed with inactive or low intensity recovery phases of variable duration. In order to characterize different HIIT-based protocols, exercise intensity is usually defined as relative percentages of individual maximal cardiorespiratory fitness (VO2max) or relative maximal power output values. Nevertheless, the need for specific technological equipment to assess these parameters usually limit the prescription and recommendations of HIIT in clinical settings and other public health contexts at massive level. Additionally, the use of self-perceived exertion scales and heart rate (HR) variations upon HIIT have been demonstrating to be accessible and feasible strategies to regulate exercise intensity during HIIT. For example, it was reported that HR and self-perceived exertion scores increased progressively in T2D subjects, parallel to the oxygen consumption rate throughout an acute HIIT session performed on cycle ergometer. Consequently, it is conceivable to hypothesize that determining HR variations during HIIT might optimize the recommendation of this training methodology in metabolically compromised subjects as those at risk or with T2D diagnosed. Therefore, the aim of the present study was To describe and compare the acute heart rate changes in response to an incremental maximal exercise test and a single HIIT session between normoglycaemic (NG), prediabetes (Pre-T2D) and type 2 diabetes mellitus (T2D) subjects.",NO,Type2 Diabetes Mellitus|Hyperglycemia|Heart Rate|Exercise Training,OTHER: Behavioral|OTHER: Exercise training intervention,"Maximum heart rate, Measured before and after 12 weeks of high-intensity interval training, 12 weeks","Resting heart rate, Measured before and after 12 weeks of high-intensity interval training, 12 weeks|Heart rate pre each HIIT-interval, Measured before and after 12 weeks of high-intensity interval training, 12 weeks|Heart rate post each HIIT-interval, Measured before and after 12 weeks of high-intensity interval training, 12 weeks",,Universidad de Los Lagos,Universidad de La Frontera,FEMALE,ADULT,NA,75,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: PREVENTION,RP010317,2018-01-04,2018-04-04,2018-04-07,2019-04-17,,2019-04-17,"Cristian ALvarez, Osorno, 5290000, Chile","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/76/NCT03917576/Prot_SAP_000.pdf"
NCT04108299,Family Intervention for Chinese Americans With Type 2 Diabetes,https://clinicaltrials.gov/study/NCT04108299,,COMPLETED,"The goal of this pilot study is to examine the feasibility and acceptability of a family-oriented SMS intervention in 30 Chinese Americans with T2D and their family members. Participants will be randomized to one of 2 arms (n=15 each): 1) wait-list control and 2) SMS intervention. Both groups will continue to receive standard of care treatment for their T2D. The SMS group will receive brief lifestyle counseling videos via SMS links. At the end of the study, the wait-list control group will be provided the opportunity to receive the counseling videos.",NO,Type 2 Diabetes,BEHAVIORAL: Wait-list control group|BEHAVIORAL: SMS intervention,"Percentage of Videos Watched by Participants, Measure of SMS intervention feasibility., Up to Month 6|Satisfaction Questionnaire Score, 10-item assessment of acceptability of SMS intervention. Higher scores indicate greater acceptability/satisfaction., Month 6","Change in HbA1c Level, Participants receive HbA1c blood test at their doctors' office every 3-6 months; HbA1c testing results will be abstracted from the medical record at the participant's health care facility., Baseline, Month 6|Change in Diabetes Management Self-Efficacy Scale (DMSES) Score, The DMSES is an 8-item assessment asking participants to rate their confidence level in performing diabetes-specific self-management behaviors, using a 10-point Likert scale ranging from 1 (not at all confident) to 10 (totally confident). The total score is the sum of responses and ranges from 8 to 80; higher scores indicate greater self-efficacy. An increase in scores indicates self-efficacy improved during the observational period., Baseline, Month 6|Change in Summary of Diabetes Self-Care Activities (SDSCA) Score, The SDSCA is a 13-item assessment of participants' adherence to diabetes self-management behaviors. This scale consists of 13 items and asks participate to describe their diabetes self-care activities over the past 7 days. The total score is the sum of responses and ranges from 0 to 91; higher scores indicate greater adherence to self-management behaviors. An increase in scores indicates adherence improved during the observational period., Baseline, Month 6|Change in Michigan Diabetes Knowledge Test Score, The Michigan Diabetes Knowledge Test is a 23-item assessment of general knowledge of diabetes. Scores range from 0 (minimum) to 100 (maximum), with higher scores indicating greater knowledge of diabetes. An increase in scores indicates knowledge increased during the observational period., Baseline, Month 6|Change in Mediterranean Dietary Screener (MEDAS) Score, The MEDAS is a 14-item assessment of participants' adherence to the Mediterranean diet. Total scores are classified as low (0-7 points), moderate (8-10 points) and high (11-17 points). An increase in scores indicates adherence increased during the observational period., Baseline, Month 6|Change in International Physical Activity Questionnaire (IPAQ)-short version Score, The IPAQ calculates the metabolic equivalent (MET) score by asking participants the days and minutes exercised in three categories of intensity (vigorous, moderate, and walking) during the previous one week. Higher scores indicate higher levels of physical activity. An increase in scores indicates physical activity increased during the observational period., Baseline, Month 6",,NYU Langone Health,,ALL,"ADULT, OLDER_ADULT",NA,46,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH",19-01275,2021-04-21,2022-07-30,2022-07-30,2019-09-30,,2022-10-28,"NYU Langone Health, New York, New York, 10016, United States","Informed Consent Form, https://storage.googleapis.com/ctgov2-large-docs/99/NCT04108299/ICF_000.pdf"
NCT04029298,Home-based Prediabetes Care in Acoma Pueblo - Study 1,https://clinicaltrials.gov/study/NCT04029298,,WITHDRAWN,"The prevalence of overweight, obesity and T2D among American Indians (AIs) in the Albuquerque service area of Indian Health Services (IHS) serving all pueblos in New Mexico including Pueblo of Acoma is disproportionately elevated. Specifically, among AI, adults age 18 and over in the IHS Albuquerque Service Area, 51% have a BMI \> 30, which significantly exceeds the rate of obesity observed nationally (35.3%) and the Healthy People 2020 target of 30.5%. Likewise, the rate of T2D (22.8%) among the adult AI population in our Albuquerque service area is almost double the rate of the U.S. adult population (12.2%), and the age-adjusted diabetes mortality rate for AIs was 104.7 per 100,000 compared to 23.1 per 100,000 among non-Hispanic Whites in the region. At the same time, the median age of diagnosis of T2D among AI adults was much younger (42.2 years) than the national average (53.8 years).

Our major goal of implementing educational interventions to slow the current rate of increase in diabetes in Native communities is aligned with NIH's (NIGMS) and NM INBRE's vision in reducing health disparity using innovative interventions. The investigators propose following aims:

Aim 1: Recruit and Screen 300 community members in Acoma Pueblo, NM to identify incident cases of pre-diabetes for the proposed study of Home Based Diabetes Care (HBDC);

Aim 2: Enroll 150 Acoma Natives aged 21-70 years, at risk for T2D (i.e., overweight, obese, and/or with at least one affected first degree relative or a history of gestational DM) and conduct HBDC for a 16-week lifestyle intervention in a longitudinal cohort study. Randomize household in a 1:1 allocation to enter either the intervention arm immediately or after a 12-month waiting list in control arm. Control participants will be treated with usual care. Participants randomized to the waiting list will enter the intervention group 12 months after entering the study. Both intervention groups will be followed longitudinally for total of 12 months.

Compared with people who will receive ""usual care (control group)"", prediabetic participants receiving 4 months of the HBDC will exhibit improved risk factor profiles for diabetes, obesity and heart disease, improved Patient Activation Measures, improved adherence with medical treatment, and improved Quality of Life scores.",NO,PreDiabetes,BEHAVIORAL: Lifestyle Interventions,"Change in BMI, Change in BMI will be determined using a SECA 876 Floor Scale (SECA Inc., Chino, CA) for weight measurement, and height will be assessed using SECA 217 Portable Stadiometer with floor scale adapter. Height and weight will be reported as BMI in kg/m2, with a reference range of 18.5-24.9 kg/m2., Baseline, 4, 12 months (intervention group); Baseline, 12, 16, 28 months (control/delayed intervention group)|Change in hemoglobin A1c, To reproduce real-life community healthcare conditions, change in A1c will be assessed in both study groups with point-of-care measurement as an indicator of 90 day glucose homeostasis, with normal range of \<5.7%., Baseline, 4, 12 months (intervention group); Baseline, 12, 16, 28 months (control/delayed intervention group)","Type 2 diabetes incidence, T2D incidence determined at each outcome assessment according to the criteria established by the American Diabetes Association (FPG  126 mg/dL and/or A1c \> 6.4%), Baseline, 4, 12 months (intervention group); Baseline, 12, 16, 28 months (control/delayed intervention group)|Waist-to-hip ratio, The waist-to-hip ratio will be based on the Diabetes Prevention Program protocol., Baseline, 4, 12 months (intervention group); Baseline, 12, 16, 28 months (control/delayed intervention group)|Change in fasting blood glucose, i-STAT system, Abbott Laboratories, Princeton, NJ, Baseline, 4, 12 months (intervention group); Baseline, 12, 16, 28 months (control/delayed intervention group)|Change in blood pressure, Systolic and diastolic blood pressure will be determined using 2 measures after 5 minutes of sitting using an electronic implement (Prestige Medical, Northridge CA), Baseline, 4, 12 months (intervention group); Baseline, 12, 16, 28 months (control/delayed intervention group)|Change in fasting lipid panel, HDL, LDL, total cholesterol, and triglycerides, Baseline, 4, 12 months (intervention group); Baseline, 12, 16, 28 months (control/delayed intervention group)|Physical Activity Measure, Weekly activity logs, as well as pedometer data, will be collected over a one week period prior to assessment at 0, 8, and 16 weeks., Baseline, 8, and 16 weeks|Patient Activation Measure (PAM), The investigators will use a short version of PAM using a 13-item survey tool designed to assess a person's knowledge, skill, and confidence in managing his or her own healthcare. The response options for the 13 PAM questions use a categorical agreement scale with 4 response options: (i) strongly disagree, (ii) disagree, (iii) agree, (iv) strongly agree, and N/A. The raw score will be calculated by adding responses to the 13 questions. If all questions are answered (i.e., no ""N/A"" is used), the range of raw scores would be 13 to 52. If there is at least 1 item with a response of N/A, the total score will be divided by the number of items completed and multiplied by 13 to yield a normalized raw score. A nomogram provided by Dr. Hibbard converts raw scores to an ""activation score,"" ranging from 0 to 100. The survey has been fully developed and validated., 0, 6, and 12 weeks and at 12 month follow-up in all participants|Adherence to treatment, For the purposes of data analysis, the investigators have devised a simple three-point system for determining adherence. Participants will receive one point for each of three benchmarks achieved: (a) \>80% of prescribed medications taken over the past 30 days (medications counted will include anti-hypertensive medications, lipid-lowering medications, and glucose lowering medications); (b) \>80% of all health-related appointments kept during the past six months; and (c) 100% of activity log books kept over the past two weeks. Data on ""appointments kept"" will include a composite of scheduled IHS clinic appointments. Higher points are indicative of greater adherence to treatment., Baseline, 4, 12 months (intervention group); Baseline, 12, 16, 28 months (control/delayed intervention group)",,University of New Mexico,,ALL,ADULT,NA,0,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,19-145-study 1,2023-03-01,2024-07,2024-07,2019-07-23,,2023-02-21,"Pueblo of Acoma, Acoma Pueblo, New Mexico, 87034, United States","Informed Consent Form, https://storage.googleapis.com/ctgov2-large-docs/98/NCT04029298/ICF_000.pdf"
NCT03844646,Continuous Glucose Monitoring to Aid Weight Loss in Prediabetes,https://clinicaltrials.gov/study/NCT03844646,,TERMINATED,The primary objective of this study is to determine whether intermittent use of continuous glucose monitor will facilitate weight loss in individuals who are overweight/obese with prediabetes.,YES,Weight Loss|PreDiabetes,DEVICE: CGM|OTHER: Dietitian,"Amount of Weight Lost (kg), Weight lost during the study, Baseline to end of study (3 months)","Number of Participants Reporting at Least 5 Days of Moderate Physical Activity of 30 Minutes or More, Baseline to end of study (3 months)",,Stanford University,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),ALL,"ADULT, OLDER_ADULT",NA,12,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,49402|P30DK116074,2019-08-01,2021-12-31,2021-12-31,2019-02-18,2022-12-18,2023-01-31,"Stanford, Stanford, California, 94305, United States","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/46/NCT03844646/Prot_SAP_001.pdf"
NCT02806700,Twitter and Diabetes,https://clinicaltrials.gov/study/NCT02806700,,COMPLETED,"Twitter use is surprisingly well represented across broad demographic population segments and health-related messages. The promise of using Twitter is that its use is growing rapidly, it allows the investigators to view communications that were impossible to intercept before, and it potentially provides information faster and less expensively than collection from other media channels. Prior work also supports that social media interventions can improve health behavior change (e.g. weight loss, physical activity) and outcomes.The overarching goals of this proposal are to understand the uses and limitations of this communication channel to improve patients' ability to manage their CV health condition.",NO,Diabetes|Cardiovascular Disease,BEHAVIORAL: Twitter Diabetes Intervention,"Patient Activation, PAM scale with an anticipated 2-3 point difference, 6 months","HbA1c, self reported HbA1c, 6-12 months",,University of Pennsylvania,,ALL,"ADULT, OLDER_ADULT",NA,225,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,R01: HL122457-0IA1,2016-06,2018-05,2018-08,2016-06-21,,2018-08-01,"University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States","Study Protocol, https://storage.googleapis.com/ctgov2-large-docs/00/NCT02806700/Prot_000.pdf|Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/00/NCT02806700/SAP_001.pdf"
NCT03421262,Pregnancy Outcomes and Medical Costs According to Gestational Diabetes Mellitus Diagnostic Criteria,https://clinicaltrials.gov/study/NCT03421262,POMEC,UNKNOWN,The aim of the study is to evaluate differences in pregnancy outcomes and medical costs depending on gestational diabetes diagnostic criteria used (one vs two-step approach).,NO,Gestational Diabetes,DIAGNOSTIC_TEST: IADPSG Criteria|DIAGNOSTIC_TEST: NDDG Criteria,"Large for gestational age, Infant birthweight \>90th centile using customized growth curves, At birth of infant","Macrosomia, infant birthweight \>=4kg, At birth of infant|Small for gestational age, infant birthweight \<10th centile using customized growth curves, At birth of infant|Hypertension in pregnant, classification according to American College of Obstetricians and Gynecologists (Task Force on Hypertension in Pregnancy)., First 3 months postpartum|Neonatal obstetric trauma, rate of shoulder dystocia, clavicle fracture, brachial plexus injury and intrapartum asphyxia, At birth of infant|Congenital anomalies, Coding of EUROCAT, At birth of infant|Neonatal hypoglycemia, neonatal plasma glucose levels of \<2.5 mmol/L in the first 24 hours of life and \<2.8 mmol/L thereafter., up to 4 weeks after delivery|Neonatal hypocalcemia, neonatal calcium levels of \<7mg/dl, up to 4 weeks after delivery|Neonatal hyperbilirubinemia, hyperbilirubinemia treated with phototherapy, up to 4 weeks after delivery|Neonatal polycythemia, hematocrit from a peripheral venous sample is \>65 percent, up to 4 weeks after delivery|Respiratory Distress Syndrome, onset of progressive respiratory failure shortly after birth, in conjunction with a characteristic chest radiograph (after ruling out other causes)., up to 4 weeks after delivery|Infant Outcomes, Pregnancy loss (Miscarriage, stillbirth, neonatal death), up to 4 weeks after delivery|Hypertrophic cardiomyopathy, increased left ventricular (LV) wall thickness 15 mm is imaged anywhere in the LV wall (by transthoracic echocardiography), up to 4 weeks after delivery|Polyhydramnios, Amniotic fluid index 25 cm, At birth of infant|Gestational age at delivery, Gestational age was defined as completed weeks based on last menstrual period or the earliest ultrasound assessment if discordant., At birth of infant|Cesarean section, delivery of a baby through a surgical incision in the mother's abdomen and uterus, At birth of infant|Perinatal mortality, infant deaths that occur at less than 7 days of age and fetal deaths with a gestational age of 28 weeks or more., First 7days postpartum|NICU admission, NICU admission for treatment or surveillance, up to 4 weeks after delivery|Maternal hospital stay, Length of hospital stay (days), up to 4 weeks from maternal discharge|Neonatal hospital stay, Length of hospital stay (days), up to 4 weeks from neonatal discharge|Evaluation of mediterranean diet adherence, using Mediterranean Diet Adherence Screener (MEDAS) questionnaire. Score betwwen 0-14; high score indicate maximum mediterranean diet adherence., up to 12-14weeks from last menstrual period.|Evaluation of health-related physical activity, using International Physical Activity Questionnaire (IPAQ). Data collected with IPAQ can be used as a continuous measure (Metabolic Equivalent of Task \[MET\]-minutes/week) or caterorical measure (low, moderate or high physical activity), up to 12-14weeks from last menstrual period.|Medical cost, Economic cost include: laboratory costs; glucose bottles (50 g, 100 g and 75 g); pharmaceutical expenditure (exact insulin doses consumed, total pens, needles, strips); medical visits during pregnany and postpartum (endocrinologist,educational nurses, obstetrician and midwifes); total number of tests (ultrasonds, cardiotocography record); cost of intensive care unit admissions (Length of stay and complexity) and total hospital admission costs.

All these variables will be expressed as cost ()., First 3 months postpartum",,Hospital Mutua de Terrassa,,FEMALE,ADULT,NA,3644,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,00003,2017-06-01,2018-11-27,2019-12,2018-02-05,,2018-02-05,"Hospital Universitari Mutua Terrassa, Terrassa, Barcelona, 08221, Spain","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/62/NCT03421262/Prot_SAP_000.pdf"
NCT03403231,INcreasing Veteran EngagemeNT to Prevent Diabetes (INVENT),https://clinicaltrials.gov/study/NCT03403231,INVENT,COMPLETED,"This study will evaluate a VA MyHealtheVet Secure Messaging intervention that uses different intervention messaging strategies designed to increase engagement in behaviors to prevent type 2 diabetes.

The investigators will enroll 144 eligible Veterans into a 12-week MyHealtheVet Secure Messaging intervention. Eligible Veterans include those who are currently using MyHealtheVet secure messaging, meet inclusion/exclusion criteria, and have received an HbA1c test within the last 6 months that meets the ADA/CDC classification for prediabetes. Study participants will be surveyed about their engagement in behaviors to prevent TDM2 and mediators of this engagement. After completing a baseline survey, participants will be randomly assigned to receive different novel presentations of information about ways to prevent T2DM through both Secure Messaging and US Mail. The investigators will test the 5 presentations that each: (1) represent an innovative approach from behavioral economics or health psychology with great promise to increase engagement in behaviors to prevent T2DM among patients with prediabetes; and (2) have not been tested in this setting.",YES,Prediabetes,BEHAVIORAL: INVENT Secure Messaging Intervention,"Engagement in Recommended Behaviors to Prevent Type 2 Diabetes, The investigators will use survey and medical record data to evaluate changes in participants' engagement in recommended behaviors to prevent type 2 diabetes., 3 months","Motivation to Prevent Type 2 Diabetes, The investigators will use survey data to evaluate mean change in motivation level to prevent diabetes between baseline and 3-months. The Treatment Self-Regulation Questionnaire (TSRQ) was included in the survey and respondents were asked about their level of motivation from 1 (Not at all motivated) to 10 (Highly motivated)., 3 months|Importance of Preventing Type 2 Diabetes, The investigators will use survey data to evaluate mean changes in level of importance of preventing diabetes from baseline to 3 months. The Treatment Self-Regulation Questionnaire (TSRQ) was included in the survey and respondents were asked about their level of perceived importance from 1 (Not at all important) to 10 (Extremely important)., 3 months|Use of Medication for T2DM Prevention, The investigators will use medical record data and survey data to evaluate whether participants began the use of medication for T2DM prevention from baseline to 3 months., 3 months|Perception for Risk for T2DM, The investigators will use survey data to evaluate mean changes in perception of risk for T2DM from baseline to 3 months. The Adriaanse T2DM Risk Perception Scale, which was included in the survey, measured self-assessed risk perception from 0 denoting no choice of developing T2DM to 100 denoting absolute confidence in developing T2DM, 3 months|Knowledge of Strategies to Prevent T2DM, The investigators will use survey data to evaluate changes in knowledge of strategies to prevent Type 2 Diabetes between baseline and 3-month assessment. Respondents were given 3 open-ended questions to report things they could do to prevent diabetes. Each respective response to the 3 questions were coded and scored according to whether they indicated engagement in the following activities: weight loss, physical activity, use of metformin, or enrollment into a diabetes prevention program. Each question denoted with a positive response were coded with 1 whereas those that did not were coded as a 0. The three questions were summed into a final score ranging from 0 (no report of engagement in the aforementioned healthy activities) with the worst outcome to 3 (a report of 3 of the 4 aforementioned healthy activities) with the best outcome. The final scores were generated based on the mean difference between baseline and 3-month scores., 3 months|Participation in Weight-related Wellness Programs, The investigators will use survey data to evaluate how many participants enrolled in weight-related wellness programs from baseline to 3 months., 3 months|Weight Loss Behaviors, The investigators will use survey data to evaluate changes in weight loss behaviors at the 3-month post intervention assessment., 3 months|Physical Activity, The investigators will use survey data to evaluate changes in physical activity after the 3-month post intervention assessment. The International Physical Activity Questionnaire - Short Form (IPAQ-SF) was used to measure physical activity change. Respondents were asked to report how many hours and minutes within the past week they completed of vigorous physical activity, moderate physical activity, and brisk walking. The total sum of minutes for these three questions were subsequently coded into a yes/no binary variable for whether respondents met a recommended 150 minutes of overall physical activity within 7 days of being assessed. The values provided reflect a proportion of respondents that met or exceeded the 150 minute threshold of overall physical activity based on the newly generated variable that combined total minutes of vigorous physical activity, moderate physical activity, and brisk walking., 3 months",,VA Office of Research and Development,,ALL,"CHILD, ADULT, OLDER_ADULT",NA,144,FED,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: PREVENTION,CDX 15-002|CDA 13-267,2018-02-01,2020-03-01,2020-09-30,2018-01-18,2021-03-24,2023-07-25,"VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, 48105-2303, United States","Study Protocol, https://storage.googleapis.com/ctgov2-large-docs/31/NCT03403231/Prot_000.pdf"
NCT01474018,QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 Diabetes,https://clinicaltrials.gov/study/NCT01474018,,COMPLETED,"QR-Bromocriptine as an add-on treatment to insulin and metformin in the management of type 2 diabetes will result in improved glycemic control, reduced exogenous insulin requirement, increased lean fat mass and improved pancreatic beta-cell function.",YES,"Diabetes Mellitus, Type 2",DRUG: QR-bromocriptine,"Change in A1c, Change from baseline HbA1c between subjects receiving QR-Bromocriptine + metformin + insulin compared to those subjects receiving metformin + insulin, Baseline - 24 weeks","Total Daily Insulin Dose, Change in total daily insulin dose in patients treated with QR-Bromocriptine +metformin +insulin compared to metformin + insulin alone, Baseline - 24 weeks",,University of Texas Southwestern Medical Center,,ALL,"ADULT, OLDER_ADULT",PHASE4,15,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,QR-Bromo,2011-11,2012-05,2012-06,2011-11-17,2019-01-07,2019-09-16,"UT Southwestern Medical Center, Dallas, Texas, 75390, United States|UT Southwestern, Dallas, Texas, 75390, United States","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/18/NCT01474018/Prot_SAP_000.pdf"
NCT03595384,Soccer-based Adaptation of the Diabetes Prevention Program,https://clinicaltrials.gov/study/NCT03595384,,COMPLETED,"This is a longitudinal pre-post pilot intervention study evaluating feasibility of implementation of a soccer-based Diabetes Prevention Program (DPP) and preliminary changes in physical activity and diet-related measures. Overweight participants at high risk for type 2 diabetes mellitus (T2DM) will be recruited through soccer interest groups, local leagues and Hispanic health organizations. After a baseline assessment visit, participants will attend soccer practice twice a week for 12 weeks while completing the National Diabetes Prevention Program (NDPP) core curriculum online modules with facilitated discussion by trained coaches during each soccer practice. Participants will then be invited to join an established small-sided soccer league in their community (for 12 weeks) offering one game per week and will also complete the NDPP maintenance modules and physical activity and diet self-tracking via mobile health technologies. After the core (first 12 weeks) and maintenance intervention periods (second 12 weeks) baseline measurements will be repeated. Data on the feasibility of this DPP soccer-based adaptation will inform future randomized, controlled trials testing the effectiveness of this translation model to reduce T2DM risk while extrapolating to other sports-based adaptation and age, gender and racial sub-populations.",YES,Diabetes,BEHAVIORAL: Soccer-based adaptation to the DPP,"Number of Participants Completing the Study, Feasibility of the study will be assessed by the number of participants completing the study., Week 24|Participant Satisfaction With Overall Program, Participants indicate how satisfied they were with the overall program with a single item which was scored on a scale of 1 (poor) to 10 (excellent)., Week 24","Weight, Body composition will be assessed by weight in kilograms (kg)., Baseline, Week 12, Week 24|Steps Per Day, Participants will be asked to wear a Garmin fitness tracker throughout the study and physical activity will be measured as steps taken per day., Baseline, Week 12, Week 24|Intake of Added Sugars, The dietary behavior of consumption of added sugars was measured by using the Nutrition Database System for Research (NDSR) 24-hour dietary recall. The NDSR is a dietary analysis software application used to collect and calculate nutritional intake., Baseline, Week 12, Week 24|Intake of Fruit, The dietary behavior of consumption of fruit was measured by using the NDSR 24-hour dietary recall. The NDSR is a dietary analysis software application used to collect and calculate nutritional intake. The NDSR calculates the number of servings from 7 subcategories including citrus fruits, fruits other than citrus, avocado, as well as processed fruits. Serving amounts for all fruit are calculated by the NDSR software based on standard serving sizes for each specific food item. The total servings from all subcategories are reported here., Baseline, Week 12, Week 24|Intake of Vegetables, The dietary behavior of consumption of vegetables was measured by using the NDSR 24-hour dietary recall. The NDSR is a dietary analysis software application used to collect and calculate nutritional intake. The NDSR calculates the number of servings from 10 subcategories including potatoes, juice, green or yellow vegetables, and legumes. Serving amounts for all fruit are calculated by the NDSR software based on standard serving sizes for each specific food item. The total servings from all subcategories are reported here., Baseline, Week 12, Week 24|Change in International Physical Activity Questionnaire (IPAQ) Score, The International Physical Activity Questionnaire (IPAQ) includes 7-items asking respondents how many days in the past week they participated in vigorous, moderate and mild activities and how many minutes per day they spent on those activities. Data collected with IPAQ can be reported as a continuous measure and is computed by weighting each type of activity by its energy requirements defined in Metabolic Equivalent of Tasks (METs) to yield a score in MET-minutes (the MET score of an activity multiplied by the minutes performed). MET-minutes per week will be compared between study time points., Baseline, Week 12, Week 24|Waist Circumference, Body composition will be assessed by waist circumference measured in centimeters (cm)., Baseline, Week 12, Week 24",,Emory University,Georgia Center for Diabetes Translation Research|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Southern Denmark,MALE,ADULT,NA,41,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,IRB00100342|P30DK111024,2018-04-29,2018-12-16,2018-12-16,2018-07-23,2022-07-15,2022-08-12,"Emory University Rollins School of Public Health, Atlanta, Georgia, 30322, United States","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/84/NCT03595384/Prot_SAP_000.pdf|Informed Consent Form, https://storage.googleapis.com/ctgov2-large-docs/84/NCT03595384/ICF_001.pdf"
NCT03607799,A Culturally-tailored Personalized Nutrition Intervention in South Asian Women at Risk of Gestational Diabetes,https://clinicaltrials.gov/study/NCT03607799,DESI-GDM,RECRUITING,"This trial will assess the impact of a culturally tailored, personalized nutrition intervention on glycemic response to an oral glucose load (as measured by the area-under-the curve glucose) in high-risk pregnancies of South Asian women. The intervention targets two at-risk individuals: mother and infant, ""breaking the cycle"" of maternal gestational dysglycemia, excess infant adiposity and insulin resistance, and CVD in both mother and baby. The findings of this study will be important in guiding future evidence-based recommendations and public health policies to manage gestational glycemia in pregnant women at risk of GDM.",NO,"Diabetes, Gestational",BEHAVIORAL: Dietary Intervention|BEHAVIORAL: Control,"Glucose area-under-the-curve (glucose AUC), A measure of glycemic response, glucose AUC is a continuous measure of the response to a 75-g oral glucose tolerance test, and is calculated by the trapezoidal method using the fasting, 1-h, and 2-h glucose., 3 months","Gestational diabetes mellitus, Gestational diabetes mellitus is classified using the cut-offs derived in a large cohort of South Asian women from the ""Born in Bradford"": fasting glucose level \>= 5.2 mmol/L, or 2-hour post-load level \>=7.2 mmol/L., 3 months","Maternal blood pressure, We measure maternal blood pressure at baseline and the OGTT visit., 3 months|Maternal pregnancy complications, Pregnancy complications will be noted at coaching contacts., 3 months",McMaster University,Hamilton Health Sciences Corporation|Population Health Research Institute,FEMALE,"ADULT, OLDER_ADULT",NA,190,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,4886,2020-11-26,2024-06-30,2024-12-31,2018-07-31,,2023-10-23,"Farah Khan, Hamilton, Ontario, L8S4K1, Canada","Study Protocol, https://storage.googleapis.com/ctgov2-large-docs/99/NCT03607799/Prot_000.pdf|Informed Consent Form, https://storage.googleapis.com/ctgov2-large-docs/99/NCT03607799/ICF_001.pdf"
NCT04107935,"Telemedicine for Reach, Education, Access and Treatment-ongoing",https://clinicaltrials.gov/study/NCT04107935,TREAT-ON,TERMINATED,"Diabetes (DM) management requires health care providers to provide patients with the appropriate amount of time, education and support that are necessary for quality care. Unfortunately, this is often impeded by limited access to resources, particularly in rural communities where DM rates are high and providers are scarce. Therefore, study investigators propose addressing these issues by implementing a model of care that includes diabetes educator (DE)-led planned visits with a real-time videoconferencing telemedicine program for ongoing patient support to improve DM outcomes.",YES,Diabetes Mellitus,BEHAVIORAL: TREAT-ON|BEHAVIORAL: Usual Care,"Change From Baseline in Glycemic Control, Average change in HbA1c every 3 months from baseline through 12 months was assessed using mixed model regression with repeat measures and therefore there is only one result reported per arm., Change every 3 months for 12 months.","Change From Baseline in Diabetes Self-care Behavior [Diet] Across 3 Month Intervals for 12 Months., Summary of Diabetes Self-care Activities Measure was used to evaluate self-care with questions about number of days in a week that the participant reports self-care behaviors. Individual items are scored 0 (minimum) to 7 (maximum) for number of days the behavior is performed. The total possible score ranges from 0 to 7. The higher the score for dietary behavior, the better. For this study, average change in scores from baseline through 12 months was assessed using mixed model regression with repeat measures and therefore there is only one result reported per arm., Change every 3 months for 12 months total.|Change From Baseline in Diabetes Distress Across 3 Month Intervals for 12 Months, Diabetes distress was evaluated with the 17-item Diabetes Distress Scale, which assesses four dimensions of distress - emotional, regimen, interpersonal and physician (Polonsky et al, 2005), and has shown a consistent pattern of relationships with HbA1c, diabetes self-efficacy, diet and physical activity in multiple samples of patients with T2DM (Fisher et al, 2012). Individual items are scored from 1 to 6; total scores are the average of all individual item scores; higher scores indicate greater distress (represents worse outcome). Possible score range 1 to 6. For this study, average change in scores every 3 months from baseline through 12 months was assessed using mixed model regression with repeat measures and therefore there is only 1 result reported per arm., Change every three months for 12 months total|Change From Baseline in Diabetes Empowerment Across 3 Month Intervals for 12 Months, Empowerment was measured using the 8-item Diabetes Empowerment Scale-Short Form, which measures an individual's perceived ability to manage psychosocial aspects of diabetes, assess dissatisfaction and readiness to change self-management plans and set and achieve diabetes goals (Anderson et al, 2000; Anderson et al, 2003). Possible scores are 1 to 5 for each item, summed for a possible total score of 8 to 40. Higher scores indicate greater empowerment (better outcome). For this study, average change in scores every 3 months from baseline through 12 months was assessed using mixed model regression with repeat measures and therefore there is only 1 result reported per arm., Change every 3 months for 12 months total|Intervention Acceptability, Telemedicine Usability Questionnaire was used to assess telehealth usefulness, ease of use and learnability, interface quality, patient-clinician interaction, reliability, satisfaction and future use and included additional items specific to this study. Individual items are scored on a scale from one to five, with one being strongly disagree to five being strongly agree. Scores are averaged for a possible score range of one to five. The higher the score infers the better the usability of the telehealth service., 12 months|Change From Baseline in Medication Adherence Across 3 Month Intervals for 12 Months, Medication adherence was assessed with the 8-item Morisky Medication Adherence Scale (MMAS-8). The scales includes 8 items. Scores can range from 0 to 8; the higher the score, the more adherent the respondent is considered. For this study, average change in scores every 3 months from baseline through 12 months was assessed using mixed model regression with repeat measures and therefore there is only 1 result reported per arm., Change every 3 months for 12 months total",,University of Pittsburgh,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),ALL,"ADULT, OLDER_ADULT",NA,43,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,STUDY19080005|1R34DK123370-01,2020-02-04,2022-08-04,2022-12-09,2019-09-27,2023-07-24,2023-12-18,"University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, 15213, United States","Study Protocol, https://storage.googleapis.com/ctgov2-large-docs/35/NCT04107935/Prot_001.pdf|Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/35/NCT04107935/SAP_002.pdf|Informed Consent Form, https://storage.googleapis.com/ctgov2-large-docs/35/NCT04107935/ICF_000.pdf"
NCT03443635,Cooking for Health Optimization With Patients,https://clinicaltrials.gov/study/NCT03443635,CHOP,COMPLETED,"Cooking for Health Optimization with Patients (CHOP) is the first known multi-site prospective cohort study with a nested Bayesian adaptive randomized trial in the preventive cardiology field of culinary medicine. It is also the first known longitudinal study to assess the impact of hands-on cooking and nutrition education on patient outcomes, with those classes taught by medical students and other future and current medical professionals who have first been trained in those classes on how to integrate diet and lifestyle counseling of patients with their respective scopes of clinical practice. CHOP is the primary research study of the world's first known medical school based teaching kitchen, The Goldring Center for Culinary Medicine at Tulane University School of Medicine. Medical trainees and professionals are followed in this study long-term to understand how the classes impact their competencies in patient counseling, attitudes about the counseling, and their own diets. Patients who consent to being randomized to these classes compared to standard of care are studied within the nested Bayesian adaptive randomized trial to understand how the classes impact their health outcomes, clinical and food costs, and the costs of health systems caring for these patient populations. CHOP is designed as a pragmatic population health trial to hopefully improve healthcare effectiveness, equity, and cost by establishing an evidence-based, scalable, sustainable model of healthcare intervention targeting the social determinants of health, while complementing the pharmacological and/or surgical management of patients.",YES,Cardiovascular Diseases|Cardiovascular Risk Factor|Nutrition Disorders|Diabetes|Hypertension|Cancer|Depression|Obesity|Physical Activity,BEHAVIORAL: Treatment,"High or Medium (Versus Low) Mediterranean Diet Adherence, Based on 9-point Trichopoulou et al. 2003 NEJM scale (for patients, medical trainees, and providers), 6 months","Hospital Readmissions, Re-presenting to the hospital for similar presenting diagnosis (for patients), 30 days|Composite Rate of All Cause-mortality, Myocardial Infarction, and Cerebrovascular Event, (For patients), 6 months|Competencies, Educating patients on healthy diet and lifestyles according to 25 competency topics (for medical trainees), 6 months|Healthcare Costs, Direct and indirect (for patients), 6 months|Healthcare Costs, Direct and indirect (for health systems caring for the patients in the trial), 6 months|Food Costs, Grocery and restaurant costs (for patients), 6 months",,Tulane University,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1|PHASE2,7192,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,CHOP,2018-02-01,2020-12-18,2020-12-18,2018-02-23,2021-12-07,2022-04-29,"The Goldring Center for Culinary Medicine at Tulane University School of Medicine, New Orleans, Louisiana, 70119, United States","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/35/NCT03443635/Prot_SAP_000.pdf"
NCT03042936,Diabetes Prevention Program in Youth,https://clinicaltrials.gov/study/NCT03042936,,COMPLETED,The purpose of this study is to test the effectiveness of an out-of-school diabetes prevention program for youth (ages 7-15) with a family history of pre-diabetes or type 2 diabetes.,YES,Pre Diabetes,BEHAVIORAL: Insulin Superheroes Club Curriculum,"Change From Baseline Hemoglobin A1c, 16 weeks","Change From Baseline Body Mass Index Z-score, 16 weeks, 6 months, 9 months, 12 months|Change From Baseline Waist Circumference Z-score, 16 weeks, 6 months, 9 months, 12 months|Change From Baseline Systolic Blood Pressure Z-score, 16 weeks, 6 months, 9 months, 12 months|Change From Baseline Diastolic Blood Pressure Z-score, 16 weeks, 6 months, 9 months, 12 months|Change From Baseline Percent Body Fat, 16 weeks, 6 months, 9 months, 12 months|Change From Baseline Total Cholesterol, 16 weeks, 6 months, 9 months, 12 months|Change From Baseline LDL Cholesterol, 16 weeks, 6 months, 9 months, 12 months|Change From Baseline HDL Cholesterol, 16 weeks, 6 months, 9 months, 12 months|Change From Baseline Non-HDL Cholesterol, 16 weeks, 6 months, 9 months, 12 months|Change From Baseline Triglycerides, 16 weeks, 6 months, 9 months, 12 months|Change From Baseline Six Minute Walk Test Distance, 16 weeks, 6 months, 9 months, 12 months|Change From Baseline Right Handgrip Strength, 16 weeks, 6 months, 9 months, 12 months|Change From Baseline Left Handgrip Strength, 16 weeks, 6 months, 9 months, 12 months|Change From Baseline Combined Handgrip Strength, 16 weeks, 6 months, 9 months, 12 months|Change From Baseline Sit-and-reach Lower Body Flexibility, 16 weeks, 6 months, 9 months, 12 months|Change From Baseline Shuttle Run Speed, 16 weeks, 6 months, 9 months, 12 months",,University of Tennessee,,ALL,CHILD,NA,33,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,15-03716-XP,2015-03,2020-11-04,2020-11-04,2017-02-03,2020-11-09,2023-11-22,,"Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/36/NCT03042936/Prot_SAP_000.pdf"
NCT03377244,Healthy Body Healthy Souls in the Marshallese Population,https://clinicaltrials.gov/study/NCT03377244,,COMPLETED,"The primary aim is to pilot test a weight-loss intervention for Marshallese adults, referred to throughout as Healthy Bodies Healthy Souls (HBHS). The HBHS intervention includes the Wholeness, Oneness, Righteousness, Deliverance Diabetes Prevention Program Lifestyle Intervention (WORD DPP) implemented at the individual level, with the additional enhancement of working with Marshallese churches to implement church-level changes to support the individual behavioral intervention of the WORD DPP. We will then compare changes in outcomes with participants in the churches who were exposed to the policy changes but did not participate in the WORD DPP, and with those enrolled in a separate DPP trial who participated in the WORD DPP but were not exposed to church-level policy changes.",YES,Weight Loss|Pre Diabetes|Overweight and Obesity,BEHAVIORAL: HBHS|BEHAVIORAL: HBHS Policy|BEHAVIORAL: WORD DPP,"Mean Percent Body Weight (Pounds) Change, Mean percent body weight (pounds) change from baseline to 6 months post-intervention (12 months post-initiation of the intervention). Participant weight (without shoes) was measured in light clothing to the nearest 0.5 lb using a calibrated digital scale., Baseline, 6 months post-intervention","Change in Mean HbA1c (%), Change in mean HbA1c (NGSP %) from baseline to 6 months post-intervention (12 months post-initiation of the intervention). A Siemens analyzer (point of care) was utilized to calculate HbA1c levels for each participant., Baseline, 6 months post-intervention|Change in Mean Systolic Blood Pressure (mmHg), Change in mean systolic blood pressure (mmHg) from baseline to 6 months post-intervention (12 months post-initiation of the intervention). Blood pressure was measured with a sphygmomanometer, with participants seated., Baseline, 6 months post-intervention|Change in Mean Diastolic Blood Pressure (mmHg), Change in mean diastolic blood pressure (mmHg) from baseline to 6 months post-intervention (12 months post-initiation of the intervention). Blood pressure was measured with a sphygmomanometer, with participants seated., Baseline, 6 months post-intervention|Change in Eating Habits Self-Efficacy, Change in eating habits self-efficacy from baseline to 6 months post-intervention (12 months post-initiation of the intervention). This self-report measure assessed participants' self-efficacy related to their ability to make healthy eating decisions in the face of real or perceived barriers (e.g. while at social events, while watching TV, etc.). This 7-item measure was adapted from items in the original Weight Efficacy Life-Style Questionnaire by Clark et al (1991) (reference provided in the References in the Protocol Section). Each of the 7 items are measured via 3 response options (""Yes/Completely Sure""=2; ""Maybe/Not Sure""=1; and ""No/Not Sure at All""=0), giving a possible range of scores of 0-14, with higher scores indicating higher self-efficacy for making healthy eating decisions in spite of barriers., Baseline, 6 months post-intervention|Change in Physical Activity Self-Efficacy, Change in physical activity self-efficacy from baseline to 6 months post-intervention (12 months post-initiation of the intervention). This self-report measure assessed participants' self-efficacy for exercising in the face of real or perceived barriers (e.g., bad weather, exercising alone, etc.). This 9-item measure was adapted from the Self-Efficacy for Exercise Scale by Resnick \& Jenkins (2000) and Resnick et al (2004) (references provided in the References in the Protocol Section). Each of the 9 items are measured via 3 response options (""Yes/Completely Sure""=2; ""Maybe/Not Sure""=1; and ""No/Not Sure at All""=0), giving a possible range of scores of 0-18, with higher scores indicating higher self-efficacy for exercising despite barriers., Baseline, 6 months post-intervention|Change in Percentage of Participants Engaging in Sufficient Levels of Physical Activity Over the Past Month, Change in percentage of participants engaging in sufficient levels of physical activity (PA) from baseline to 6 months post-intervention (12 months post-initiation of the intervention). This self-report measure assessed participants' frequency of engaging in both moderate and vigorous levels of physical activity over the past month with two items. Both items used a 4-point response scale: 1) Rarely or Never; 2) Once a week; 3) 2-4 times a week; and 4) More than 4 times a week. Each 4-point scale for moderate PA and vigorous PA was weighted: 0=Rarely or Never; 1=Once a week; 2=2-4 times a week; and 4=More than 4 times a week. The weights were then summed and dichotomized as follows: 4 = sufficient PA and \<4 = insufficient PA. Items were adapted to include relevant cultural examples of physical activity from the DASH 2 Brief Physical Activity Questionnaire (link to original items provided in the References in the Protocol Section)., Baseline, 6 months post-intervention|Change in Sugar-Sweetened Beverage Consumption, Change in participants' sugar-sweetened beverage consumption from baseline to 6 months post-intervention (12 months post-initiation of the intervention). This self-report measure assessed participants' sugar-sweetened beverage consumption over the past 30 days using two questions from 'Module 14: Sugar Sweetened Beverages' of the CDC's Behavioral Risk Factor Surveillance System (BRFSS). Participants could respond in number of times per day, per week, or per month. Responses for each question were converted to number of times per day (i.e., self-reported times per week divided by 7 or self-reported times per month divided by 30), resulting in two measures: number times soda was consumed per day and number of times sugar-sweetened fruit drinks, sweet tea, and sports drinks were consumed per day. Per BRFSS guidelines, these two measures were added together to create a total daily SSB consumption rate., Baseline, 6 months post-intervention|Change in Fruit and Vegetable Consumption, Change in participants' fruit and vegetable consumption from baseline to 6 months post-intervention (12 months post-initiation of the intervention). This self-report measure assessed participants' fruit and vegetable consumption over the past three months using three questions adapted from: Shannon et al (1997) (reference provided in the References in the Protocol Section). Each of the three items was scored as Often=2; Sometimes=1; Never=0. Items were summed to create a scale score, giving a possible range of scores of 0-6, with higher scores indicating more frequent consumption of fruit and vegetables., Baseline, 6 months post-intervention|Change in Perceived Family Support for Exercise and Dietary Habits, Change in perceived family support for exercise and dietary habits from baseline to 6 months post-intervention (12 months post-initiation of the intervention). This self-report measure was adapted to examine changes in perceived family support for engaging in healthy exercise and dietary habits. This measure consists of a 6-item scale adapted from: Gruber (2008) (reference provided in the References in the Protocol Section). Each of the 6 items are measured via 3 response options (""Often""=2; ""Sometimes""=1; and ""Never""=0), giving a possible range of scores of 0-12, with higher scores indicating higher perceived family support for exercising and eating healthier., Baseline, 6 months post-intervention",,University of Arkansas,,ALL,"ADULT, OLDER_ADULT",NA,102,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,217566,2018-09-30,2019-10-31,2019-10-31,2017-12-19,2020-11-02,2021-01-29,"University of Arkansas for Medical Sciences Northwest, Fayetteville, Arkansas, 72703, United States","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/44/NCT03377244/Prot_SAP_000.pdf"
NCT02266576,A Patient-Centered Strategy for Improving Diabetes Prevention in Urban American Indians,https://clinicaltrials.gov/study/NCT02266576,,COMPLETED,The goal of the proposed research is to identify effective patient-centered strategies to prevent diabetes in high-risk populations in real world settings. The investigators will accomplish this by conducting a randomized controlled trial comparing an enhanced Diabetes Prevention Program addressing psychosocial stressors to a standard version in a high-risk population of urban American Indian and Alaska Native people within a primary care setting.,YES,"Diabetes Mellitus, Type 2|Metabolic Syndrome|Insulin Resistance",BEHAVIORAL: Standard DPP|BEHAVIORAL: Enhanced DPP,"Change From Baseline in Body Mass Index (BMI) Through Month 12, BMI is measured as weight in kg divided by the square of height in meters., Change through month 12, with assessments at baseline, 6 months, and 12 months|Change From Baseline in the Quality of Life Short Form Survey (SF-12), SF-12 scale is a generic, multipurpose short-form survey with 12 questions selected from the SF-36 Health Survey to evaluate overall health-related quality of life. Answers are combined, scored and weighted into mental and physical functioning component scales. The scores for each scale range from 0 to 100. A higher value indicates a better quality of life of the patient., Change through month 12, with assessments at baseline, 6 months, and 12 months","Change From Baseline in Food Frequency Questionnaire (FFQ) Score as a Measure of Healthy and Unhealthy Diet Choices, The FFQ modified to incorporate culturally-relevant food choices (e.g. corn tortillas and frybread) was used. Food items were scored on a scale of 1 to 6 (6 corresponding to the greatest frequency of consumption), and categorized as ""healthy,"" ""unhealthy,"" and ""undetermined"" based on classifications previously determined by Teuful-Shone et al. ""Healthy"" foods were those recommended for increased intake (e.g. green leafy salad). ""Unhealthy"" foods were recommended for decreased intake (e.g. soft drinks), and all remaining foods were ""undetermined."" Healthy and unhealthy food scores (but not undetermined) were collected for this outcome measure. Scores were summed for a total score. Healthy food choices (6 questions) score range 3-36 (higher scores mean healthier diet). Unhealthy food choices (13 questions) score range: 13-78 (lower scores mean healthier diet)., Change through month 12, with assessments at baseline, 6 months, and 12 months|Change From Baseline in Physical Activity Measured in Metabolic Equivalents (MET) Per Week, MET is a term used to represent the intensity of exercise. A MET is the ratio of the rate of energy expended during an activity to the rate of energy expended at rest. At least 1000 MET minutes per week are needed to lower the risk of disease.

* 1 minute of light-intensity activities = 1.1 MET to 2.9 METs
* 1 minute of moderate-intensity activities = 3.0 to 5.9 METs
* 1 minute of vigorous-intensity activities = 6.0 METs or more, Change through month 12, with assessments at baseline, 6 months, and 12 months|Change From Baseline in the Center for Epidemiologic Studies - Depression Scale (CES-D) as a Measure of Mental Health Symptoms, The CES-D (Radloff, 1977) is a 20-item, self-report scale designed to assess the presence and severity of depressive symptoms over the past week. The total range is 0-80, with higher scores reflecting more severe depression symptoms., Change through month 12, with assessments at baseline, 6 months, and 12 months|Change in From Baseline in Empowerment, The Growth and Empowerment Measure (GEM) was developed to measure change in dimensions of empowerment as defined and described by Aboriginal Australians who participated in the Family Well Being programme. The GEM has two components. The 14-item Emotional Empowerment Scale has a range of 12-60, with higher scores corresponding to more ability to feel and show the signs of empowerment . The 12-item Scenarios scale has a range of 12-84, with higher scores corresponding to better emotional empowerment in different scenarios., Change through month 12, with assessments at baseline, 6 months, and 12 months","Systolic Blood Pressure, Blood pressure readings are expressed in millimeters of mercury. This unit is abbreviated as mm Hg. A normal reading would be any blood pressure below 120/80 mm Hg and above 90/60 mm Hg in an adult., Baseline, 6 months and 12 months|Diastolic Blood Pressure, Blood pressure readings are expressed in millimeters of mercury (mmHg). A normal reading would be any blood pressure below 120/80 mm Hg and above 90/60 mm Hg in an adult., Baseline, 6 months and 12 months|Fasting Blood Glucose, Performed via fasting participant finger stick with Alere Cholestech LDX POS device., Baseline, 6 months and 12 months|Symptoms of Historical Trauma, By patient report using a modified version of the Indigenous People's Survey, Baseline, 6 months and 12 months|Waist Circumference, In centimeters, measured by trained assessor using standard protocol, Baseline, 6 months and 12 months|Lipid Bioassays, LDL-cholesterol, HDL-cholesterol, and Triglycerides; performed via fasting participant finger stick with Alere Cholestech LDX POS device, Baseline, 6 months and 12 months",Stanford University,San Jose State University|Patient-Centered Outcomes Research Institute,ALL,"ADULT, OLDER_ADULT",NA,207,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,SU-30015|PCORI-PCORIAD-1306-02172,2015-06,2017-08-30,2017-08-30,2014-10-17,2019-12-09,2020-01-02,"Timpany Center of San Jose State University, San Jose, California, 95128, United States|Stanford University School of Medicine, Stanford, California, 94305, United States","Study Protocol, https://storage.googleapis.com/ctgov2-large-docs/76/NCT02266576/Prot_000.pdf|Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/76/NCT02266576/SAP_001.pdf"
NCT02481596,FAMS Mobile Health Intervention for Diabetes Self-care Support,https://clinicaltrials.gov/study/NCT02481596,,COMPLETED,"This study evaluates a family-focused mobile phone-delivered intervention, called FAMS (Family-focused Add-on for Motivating Self-care), in supporting adults with type 2 diabetes in their self-management relative to a control group. The goal of this study is to ascertain if family-focused content delivered to the patient can improve the patients' family support for diabetes self-care, self-efficacy, and adherence to diet and exercise recommendations.",YES,"Diabetes Mellitus, Type 2",BEHAVIORAL: REACH + FAMS|BEHAVIORAL: REACH|BEHAVIORAL: Helpline & A1c results,"Adherence to Diet - Use of Dietary Information, as measured by Personal Diabetes Questionnaire Use of Dietary Information for Decision Making (1=less use of information - worse to 6=more use of information - better), 3 months, 6 months|Adherence to Exercise, as measured by International Physical Activity Questionnaire-Short form \[metabolic equivalent minutes (MET-minutes) per week\] where more MET-minutes per week indicates more physical activity, 3 months, 6 months|Adherence to Diet - Problem Eating Behavior, as measured by Personal Diabetes Questionnaire diet subscale Problem Eating Behavior (1=less problem eating behavior - better to 6=more problem eating behavior - worse), 3 months, 6 months","Supportive Family Behaviors, as measured by Family and Friend Involvement in Adults' Diabetes (FIAD) helpful involvement subscale ranging from 1= less frequent helpful involvement (worse) to 5=more frequent helpful involvement (better), 3 months, 6 months|Obstructive Family Behaviors, as measured by Family and Friend Involvement in Adults' Diabetes (FIAD) harmful involvement subscale ranging from 1= less frequent harmful involvement (better) to 5=more frequent harmful involvement (worse), 3 months, 6 months|Diabetes Self-efficacy, as measured by scores on the Perceived Diabetes Self-Management Scale (4-item version) ranging from 4 = low self-efficacy (worse) to 20 = high self-efficacy (better), 3 months, 6 months",,Vanderbilt University Medical Center,,ALL,"ADULT, OLDER_ADULT",NA,512,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,140562_A,2016-05-23,2018-07,2018-07,2015-06-25,2019-07-19,2019-11-27,"Federally Qualified Health Centers & Vanderbilt Primary Care Clinics, Nashville, Tennessee, United States","Study Protocol, https://storage.googleapis.com/ctgov2-large-docs/96/NCT02481596/Prot_000.pdf|Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/96/NCT02481596/SAP_001.pdf"
NCT03419195,Cardiovascular Mechanisms of Exercise Intolerance in Diabetes and the Role of Sex,https://clinicaltrials.gov/study/NCT03419195,,COMPLETED,"This study will define the relationship of cardiac, vascular function and skeletal muscle blood flow (individually and together) to cardiovascular exercise capacity in in men and women with and without type 2 diabetes (T2DM). Identification of differences in the effects of exercise training on the integrated cardiovascular system and metabolism in men and women with and without T2DM will reveal specific adaptive responses to exercise.This study will evaluate \& compare exercise function in a total of 60 subjects from the Denver area (30 people with T2DM and 30 overweight control subjects).

Specific Aim 1: To test the hypothesis that the integration of cardiac function, macrovascular function, and microvascular function is impaired in T2D and correlates with cardiovascular exercise capacity (CVEC) impairment.

Specific Aim 2: To test the hypothesis that exercise training will elicit adaptive responses in cardiac and vascular function, muscle perfusion and metabolism with differences by T2D status.

Differences between the exercise responses in people with T2DM and healthy people will help further identify the disease process of T2DM and direct future research of treatments and interventions.",NO,Type 2 Diabetes Mellitus|Healthy|Overweight|Cardiovascular Risk Factor,OTHER: Cardiovascular exercise training,"Change in peak oxygen consumption (VO2peak), Subjects' peak oxygen consumption will be tested on a stationary bike before and after 3 months of exercise, Through study completion, approximately 4 months|Change in insulin sensitivity, The investigators will evaluate the changes in insulin sensitivity utilizing a euglycemic insulin clamp, Through study completion, approximately 4 months|Change in muscular mitochondrial function, The investigators will examine mitochondrial function using magnetic resistance (MR) spectroscopy during single leg calf exercise, Through study completion, approximately 4 months",,,"University of Colorado, Denver",VA Eastern Colorado Health Care System,ALL,ADULT,NA,124,OTHER,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,17-0356,2018-02-07,2023-03-20,2023-03-20,2018-02-01,,2023-07-12,"University of Colorado, Anschutz Medical Campus, Aurora, Colorado, 80045, United States","Informed Consent Form, https://storage.googleapis.com/ctgov2-large-docs/95/NCT03419195/ICF_001.pdf"
